0001628280-20-011753.txt : 20200805 0001628280-20-011753.hdr.sgml : 20200805 20200805134611 ACCESSION NUMBER: 0001628280-20-011753 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 201076671 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 10-Q 1 vcel-20200630.htm 10-Q vcel-20200630
000088735912/312020Q2FALSE20730675,00075,00045,19444,86445,19444,864us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationus-gaap:OtherLiabilitiesus-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentP4Y00008873592020-01-012020-06-30xbrli:shares00008873592020-07-31iso4217:USD00008873592020-06-3000008873592019-12-3100008873592020-04-012020-06-3000008873592019-04-012019-06-3000008873592019-01-012019-06-30iso4217:USDxbrli:shares0000887359us-gaap:CommonStockMember2019-12-310000887359us-gaap:WarrantMember2019-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000887359us-gaap:RetainedEarningsMember2019-12-310000887359us-gaap:RetainedEarningsMember2020-01-012020-03-3100008873592020-01-012020-03-310000887359us-gaap:CommonStockMember2020-01-012020-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000887359us-gaap:CommonStockMember2020-03-310000887359us-gaap:WarrantMember2020-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310000887359us-gaap:RetainedEarningsMember2020-03-3100008873592020-03-310000887359us-gaap:RetainedEarningsMember2020-04-012020-06-300000887359us-gaap:CommonStockMember2020-04-012020-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000887359us-gaap:CommonStockMember2020-06-300000887359us-gaap:WarrantMember2020-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000887359us-gaap:RetainedEarningsMember2020-06-300000887359us-gaap:CommonStockMember2018-12-310000887359us-gaap:WarrantMember2018-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000887359us-gaap:RetainedEarningsMember2018-12-3100008873592018-12-310000887359us-gaap:RetainedEarningsMember2019-01-012019-03-3100008873592019-01-012019-03-310000887359us-gaap:CommonStockMember2019-01-012019-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310000887359us-gaap:CommonStockMember2019-03-310000887359us-gaap:WarrantMember2019-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310000887359us-gaap:RetainedEarningsMember2019-03-3100008873592019-03-310000887359us-gaap:RetainedEarningsMember2019-04-012019-06-300000887359us-gaap:CommonStockMember2019-04-012019-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300000887359us-gaap:CommonStockMember2019-06-300000887359us-gaap:WarrantMember2019-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000887359us-gaap:RetainedEarningsMember2019-06-3000008873592019-06-30vcel:productvcel:segmentvcel:pharmacy0000887359vcel:CoronaVirusPandemicMember2020-06-30xbrli:pure0000887359us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2020-04-012020-06-300000887359us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2020-01-012020-06-300000887359us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2019-04-012019-06-300000887359us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member2019-01-012019-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMember2020-04-012020-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMember2019-04-012019-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMember2020-01-012020-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMember2019-01-012019-06-300000887359vcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMember2020-04-012020-06-300000887359vcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMember2019-04-012019-06-300000887359vcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMember2020-01-012020-06-300000887359vcel:ImplantsMemberus-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMember2019-01-012019-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMembervcel:ProviderorFacilityMember2020-04-012020-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMembervcel:ProviderorFacilityMember2019-04-012019-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMembervcel:ProviderorFacilityMember2020-01-012020-06-300000887359us-gaap:FixedPriceContractMembervcel:ImplantsMembervcel:ProviderorFacilityMember2019-01-012019-06-300000887359vcel:ImplantsMemberus-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMember2020-04-012020-06-300000887359vcel:ImplantsMemberus-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMember2019-04-012019-06-300000887359vcel:ImplantsMemberus-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMember2020-01-012020-06-300000887359vcel:ImplantsMemberus-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMember2019-01-012019-06-300000887359vcel:BiopsyKitsMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-04-012020-06-300000887359vcel:BiopsyKitsMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-04-012019-06-300000887359vcel:BiopsyKitsMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-06-300000887359vcel:BiopsyKitsMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-06-300000887359vcel:EpicelMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-04-012020-06-300000887359vcel:EpicelMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-04-012019-06-300000887359vcel:EpicelMemberus-gaap:SalesChannelDirectlyToConsumerMember2020-01-012020-06-300000887359vcel:EpicelMemberus-gaap:SalesChannelDirectlyToConsumerMember2019-01-012019-06-300000887359vcel:EpicelMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300000887359vcel:EpicelMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-04-012019-06-300000887359vcel:EpicelMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300000887359vcel:EpicelMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300000887359vcel:EpicelMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-01-012020-06-300000887359vcel:EpicelMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310000887359us-gaap:MachineryAndEquipmentMember2020-06-300000887359us-gaap:MachineryAndEquipmentMember2019-12-310000887359us-gaap:FurnitureAndFixturesMember2020-06-300000887359us-gaap:FurnitureAndFixturesMember2019-12-310000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2020-06-300000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2019-12-310000887359us-gaap:LeaseholdImprovementsMember2020-06-300000887359us-gaap:LeaseholdImprovementsMember2019-12-310000887359us-gaap:ConstructionInProgressMember2020-06-300000887359us-gaap:ConstructionInProgressMember2019-12-310000887359us-gaap:EmployeeStockOptionMember2020-01-012020-06-300000887359vcel:PriorPlansMember2020-06-300000887359vcel:OmnibusIncentivePlan2019Memberus-gaap:CommonStockMember2020-04-290000887359vcel:OmnibusIncentivePlan2019Member2020-04-280000887359vcel:OmnibusIncentivePlan2019Member2020-04-290000887359vcel:OmnibusIncentivePlan2019Member2020-06-300000887359us-gaap:EmployeeStockMember2020-06-300000887359us-gaap:EmployeeStockMember2015-01-012020-06-300000887359us-gaap:SubsequentEventMemberus-gaap:EmployeeStockMember2020-07-012020-07-310000887359us-gaap:EmployeeStockOptionMember2020-04-012020-06-300000887359us-gaap:EmployeeStockOptionMember2019-04-012019-06-300000887359us-gaap:EmployeeStockOptionMember2019-01-012019-06-300000887359us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:EmployeeStockOptionMember2020-01-012020-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2019-04-012019-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-300000887359us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2020-04-012020-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2019-04-012019-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2020-01-012020-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2019-01-012019-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2020-04-012020-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2019-04-012019-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2020-01-012020-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2019-01-012019-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-04-012019-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2020-04-012020-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2019-04-012019-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2020-01-012020-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2019-01-012019-06-300000887359us-gaap:MoneyMarketFundsMember2020-06-300000887359us-gaap:CommercialPaperMember2020-06-300000887359us-gaap:CorporateDebtSecuritiesMember2020-06-300000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-06-300000887359us-gaap:AssetBackedSecuritiesMember2020-06-300000887359us-gaap:CashEquivalentsMember2020-06-300000887359us-gaap:ShortTermInvestmentsMember2020-06-300000887359us-gaap:MoneyMarketFundsMember2019-12-310000887359us-gaap:CommercialPaperMember2019-12-310000887359us-gaap:CorporateDebtSecuritiesMember2019-12-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000887359us-gaap:AssetBackedSecuritiesMember2019-12-310000887359us-gaap:CashEquivalentsMember2019-12-310000887359us-gaap:ShortTermInvestmentsMember2019-12-310000887359vcel:LongtermInvestmentsMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-06-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2019-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2020-06-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000887359us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-06-300000887359us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-06-300000887359us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-06-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-06-300000887359us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000887359us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000887359us-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-06-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2020-06-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2019-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-06-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-300000887359us-gaap:FairValueMeasurementsRecurringMember2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000887359us-gaap:EmployeeStockOptionMember2020-04-012020-06-300000887359us-gaap:EmployeeStockOptionMember2019-04-012019-06-300000887359us-gaap:EmployeeStockOptionMember2020-01-012020-06-300000887359us-gaap:EmployeeStockOptionMember2019-01-012019-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2020-04-012020-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2019-04-012019-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-300000887359us-gaap:WarrantMember2020-04-012020-06-300000887359us-gaap:WarrantMember2019-04-012019-06-300000887359us-gaap:WarrantMember2020-01-012020-06-300000887359us-gaap:WarrantMember2019-01-012019-06-300000887359vcel:MediWoundLtdMember2019-05-310000887359vcel:MediWoundLtdMember2019-05-012019-05-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Form 10-Q
 
☒      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED: June 30, 2020 
or
☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 Commission File Number 001-35280
 
VERICEL CORPORATION
(Exact name of registrant as specified in its charter)
Michigan 94-3096597
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
 
64 Sidney Street
Cambridge, MA 02139
(Address of principal executive offices, including zip code) 

Registrant’s telephone number, including area code: (617) 588-5555 

 Securities registered pursuant to Section 12(b) of the Act: 
Title of ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock (No par value)VCELNASDAQ
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
 Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No x
 
 
As of July 31, 2020, 45,250,402 shares of Common Stock, no par value per share, were outstanding. 



VERICEL CORPORATION
 QUARTERLY REPORT ON FORM 10-Q
 TABLE OF CONTENTS
 
  Page
 PART I - FINANCIAL INFORMATION 
Item 1.
Financial Statements (Unaudited):
  
 
  
 
 
  
 
  
Item 2.
  
Item 3.
  
Item 4.
PART II — OTHER INFORMATION
Item 1.
  
Item 1A.
  
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Exhibits
  
Exhibit Index
Signature


PART I - FINANCIAL INFORMATION
 
Item 1.                                                         Financial Statements

VERICEL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands)
 
 June 30,December 31,
 20202019
ASSETS  
Current assets:  
Cash and cash equivalents$55,704  $26,889  
Short term investments25,086  42,829  
Accounts receivable (net of allowance for doubtful accounts of $207 and $306, respectively)23,655  32,168  
Inventory8,417  6,816  
Other current assets2,900  2,953  
Total current assets115,762  111,655  
Property and equipment, net7,040  7,144  
Restricted cash89  89  
Right-of-use leased assets23,800  25,103  
Long term investments—  9,247  
Total assets$146,691  $153,238  
LIABILITIES AND SHAREHOLDERS’ EQUITY  
Current liabilities:  
Accounts payable$4,535  $6,345  
Accrued expenses7,975  7,948  
Current portion of operating lease liabilities5,570  5,461  
Other liabilities41  41  
Total current liabilities18,121  19,795  
Operating lease liabilities20,881  22,242  
Other long-term liabilities93  110  
Total liabilities$39,095  $42,147  
COMMITMENTS AND CONTINGENCIES
Shareholders’ equity:  
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding — 45,194 and 44,864, respectively$499,103  $489,749  
Other comprehensive gain 146  21  
Accumulated deficit(391,653) (378,679) 
Total shareholders’ equity107,596  111,091  
Total liabilities and shareholders’ equity$146,691  $153,238  
 
The accompanying Notes to the Condensed Consolidated Financial Statements are an integral part of these statements.



VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except per share amounts)
 
 Three Months Ended June 30,Six Months Ended June 30,
 2020201920202019
Product sales, net$20,014  $26,151  $46,692  $47,961  
Cost of product sales8,660  9,022  18,582  17,662  
Gross profit11,354  17,129  28,110  30,299  
Research and development3,226  21,070  6,989  24,078  
Selling, general and administrative16,486  16,259  34,555  29,779  
Total operating expenses19,712  37,329  41,544  53,857  
Loss from operations(8,358) (20,200) (13,434) (23,558) 
Other income (expense):   
Interest income147  428  453  908  
Interest expense(1) (2) (3) (4) 
Other income (expense)(57) (18) 10  18  
Total other income (expense)89  408  460  922  
Net loss$(8,269) $(19,792) $(12,974) $(22,636) 
Net loss per share attributable to common shareholders (Basic and Diluted) $(0.18) $(0.45) $(0.29) $(0.52) 
Weighted average number of common shares outstanding (Basic and Diluted)45,137  43,956  45,031  43,841  
 
The accompanying Notes to the Condensed Consolidated Financial Statements are an integral part of these statements.



VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, amounts in thousands)
 
 Three Months Ended June 30,Six Months Ended June 30,
 2020201920202019
Net loss$(8,269) $(19,792) $(12,974) $(22,636) 
Other comprehensive loss:
Unrealized gain on investments84  35  125  38  
Comprehensive loss$(8,185) $(19,757) $(12,849) $(22,598) 
 
The accompanying Notes to the Condensed Consolidated Financial Statements are an integral part of these statements.



VERICEL CORPORATION 
CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
(Unaudited, amounts in thousands)
Common StockWarrantsAccumulated Other Comprehensive IncomeAccumulated DeficitTotal Shareholders' Equity
SharesAmountAmount
BALANCE, DECEMBER 31, 201944,864  $489,749  —  $21  $(378,679) $111,091  
Net loss—  —  —  —  (4,705) (4,705) 
Compensation expense related to stock options and restricted stock units granted, net of forfeitures—  3,768  —  —  —  3,768  
Stock option exercises57  196  —  —  —  196  
Shares issued under the Employee Stock Purchase Plan20  224  —  —  —  224  
Issuance of stock upon restricted stock unit vesting36  —  —  —  —  —  
Restricted stock withheld for employee tax remittance(14) (163) —  —  —  (163) 
Unrealized gain on investments—  —  —  41  —  41  
BALANCE, MARCH 31, 202044,963  $493,774  $—  $62  $(383,384) $110,452  
Net loss—  —  —  —  (8,269) (8,269) 
Compensation expense related to stock options and restricted stock units granted, net of forfeitures—  4,376  —  —  —  4,376  
Stock option exercises188  696  —  —  —  696  
Shares issued under the Employee Stock Purchase Plan32  257  —  —  —  257  
Issuance of stock for restricted stock unit vesting11  —  —  —  —  —  
Unrealized gain on investments—  —  —  84  —  84  
BALANCE, JUNE 30, 202045,194  $499,103  $—  $146  $(391,653) $107,596  


Common StockWarrantsAccumulated Other Comprehensive Income (Loss)Accumulated DeficitTotal Shareholders' Equity
SharesAmountAmount
BALANCE, DECEMBER 31, 201843,578  $471,180  $104  $(39) $(369,014) $102,231  
Net loss—  —  —  —  (2,844) (2,844) 
Compensation expense related to stock options and restricted stock units granted, net of forfeitures—  2,628  —  —  —  2,628  
Stock option exercises228  780  —  —  —  780  
Shares issued under the Employee Stock Purchase Plan19  218  —  —  —  218  
Unrealized gain on investments—  —  —  42  —  42  
BALANCE, MARCH 31, 201943,825  $474,806  $104  $3  $(371,858) $103,055  
Net loss—  —  —  —  (19,792) (19,792) 
Compensation expense related to stock options and restricted stock units granted, net of forfeitures—  4,183  —  —  —  4,183  
Stock option exercises227  850  —  —  —  850  
Shares issued under the Employee Stock Purchase Plan14  211  —  —  —  211  
Unrealized gain on investments—  —  —  35  —  35  
BALANCE, JUNE 30, 201944,066  $480,050  $104  $38  $(391,650) $88,542  




VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)
 
 Six Months Ended June 30,
 20202019
Operating activities:  
Net loss$(12,974) $(22,636) 
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:  
Depreciation and amortization expense1,079  698  
Stock compensation expense8,144  6,810  
Foreign currency translation loss45  13  
Loss on sale of fixed assets30  —  
Amortization of premiums and discounts on marketable securities(25) (408) 
Amortization and interest accretion related to operating leases1,603  1,139  
Changes in operating assets and liabilities:  
Inventory(1,601) (1,230) 
Accounts receivable8,513  2,370  
Prepaid and other current assets53  680  
Accounts payable(1,692) (2,238) 
Accrued expenses27  (2,229) 
Operating lease liabilities(1,537) (1,007) 
Other non-current assets and liabilities, net—  (187) 
Net cash provided by (used for) operating activities1,665  (18,225) 
Investing activities:  
Purchases of short term investments(5,657) (32,402) 
Maturities of short term investments32,797  45,477  
Expenditures for property, plant and equipment(1,186) (1,224) 
Net cash provided by investing activities25,954  11,851  
Financing activities:  
Net proceeds from common stock issuance due to stock option exercises1,373  2,059  
Payments on employee's behalf for taxes related to vesting of restricted stock unit awards(163) —  
Other(14) (9) 
Net cash provided by financing activities1,196  2,050  
Net increase in cash, cash equivalents, and restricted cash28,815  (4,324) 
Cash, cash equivalents, and restricted cash at beginning of period26,978  18,286  
Cash, cash equivalents, and restricted cash at end of period$55,793  $13,962  
 
The accompanying Notes to the Condensed Consolidated Financial Statements are an integral part of these statements.


VERICEL CORPORATION
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
1.     Organization
 
Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced cell therapies for the sports medicine and severe burn care markets. Vericel currently markets two cell therapy products, MACI® and Epicel®, in the United States. Vericel obtained both products in May 2014, as part of the acquisition of certain assets and the assumption of certain liabilities from Sanofi, a French société anonyme (Sanofi).

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Company also markets Epicel® (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA). The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of biopharmaceuticals for use in the treatment of specific diseases.

COVID-19

The novel coronavirus (COVID-19) outbreak was first reported by China in late December 2019 and rapidly spread globally. The World Health Organization (WHO) declared the outbreak a pandemic on March 11, 2020 and the President of the United States declared a national health emergency two days later. Subsequently most states' governments, including those in Massachusetts and Michigan where the Company's operations are located, issued orders requiring businesses that do not conduct essential services to temporarily close their physical workplaces to employees and customers. The status of such orders varies on a state-by-state basis and is likely to continue to vary. Because Vericel is deemed an essential business, the Company is exempt from these state orders in their current form.

Notwithstanding being an essential business, the Company’s business and operations have been, and are expected to continue to be, adversely impacted by the effects of COVID-19 as a result of various factors including, without limitation, patients’ potential reluctance to undergo elective surgical procedures, healthcare facility restrictions regarding elective surgical procedures, the recent economic downturn due to the pandemic, the imposition of related public health measures and travel and business restrictions and disruptions to the ability of the Company’s employees to perform their jobs.

The implantation of MACI is an elective surgical procedure. On March 13, 2020 and March 14, 2020, the American College of Surgeons and United States Surgeon General, respectively, recommended that each hospital, health system, and surgeon minimize, postpone, or cancel electively scheduled surgeries, which has resulted in a reduction in MACI sales. The stated purpose for these recommendations was that every elective surgery could spread COVID-19 within a facility, use up personal protective equipment (PPE) which may be needed by healthcare workers treating COVID-19 patients, and burden hospital workforce who may be needed to respond to COVID-19. These recommendations were followed by numerous state level executive orders either banning or partially banning elective surgeries. As a result of these restrictions, beginning in mid-March 2020, the Company started to experience a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders. By early April 2020, 45 states, representing over 95% of total U.S. surgical capacity had issued either mandates or recommendations and guidelines suspending elective surgical procedures. These restrictions began to ease in May and, by the end of June 2020, states representing an estimated 90% total U.S. surgical capacity had lifted restrictions suspending elective procedures. It is likely that restrictions will continue to be both lifted and re-imposed as regional COVID 19 cases rates fall and rise. The Company’s MACI business will continue to be negatively impacted so long as multiple state orders and/or facilities restrict elective surgical procedures.




Going Concern

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.  As of June 30, 2020, the Company had an accumulated deficit of $391.7 million and incurred a net loss of $8.3 million and $13.0 million for the three and six months ended June 30, 2020, respectively.  The Company had cash and cash equivalents of $55.8 million and investments of $25.1 million as of June 30, 2020. The Company expects that existing cash, cash equivalents and investments will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these financial statements. However, the continuing effects of the COVID-19 pandemic may require the Company to engage in layoffs, furloughs and/or reductions in salary, all of which may result in irrecoverable losses of customers and significantly impact long-term liquidity. If elective surgery restrictions are reinstated on a widespread basis, significantly impacting the Company's business, the Company may need to access additional capital; however, the Company may not be able to obtain financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders.

2. Basis of Presentation
The accompanying condensed consolidated financial statements as of June 30, 2020 and for the three and six months ended June 30, 2020 are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in U.S. GAAP requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to continue to contain it or treat COVID-19, as well as the economic impact on our customers. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. As of June 30, 2020, the Company has not recorded impairments to investments, inventory, other current assets or long-lived assets as a result of the COVID-19 pandemic and does not expect material impairments in the future. The Company has assessed the impact of COVID-19 on accounts receivables (see note 4).
 
These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on February 25, 2020 (Annual Report).




Consolidated Statement of Cash Flows

The following table presents certain supplementary cash flows information for the six months ended June 30, 2020 and 2019:
Six Months Ended June 30,
(In thousands)20202019
Supplementary Cash Flows information:
Non-cash information:
Right-of-use asset and lease liability recognized$429  $560  
Additions to property, plant and equipment included in accounts payable55  365  
Cash information:
Interest paid (net of interest capitalized)$3  $4  

Total cash, cash equivalents, and restricted cash of $55.8 million as of June 30, 2020, shown in the statement of cash flows is comprised of cash and cash equivalents of $55.7 million and restricted cash of $0.1 million which is included in other long term assets on the consolidated balance sheet. As of June 30, 2019, cash and cash equivalents were $14.0 million and the Company did not have any restricted cash.

3. Recent Accounting Pronouncements

Measuring Credit Losses on Financial Instruments

The FASB issued updated guidance on measuring credit losses on financial instruments. The guidance removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Prior to the updated guidance, credit losses are recognized when it is probable that the loss has been incurred. The revised guidance removes all recognition thresholds and requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that a company expected to collect over the instrument’s contractual life. The Accounting Standard Update (ASU) 2016-13, Financial Instruments-Credit Losses (Topic 326), became effective for the Company January 1, 2020. See note 4 and note 8 for further discussion.

Fair Value Measurement Disclosure

The FASB issued updated guidance through ASU 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The revised guidance is intended to develop a more consistent disclosure framework that will increase clarity, remove, modify and add certain fair value disclosures to improve the effectiveness of the Company’s disclosures in the notes of the financial statements. This guidance became effective for the Company January 1, 2020 and had no impact to its condensed consolidated financial statements.

Simplifying the Accounting for Income Taxes

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company is currently in the process of evaluating the impact to its condensed consolidated financial statements.



4. Revenue
Revenue Recognition and Net Product Sales
The Company recognizes product revenue from sales of MACI kits, MACI implants and Epicel grafts following the five-step model in Accounting Standards Codification 606, Revenue Recognition, (ASC 606).
MACI Kits
MACI kits are sold directly to hospitals based on contracted rates in the approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit at which time the customer (the facility) is in control of the kit. The kit provides the doctor the ability to biopsy a sampling of cells to provide to the Company that can be used later to manufacture the implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cell tissue. The customer’s order of an implant is separate from the process of ordering the kit. Therefore, the sale of the kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.
MACI Implants
The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (Orsini) and AllCare Plus Pharmacy, Inc. (AllCare) to distribute its MACI product in arrangements whereby the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to receive payment from customers. The Company has engaged a third-party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical (DMS) for military implants. The sales directly to DMS are sold at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenues from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration which the Company expects to collect in exchange for MACI implants (the transaction price) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and other than customary prompt pay discounts, there are typically no forms of variable consideration.

When the Company sells MACI the patient is responsible for payment, however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates or a fee schedule. Net product revenue is recognized net of contractual allowances, which considers historical collection experience from both the payer and patient and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. These estimates include the impact of contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company's accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling account receivables based on similar risk characteristics. The loss percentage is based on current and historical information as well as reasonable and supportable forecasts. This loss percentage was applied to the accounts receivables as of June 30, 2020. The total allowance for uncollectible consideration was $4.4 million as of June 30, 2020 and $3.9 million at December 31, 2019. The allowance includes less than $0.1 million of which is related to COVID-19 potential impacts on accounts receivable from third-party insurers, government payers, hospitals and patients. Changes to the estimate of the amount of consideration that will not be collected could have a material impact to the revenue recognized. A 0.5% change to the estimated uncollectible percentage could result in approximately a $0.1 million decrease in the revenue recognized for the six months ended June 30, 2020.

Changes in estimates of the transaction price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior period sales for the three and six months ended June 30, 2020 resulted in a decrease to revenue of $0.2 million and increase to revenue of $1.1 million, respectively, and an increase to revenue of $0.09 million and $0.05 million, respectively for the same period in 2019. The changes in estimates recorded during the three and six months ended June 30, 2020, were primarily due to completion of the billing claims process for implants that occurred in late 2019. Upon completion of the billing claims process, the Company concluded that it was probable that a significant reversal in the amount of revenue recognized would not occur.




Epicel
The Company sells Epicel directly to hospitals based on contracted rates stated in the approved contract or purchase order. Similar to MACI, there is no obligation to manufacture skin grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenues from sales of Epicel upon delivery to the hospital at which time the customer is in control of the skin grafts and the claim is billable to the hospital.
Revenue by Product and Customer
The following table and description below shows the products from which the Company generated its revenue:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2020201920202019
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)$9,790  $12,989  $21,218  $22,776  
Implants subject to third party reimbursement sold through a specialty pharmacy (b)2,819  3,459  6,335  6,202  
Implants sold direct based on contracted rates (c)1,806  3,450  4,916  6,676  
Implants sold direct subject to third party reimbursement (d)589  281  1,016  603  
Biopsy kits - direct bill348  557  811  1,099  
Change in estimates related to prior periods (e)(248) 87  1,095  50  
Epicel
     Direct bill (hospital)4,910  5,328  11,301  10,555  
Total revenue$20,014  $26,151  $46,692  $47,961  
(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.
(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period.




Concentration of Credit Risk

The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below.
Revenue ConcentrationAccounts Receivable Concentration
Three Months Ended June 30,Six Months Ended June 30,June 30,December 31,
202020192020201920202019
Epicel6 %6 %10 %8 %3 %2 %

5. Selected Balance Sheet Components
 
Inventory

Inventory as of June 30, 2020 and December 31, 2019:
 
(In thousands)June 30, 2020December 31, 2019
Raw materials$7,853  $6,085  
Work-in-process513  541  
Finished goods51  190  
Inventory$8,417  $6,816  
 
Property and Equipment

Property and Equipment, net as of June 30, 2020 and December 31, 2019:
 
(In thousands)June 30, 2020December 31, 2019
Machinery and equipment$3,279  $3,152  
Furniture, fixtures and office equipment810  775  
Computer equipment and software6,393  6,174  
Leasehold improvements5,256  5,256  
Construction in process1,311  859  
Financing right-of-use lease129  148  
Total property and equipment, gross17,178  16,364  
Less accumulated depreciation(10,138) (9,220) 
$7,040  $7,144  
 
Depreciation expense for the three and six months ended June 30, 2020 was $0.5 million and $1.1 million, respectively, and $0.4 million and $0.7 million for the same periods in 2019.
 
Accrued Expenses

Accrued Expenses as of June 30, 2020 and December 31, 2019 are as follows:
 
(In thousands)June 30, 2020December 31, 2019
Bonus related compensation$2,872  $5,116  
Employee related accruals2,578  1,785  
Other accrued expenses2,525  1,047  
Accrued expenses$7,975  $7,948  




6.  Leases

The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases offsite warehouse space, vehicles and computer equipment. Certain of the Company’s lease agreements include lease payments that are adjusted periodically for an index or rate. The leases are initially measured using the projected payments adjusted for the index or rate in effect at the commencement date. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. All operating lease commitments with a lease term greater than 12 months are recognized as right to use assets and liabilities, on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the balance sheet and for both the three and six months ended June 30, 2020 and 2019, lease expense of less than $0.1 million was recorded related to short-term leases.

The contribution toward the cost of tenant improvements is recorded as a reduction of the operating lease assets. For the three and six months ended June 30, 2020, the Company recognized $1.4 million and $2.9 million of operating lease expense and $1.3 million and $2.6 million for the same periods in 2019.

For both the three and six months ended June 30, 2020 and 2019, the Company recognized less than $0.1 million of financing lease expense. The Company’s leases contain non-lease components and activities that do not transfer a good or service to the Company. The Company elected not to combine lease and non-lease components and therefore non-lease costs were not included in the net lease assets or lease liabilities.

Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:

(In thousands)ClassificationJune 30, 2020December 31, 2019
Assets
OperatingRight-of-use assets$23,800  $25,103  
FinanceProperty and equipment, net129  148  
$23,929  $25,251  
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$5,570  $5,461  
FinanceOther liabilities41  41  
$5,611  $5,502  
Non-current
OperatingOperating lease liabilities$20,881  $22,242  
FinanceOther long-term liabilities93  110  
$20,974  $22,352  


7.     Stock-Based Compensation
 
Stock Option, Restricted Stock Units and Equity Incentive Plans
 
The Company has historically had various stock incentive plans and agreements that provide for the issuance of nonqualified and incentive stock options and restricted stock units as well as other equity awards.  Such awards may be granted by the Company’s Board of Directors to certain of the Company’s employees, directors and consultants. 

Options and restricted stock units granted to employees and non-employees under these plans expire no later than ten years from the date of grant and generally become exercisable over a four year period, under a graded-vesting methodology for stock options and annually on the anniversary grant date for restricted stock units, following the date of grant.  The Company generally issues new shares upon the exercise of stock options or vesting of restricted stock units.

The 2019 Omnibus Incentive Plan (2019 Plan) was approved on May 1, 2019 and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units.  The exercise price of stock options granted under the 2019 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant.  The 2019 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan and the 2017 Omnibus Incentive Plan (Prior Plans), and no new grants have been granted under the Prior Plans after approval.  However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2019 Plan.

The Amended and Restated 2019 Omnibus Incentive Plan (Amended and Restated 2019 Plan) was approved on April 29, 2020. Amendments to the Amended and Restated 2019 Omnibus Plan included increasing the total number of shares of the Company's common stock reserved for issuance under the 2019 Plan by 2,400,000 shares, a revised ratio at which "full- value" awards are counted against the share reserve from 1.25 to 1.4, and extending the term of the plan to April 29, 2030.
 
As of June 30, 2020, there were 4,267,255 shares available for future grant under the Amended and Restated 2019 Plan.

Employee Stock Purchase Plan

Employees are able to purchase stock under the Vericel Corporation Employee Stock Purchase Plan (ESPP). The ESPP allows for the issuance of an aggregate of 1,000,000 shares of common stock of which 672,907 have been issued since the inception of the benefit in 2015. Participation in this plan is available to substantially all employees. The ESPP is a compensatory plan accounted for under the expense recognition provisions of the share-based payment accounting standards. Compensation expense is recorded based on the fair market value of the purchase options at the grant date, which corresponds to the first day of each purchase period and is amortized over the purchase period. In July 2020, employees purchased 44,137 shares resulting in proceeds from the sale of common stock of $0.3 million under the ESPP for the second quarter of 2020.

Service-Based Stock Options
 
During the three and six months ended June 30, 2020, the Company granted service-based options to purchase common stock of 110,750 and 1,296,890, respectively, and 152,500 and 1,638,510, respectively, for the same periods in 2019.  The exercise price of the options is the fair market value per share of common stock on the grant date, generally vest over four years (other than non-employee director options which vest over one year) and have a term of ten years. The Company issues new shares upon the exercise of stock options.  The weighted average grant-date fair value of service-based options granted during the three and six months ended June 30, 2020 was $8.82 and $8.66, respectively and $11.94 and $12.74, respectively, for the same periods in 2019.




Restricted Stock Units

During the three and six months ended June 30, 2020 and 2019, the Company granted 10,700 and 196,836, service-based restricted stock units, respectively and 10,500 and 186,922, respectively, for the same periods in 2019. The restricted stock units vest annually over four years in equal installments commencing on the first anniversary of the grant date (other than non-employee director options which vest over one year from the grant date). The Company issues new shares upon the vesting of restricted stock units. Restricted stock awards are recorded at fair value at the date of grant, which is based on the closing share price on the grant date. Compensation expense is recorded for restricted stock units that are expected to vest based on their fair value at grant date and is amortized over the expected vesting period. The weighted average grant-date fair value of restricted stock units granted during the three and six months ended June 30, 2020 was $14.49 and $11.41, respectively and $16.62 and $17.71, respectively, for the same periods in 2019. The aggregate fair value of restricted stock units granted in the three and six months ended June 30, 2020 was $0.2 million and $2.2 million, respectively and $0.2 million and $3.3 million, respectively, for the same periods in 2019.

As a result of 36,212 units vesting during the three months ended March 31, 2020, 13,872 shares were withheld for payment of taxes on the employee's behalf and retired from the 2019 Plan. During the three months ended June 30, 2020, 10,500 units vested and no shares were withheld for payment of taxes, as no shares are withheld at vesting for shares awarded to the Company's Board of Directors.

Stock Compensation Expense
 
Non-cash stock-based compensation expense (employee stock purchase plan, service-based stock options and restricted stock units) included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table: 
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2020201920202019
Cost of goods sold$568  $716  $997  $976  
Research and development484  886  $1,060  1,410  
Selling, general and administrative3,325  2,581  $6,087  4,424  
Total non-cash stock-based compensation expense$4,377  $4,183  $8,144  $6,810  




8. Cash Equivalents and Investments

Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities as of June 30, 2020 and December 31, 2019:
June 30, 2020
Gross UnrealizedEstimated Fair Value
Amortized CostGainsLossesCredit Losses
Money market funds$44,985  $—  $—  —  $44,985  
Commercial paper3,685  —  —  —  3,685  
Corporate notes8,840  55  —  —  8,895  
U.S. government securities7,776  67  —  —  7,843  
U.S. asset-backed securities4,640  23  —  —  4,663  
$69,926  $145  $—  $—  $70,071  
Classified as:
Cash equivalents$44,985  
Short term investments25,086  
$70,071  
December 31, 2019
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLosses
Money market funds$5,381  $—  $—  $5,381  
Commercial paper11,892  —  —  11,892  
Corporate notes18,369  11  —  18,380  
U.S. government securities11,291  4  —  11,295  
U.S. asset-backed securities10,503  6  —  10,509  
$57,436  $21  $—  $57,457  
Classified as:
Cash equivalents$5,381  
Short-term investments42,829  
Long term investments9,247  
$57,457  

As of June 30, 2020 and December 31, 2019, we held both short-term and long-term investments. Investments classified as short-term have maturities of less than one year. Investments classified as long-term are those that: (i) have a maturity of greater than one year, and (ii) we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale. The Company's investment strategy is to buy short-duration marketable securities with a high credit rating. As of June 30, 2020, all marketable securities held by the Company had remaining contractual maturities of three years or less.

Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders’ equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, Financial Instruments - Credit Losses, to determine if the impairment is credit-related or non credit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and non credit-related impairment is recognized in other comprehensive income, net of taxes. There were no material realized losses on marketable securities for the three and six months ended June 30, 2020 and 2019.

The Company evaluated its investments for impairment under ASC 326. Any allowance for credit losses are recorded at the lower of either the fair market value less book value or the difference between the present value of future cash flows and the book value. As of June 30, 2020, the analysis under ASU 2016-13 and the current macroeconomic impact of the COVID-19 pandemic did not result in material allowances for credit losses. There have been no impairments of the Company’s assets measured and carried at fair value as of June 30, 2020.




9. Fair Value Measurements
 
The Company’s fair value measurements are classified and disclosed in one of the following three categories:
 
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
 
There was no movement between Level 1 and Level 2 or between Level 2 and Level 3 from December 31, 2019 to June 30, 2020. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities and asset-backed securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:
 June 30, 2020December 31, 2019
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$44,985  $44,985  $—  $—  $5,381  $5,381  $—  $—  
Commercial paper3,685  —  3,685  —  11,892  —  11,892  —  
Corporate notes8,895  —  8,895  —  18,380  —  18,380  —  
U.S. government securities7,843  —  7,843  —  11,295  —  11,295  —  
U.S. asset-backed securities4,663  —  4,663  —  10,509  —  10,509  —  
$70,071  $44,985  $25,086  $—  $57,457  $5,381  $52,076  $—  

The fair values of the cash equivalents and marketable securities are based on observable market prices. See note 8 for impact of ASU 2016-13 on the investment valuation.



10.  Net Loss Per Common Share

The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method:
 Three Months Ended June 30,Six Months Ended June 30,
(Amounts in thousands, except per share amounts)2020201920202019
Numerator:  
Net loss$(8,269) $(19,792) $(12,974) $(22,636) 
Denominator:   
Basic and diluted EPS: weighted-average common shares outstanding45,137  43,956  45,031  43,841  
Net loss per share attributable to common shareholders (basic and diluted)$(0.18) $(0.45) $(0.29) $(0.52) 
Anti-dilutive shares excluded from the calculation of diluted earnings per share(a) (amounts in millions):
Stock options6.0  5.6  6.0  5.6  
Restricted stock unit awards0.3  0.2  0.3  0.2  
Warrants—  0.1  —  0.1  
(a) Common equivalent shares are not included in the diluted per share calculation where the effect of their inclusion would be anti-dilutive. 

11. NexoBrid License and Supply Agreements

On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound Ltd. (MediWound) to commercialize NexoBrid® and any improvements to NexoBrid in all countries of North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

NexoBrid is currently in clinical development in North America, and pursuant to the terms of the license agreement, MediWound will continue to conduct all clinical activities described in the development plan to support the BLA filing with the United States Food and Drug Administration (FDA) under the supervision of a Central Steering Committee comprised of members of each party. On June 30, 2020, the Company announced the submission of the BLA to the FDA seeking the approval of NexoBrid. NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic in the United States, European Union and other international markets.

In May 2019, the Company paid MediWound $17.5 million in consideration of the license. The $17.5 million upfront payment was recorded to research and development expense during 2019, as the license was considered in process research and development.  The Company is also obligated to pay MediWound $7.5 million upon U.S. regulatory approval of the BLA for NexoBrid and up to $125 million contingent upon meeting certain sales milestones.  The first sales milestone of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75 million.  The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. The U.S. Biomedical Advanced Research and Development Authority (BARDA) has committed to procure NexoBrid, and the Company will pay a percentage of gross profits to MediWound on initial committed amounts and a royalty on any additional BARDA purchases of NexoBrid beyond the initial committed amount.  The Company also entered into a supply agreement with MediWound under which MediWound will manufacture NexoBrid for the Company on a unit price basis which may be increased based on a published index. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply. As of June 30, 2020, the milestone payments are not yet probable and therefore, not considered a liability.





12. Commitments and Contingencies
 
The Company's purchase commitments consist of minimum purchase amounts of materials used in the Company's cell manufacturing process to manufacture its marketed cell therapy products.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vericel Corporation is a leader in advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets, and a developer of cell therapies for use in the treatment of patients with severe diseases and conditions. We currently market two FDA approved autologous cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. We also market Epicel® (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA). We hold an exclusive license for North America commercial rights to NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns.
COVID-19

The novel coronavirus (COVID-19) outbreak was first reported by China in late December 2019 and rapidly spread globally. The World Health Organization (WHO) declared the outbreak a pandemic on March 11, 2020 and the President of the United States declared a national health emergency. Subsequently most states' governments, including those in Massachusetts and Michigan where the Company's operations are located, issued orders requiring businesses that do not conduct essential services to temporarily close their physical workplaces to employees and customers. The status of such orders varies on a state-by-state basis and is likely to continue to vary. Because Vericel is deemed an essential business the Company is exempt from these state orders in their current form.

Notwithstanding being an essential business, the Company’s business and operations have been, and are expected to continue to be, adversely impacted by the effects of COVID-19 as a result of various factors including, without limitation, patients’ potential reluctance to undergo elective surgical procedures, healthcare facility restrictions regarding elective surgical procedures, the recent economic downturn due to the pandemic, the imposition of related public health measures and travel and business restrictions and disruptions to the ability of the our employees to perform their jobs.

The implantation of MACI is an elective surgical procedure. On March 13, 2020 and March 14, 2020, the American College of Surgeons and the United States Surgeon General, respectively, recommended that each hospital, health system, and surgeon minimize, postpone, or cancel electively scheduled surgeries, which has resulted in a significant reduction in MACI sales. The stated purpose for these recommendations was that every elective surgery could spread COVID-19 within a facility, use up personal protective equipment (PPE) which may be needed by healthcare workers treating COVID-19 patients, and burden hospital workforce who may be needed to respond to COVID-19. These recommendations were followed by numerous state level executive orders either banning or partially banning elective surgeries. By early April 2020, 45 states, representing over 95% of total U.S. surgical capacity had issued either mandates or recommendations and guidelines suspending elective procedures. These restrictions began to ease in May and, by the end of June 2020, states representing an estimated 90% total U.S. surgical capacity had lifted restrictions suspending elective procedures. As a result of these restrictions, beginning in mid-March 2020, the Company started to experience a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders. The impact has varied over time and has been heavily correlated with the amount of surgical capacity under restrictions.

Although many states have eased restrictions, as the COVID-19 virus has spread across the country other states have implemented or re-imposed restrictions on elective surgical procedures, and certain facilities, independent of state restrictions, have imposed restrictions on elective surgeries. The restrictions that currently are in force vary significantly. Some states and facilities have put in place restrictions which apply only to surgeries which require an overnight stay in a hospital and thus have little impact on MACI as over 95% of MACI surgeries do not result in an overnight stay. However, other state and facility restrictions do cover all elective surgeries. Similarly, some restrictions do not cover ambulatory surgery centers where approximately 50% of MACI procedures are performed, while others cover all elective surgeries regardless of site. It is likely that restrictions will continue to be both lifted and re-imposed as regional COVID-19 rates fall and rise. The Company’s MACI business will continue to be negatively impacted so long as multiple state orders and/or facilities restrict elective surgical


procedures. Although we believe Epicel may be less directly impacted by COVID-19 given the critical nature of severe burn injuries, trauma injury admissions have reportedly been reduced as a result of the various COVID-19 related restrictions and potential reluctance on the part of patients to seek care in light of COVID-19. In addition, any prolonged material disruption of the Company’s employees, distributors, suppliers or customers will impact its sales and operating results that could lead to potential inventory write-offs, credit losses in accounts receivable, or impairment of long-lived assets.

We have implemented a number of initiatives to maintain our near-term and future growth opportunities while supporting patients and reducing non-essential discretionary spending, including the imposition of a temporary moratorium on new employee hiring. In March 2020, we initiated protective measures in response to the COVID-19 outbreak including the canceling of all business-related international travel, requesting employees limit non-essential personal travel, enhancing our facilities’ janitorial and sanitary procedures and the provision of certain personal protective equipment to employees working in our offices, encouraging employees to work from home to the extent their job function enables them to do so, limiting third-party access to our facilities, encouraging the use of virtual meetings, and modifying the manner and schedule of on-site production activities. We have also instituted daily health screening for all of our employees. We are reviewing all of these measures on a daily basis as the situation evolves, and we will take additional actions to the extent they are needed in the future.

We continue to manufacture MACI and Epicel and are maintaining a significant safety stock of all key raw materials.  We do not expect current supply chain interruptions will impact the Company’s ongoing manufacturing operations.  With respect to customer delivery, MACI final product has an established shelf life of 6 days and established shipping shelf life of 3 days.  Currently, MACI is picked up by courier and shipped by commercial air or ground transportation to our customer’s location.  Epicel final product has an established shelf life of 24 hours and is hand carried to customer hospital sites by courier. Transportation is primarily commercial or charter airline.  Although we have not experienced material shipping delays or increased costs to date, significant disruption of air travel could result in the inability to deliver MACI or Epicel final products to customer sites within appropriate timeframes, which could further adversely impact our business. There is no expected impact of COVID-19 on the Company's distributors or third-party service providers' ability to manage patient cases.

For a discussion of additional risks associated with COVID-19, please see Item 1A. Risk Factors.
 
Manufacturing
 
We have a cell-manufacturing facility in Cambridge, Massachusetts which is used for U.S. manufacturing and distribution of MACI and Epicel.
 
Product Portfolio
 
Our marketed products include two FDA-approved autologous cell therapies: MACI, a third-generation autologous implant for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients and Epicel, a permanent skin replacement for adult and pediatric patients with deep dermal or full thickness burns greater than or equal to 30% of TBSA. Both products are currently marketed in the U.S. In addition, we have entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in all countries of North America. NexoBrid is currently in clinical development in North America. Until 2017, our active product candidate portfolio included ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to dilated cardiomyopathy, or DCM. We have no current plans to continue the development of ixmyelocel-T.

MACI
 
MACI is a third-generation product for autologous chondrocyte implantation (ACI), a class of methods for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

In the U.S., the physician target audience which repairs cartilage defects is concentrated and is partly comprised of a group of orthopedic surgeons who self-identify and/or have a formal specialty as sports medicine physicians. We believe this target audience is approximately 3,000 physicians. In addition to sports medicine physicians there is a population of approximately 8,000 general orthopedic surgeons who treat cartilage injuries, although typically at a much lower average volume relative to the sports medicine segment. As of June 30, 2020, we have expanded the number of MACI sales representatives to 76 to enable the sales force to call on 2,000 of the general orthopedic surgeons. Amid the COVID-19 outbreak, the sales representatives and clinical support specialists are adapting their practices to support physician education initiatives using virtual tools in regions where executive orders or hospital restrictions preclude their physical presence. MACI sales and clinical representatives are continuing to provide on-site assistance for MACI surgical procedures, so long at the representative’s presence is in accordance with governmental orders and the policies and procedures of the relevant hospital or surgical center. Most private payers have a


medical policy that covers treatment with MACI with the top 30 largest commercial payers having a formal medical policy for MACI or ACI in general. Even for private payers which have not yet approved a medical policy for MACI, for medically appropriate cases, we often obtain approval on a case-by-case basis. For the three and six months ended, June 30, 2020, net revenues for MACI were $15.1 million and $35.4 million, respectively, and $20.8 million and $37.4 million, respectively, for the same periods in 2019.
 
Epicel
 
Epicel is a permanent skin replacement for deep dermal or full thickness burns greater than or equal to 30% of total body surface area (TBSA).  Epicel is regulated by the Center for Biologics Evaluation and Research, or CBER of the U.S. Food and Drug Administration, or FDA under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns. Epicel was designated as a Humanitarian Use Device (HUD) in 1998 and a Humanitarian Device Exception (HDE) application for the product was submitted in 1999.  HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S. Under an HDE approval, a HUD cannot be sold for an amount that exceeds the cost of research and development, fabrication and distribution unless certain conditions are met.
 
A HUD is eligible to be sold for profit after receiving HDE approval if the device meets certain eligibility criteria, including where the device is intended for the treatment of a disease or condition that occurs in pediatric patients and such device is labeled for use in pediatric patients. If the FDA determines that a HUD meets the eligibility criteria, the HUD is permitted to be sold for profit so long as the number of devices distributed in any calendar year does not exceed the Annual Distribution Number (ADN). The ADN is defined as the number of devices reasonably needed to treat a population of 8,000 individuals per year in the U.S.

On February 18, 2016, the FDA approved our HDE supplement to revise the labeled indications of use to specifically include pediatric patients. The revised product label also now specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a physician-sponsored study comparing outcomes in patients with massive burns treated with Epicel relative to standard care. Because of the change in the label to specifically include use in pediatric patients, Epicel is no longer subject to the HDE profit restrictions. In conjunction with adding the pediatric labeling and meeting the pediatric eligibility criteria, the FDA has determined the ADN number for Epicel is 360,400 which is approximately 45 times larger than the volume of grafts sold in 2018. We currently have a ten-person field force comprised of 7 sales representatives and 3 clinical support specialists which is adapting its practices to support physician education initiatives using virtual tools in regions where executive orders or hospital restrictions preclude their physical presence. Epicel sales and clinical representatives are continuing to provide on-site assistance for Epicel surgical procedures, so long at the representative’s presence is in accordance with governmental orders and the policies and procedures of the relevant hospital or surgical center. For the three and six months ended June 30, 2020, net revenues for Epicel were $4.9 million and $11.3 million, respectively and $5.3 million and $10.6 million, respectively, for the same periods in 2019.

NexoBrid

Our preapproval stage portfolio includes NexoBrid, a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns. NexoBrid is currently in clinical development in North America, and on June 30, 2020, we announced the submission of a BLA to the FDA seeking the approval of NexoBrid. NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic in the United States, European Union and other international markets. Pursuant to the terms of our existing license agreement, MediWound will continue to conduct all clinical activities described in the development plan to support the BLA with the FDA under the supervision of a Central Steering Committee comprised of members of each party.

Ixmyelocel-T

Our preapproval stage portfolio also includes ixmyelocel-T, a unique multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. This multicellular therapy was developed for the treatment of advanced heart failure due to DCM.

On September 29, 2017, the FDA indicated we would be required to conduct at least one additional Phase 3 clinical study to support a BLA for ixmyelocel-T.  Given the expense required to conduct further development and our focus on growing our existing commercial products, at this time we have no current plans to initiate or fund a Phase 3 trial on our own.




Results of Operations
 
Net Loss
 
Our net loss for the three and six months ended June 30, 2020 totaled $8.3 million and $13.0 million, respectively, and $19.8 million and $22.6 million, respectively, for the same periods in 2019.
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2020201920202019
Net revenues$20,014  $26,151  $46,692  $47,961  
Cost of product sales8,660  9,022  18,582  17,662  
Gross profit 11,354  17,129  28,110  30,299  
Total operating expenses19,712  37,329  41,544  53,857  
Loss from operations(8,358) (20,200) (13,434) (23,558) 
Other income89  408  460  922  
Net loss$(8,269) $(19,792) $(12,974) $(22,636) 
 
Net Revenues

  Net revenues decreased for the three and six months ended June 30, 2020 compared to the same periods in 2019 primarily due to the effects of the COVID-19 pandemic. Beginning in mid-March 2020, the Company experienced a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders. Due to state and local restrictions on elective surgery the majority of US surgical capacity was unavailable during April 2020 with some recovery occurring in May in certain geographies. The decrease in MACI volume largely tracked with the available surgical capacity across the country in April and May. By June, the restrictions on elective surgeries had been eased across most states but capacity still lagged pre-COVID levels due to new procedures in place at hospitals such as testing patients before treatment and increased cleaning time between patient treatments.

Net revenues for the three and six months ended June 30, 2020 and 2019 are shown below.
 
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (In thousands)2020201920202019
MACI$15,104  $20,823  $35,391  $37,406  
Epicel4,910  5,328  11,301  10,555  
 $20,014  $26,151  $46,692  $47,961  
 
 Seasonality. Over the last four years ACI sales volumes from the first through the fourth quarter have on average represented 19% (16%-24% range), 23% (21%-25% range), 22% (20%-23% range) and 36% (32%-38% range) respectively, of total annual volumes. MACI orders are consistently stronger in the fourth quarter due to several factors including insurance deductible limits and the time of year patients prefer to start rehabilitation. However, given the disruption due to COVID-19 related elective surgery restrictions seasonality patterns in 2020 are not expected to follow historical trends. Due to the low incidence and sporadic nature of severe burns, Epicel revenue has inherent variability from quarter to quarter and does not exhibit significant seasonality.  Over the past four years, Epicel revenue in a single quarter has ranged from as high as 34% to as low as 17% of annual revenue.




Gross Profit and Gross Profit Ratio 
Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2020201920202019
Gross profit$11,354  $17,129  $28,110  $30,299  
Gross profit %57 %66 %60 %63 %
 
Gross profit decreased for the three and six months ended June 30, 2020 compared to the same period in 2019 primarily due to the decrease in revenue caused by the COVID-19 pandemic.

Research and Development Costs 
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2020201920202019
Research and development costs$3,226  $21,070  $6,989  $24,078  
 
The following table summarizes the approximate allocation of cost for our research and development projects:
 
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2020201920202019
ACI$1,657  $2,231  $3,753  4,390  
Epicel686  1,091  1,713  1,937  
Nexobrid876  17,748  1,507  17,748  
Other7  —  16  3  
Total research and development costs$3,226  $21,070  $6,989  $24,078  
 
Research and development expenses for the three months ended June 30, 2020 were $3.2 million compared to $21.1 million for the same period in 2019. The prior period included $17.5 million for the upfront payment to MediWound for the North American rights to NexoBrid.

Research and development expenses for the six months ended June 30, 2020 were $7.0 million compared to $24.1 million for the same period in 2019. The prior period included $17.5 million for the upfront payment to MediWound for the North American rights to NexoBrid.

Selling, General and Administrative Costs 
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2020201920202019
Selling, general and administrative costs$16,486  $16,259  $34,555  $29,779  
 
Selling, general and administrative expenses for the three months ended June 30, 2020 were $16.5 million compared to $16.3 million for the same period in 2019. The increase in selling, general and administrative expenses during the three months ended June 30, 2020 is due primarily to an incremental $0.9 million in MACI sales force expenses due to the sales force expansion in the second quarter of 2020 and $0.7 million of additional stock compensation expenses, which were largely offset by a reduction in variable and discretionary spend as a result of the COVID-19 pandemic.

Selling, general and administrative expenses for the six months ended June 30, 2020 increased to $34.6 million from $29.8 million for the same period in 2019. The increase in selling, general and administrative expenses during the six months ended June 30, 2020 is due primarily to an incremental $1.6 million in MACI sales force expenses driven by the sales force expansion in the second quarter of 2020 and the full quarter impact of hires made in the second quarter of 2019, $1.6 million of additional stock compensation expense and $0.6 million of incremental reimbursement support costs.





Other Income (Expense) 
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2020201920202019
Net interest income$146  $426  $450  $904  
Other income (expense)(57) (18) 10  18  
Total other income (expense)$89  $408  $460  $922  
 
The decrease in interest income for the three and six months ended June 30, 2020 compared to the same period in 2019 is due primarily to a decrease in interest income as a result of lowering our investment balance and decreasing rates of returns on our investments in various marketable debt securities compared to the prior period.

Stock Compensation
 
Non-cash stock-based compensation expense included in cost of goods sold, research and development expenses and general, selling and administrative expenses is summarized in the following table: 
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2020201920202019
Cost of goods sold$568  $716  $997  $976  
Research and development484  886  $1,060  1,410  
Selling, general and administrative3,325  2,581  $6,087  4,424  
Total non-cash stock-based compensation expense$4,377  $4,183  $8,144  $6,810  

The increase in stock-based compensation expense for the three and six months ended June 30, 2020 is due primarily to fluctuations in stock prices which impacts the fair value of the options and restricted stock units awarded and the expense recognized in the period.


Liquidity and Capital Resources
 
Our primary focus has been to invest in our existing commercial business with the goal of growing revenue. We have raised significant funds in order to complete our product development programs and to market and commercialize our products.  To date, we have financed our operations primarily through cash received through Epicel and MACI sales and public and private sales of our equity securities.

Our cash and cash equivalents totaled $55.7 million and short-term investments totaled $25.1 million as of June 30, 2020. The $1.7 million of cash provided by operations during the six months ended June 30, 2020 was the result of cash collections and a decrease in accounts receivable of $8.5 million from a decrease in sales volume from prior quarter and collections on prior period sales, including noncash charges of $8.1 million in stock compensation expense and $1.1 million in depreciation and amortization expense offset by a $13.0 million net loss.

Our cash and cash equivalents totaled $14.0 million and short term investments totaled $52.0 million at June 30, 2019. The $18.2 million of cash used by operations during the six months ended June 30, 2020 was largely the result of our net loss of $22.6 million which included a cash outflow of $17.5 million for the upfront payment for the NexoBrid License. The net loss was offset by noncash charges including $6.8 million in stock compensation expense, and $0.7 million in depreciation and amortization expense.

The change in cash provided by investing activities during the six months ended June 30, 2020 is the result of $32.8 million of investment maturities offset by $5.7 million in short term investment purchases and property plant and equipment purchases of $1.2 million primarily for manufacturing upgrades through June 30, 2020. The cash provided by investing activities for the six months ended June 30, 2019 is the result of $32.4 million in short term investments purchases offset by $45.5 million of maturities and property plant and equipment purchases of $1.2 million primarily for manufacturing upgrades and leasehold improvements.



The change in cash provided from financing activities is the result of net proceeds from the exercise of stock options of $1.4 million, slightly offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $0.2 million during the six months ended June 30, 2020. The change in cash provided from financing activities is the result of proceeds from the exercise of stock options of $2.1 million during the six months ended June 30, 2019.

We believe that, based on our current cash on hand, cash equivalents and investments will be sufficient to support our current operations through at least 12 months from the issuance of these financial statements. However, the continuing effects of the COVID-19 pandemic may require us to engage in layoffs, furloughs, and/or reductions in salary, all of which may result in irrecoverable losses of customers and significantly impact long-term liquidity. We have implemented a number of initiatives to maintain our near-term and future growth opportunities while supporting patients and reducing non-essential discretionary spending.

If elective surgery restrictions are reinstated, we may need to access additional capital; however, we may not be able to obtain financing on acceptable terms or at all. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access financing as and when needed. The terms of any financing may adversely affect the holdings or the rights of our shareholders. Actual cash requirements may differ from projections and will depend on many factors, including the ultimate duration of the effects of the COVID-19 pandemic, the level of future research and development, the scope and results of ongoing and potential clinical trials, the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, costs of possible acquisition or development of complementary business activities, and the cost to market our products.
 
Off-Balance Sheet Arrangements

At June 30, 2020, we were not party to any off-balance sheet arrangements.

Critical Accounting Policies
 
Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these condensed consolidated financial statements requires the application of appropriate technical accounting rules and guidance, as well as the use of estimates. The application of these policies necessarily involves judgments regarding future events. These estimates and judgments, in and of themselves, could materially impact the condensed consolidated financial statements and disclosures based on varying assumptions. The accounting policies discussed in our Form 10-K, filed with the SEC on February 25, 2020 (Annual Report), for the fiscal year ended December 31, 2019 are considered by management to be the most important to an understanding of the consolidated financial statements because of their significance to the portrayal of our financial condition and results of operations. There have been no material changes to that information disclosed in our Annual Report during the six months ended June 30, 2020.

Forward-Looking Statements

This report, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act).  Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking.  These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “estimates,” “plans,” “projects,” “trends,” “opportunity,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “target,” “achieve,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.  Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them.  The factors described in our Annual Report, among others, could have a material adverse effect upon our business, results of operations and financial conditions.
 
Because the factors referred to in the preceding paragraph could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements we make, you should not place undue reliance on any such forward-looking statements.  Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events.  New factors emerge from time to time, and it is not possible for us to predict which factors will arise.  In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  These forward-looking statements include statements regarding:


 
•manufacturing and facility capabilities;
•potential strategic collaborations with others;
•future capital needs and financing sources;
•adequacy of existing capital to support operations for a specified time;
•reimbursement for our products;
•submission of a BLA for NexoBrid to the FDA;
•product development and marketing plans;
•features and successes of our therapies;
•clinical trial plans, including publication thereof;
•the effects of the COVID-19 pandemic on our business, including economic slowdowns or recessions, impact to our operations or to the healthcare industry generally, which could reduce demand for our products;
•anticipation of future losses;
•replacement of manufacturing sources;
•commercialization plans; or
•revenue expectations and operating results.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
 
As of June 30, 2020, we held marketable debt securities, which are classified as available-for-sale and carried at fair value in the accompanying consolidated balance sheet included in this Form 10-Q. The fair value of our cash equivalents and marketable securities is subject to changes in market interest rates. Our earnings and cash flows are subject to fluctuations due to changes in interest rates, principally in connection with our investments in marketable debt securities. We do not believe we are materially exposed to changes in interest rates related to our investments, and we do not currently use interest rate derivative instruments or hedging transactions to manage exposure to interest rate changes of our investments. We estimate that a 100 basis point, or 1%, unfavorable change in interest rates would have resulted in approximately a $0.1 million and $0.3 million decrease in the fair value of our investment portfolio as of June 30, 2020 and December 31, 2019, respectively.

We have evaluated the potential credit risk exposure for our accounts receivable and available-for sale investment securities in accordance with ASC 326, Financial Instruments - Credit Losses. See note 4 and note 8, for further discussion.

We operate in the United States only. We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities due to vendors in countries outside the United States which are typically paid in Euro. We do not enter into hedging transactions and do not purchase derivative instruments.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of its certifying officers, evaluated the effectiveness of the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation as of June 30, 2020, the Company’s certifying officers concluded that the Company’s disclosure controls and procedures were effective.

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its “Certifying Officers”), as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended June 30, 2020, there were no material changes made in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). The effects of the COVID-19 pandemic did not have a material impact on our internal control over financial reporting.



PART II - OTHER INFORMATION
Item 1. Legal Proceedings
 
We are currently not party to any material legal proceedings, although from time to time we may become involved in disputes in connection with the operation of our business.
 
Item 1A. Risk Factors
 
Certain risks described below update the risk factors discussed in Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and expound upon and amend the specific risks resulting from the COVID-19 pandemic, which were first discussed by the Company in its Form 8-K filed on April 2, 2020, and which were updated in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020. Each of these risks, as well as those discussed in our previous filings could materially affect our business, financial condition, results of operations, or cash flows. The risks described below and in our previous filings are not the only risks we face. Additional risks and uncertainties not currently known or currently deemed to be immaterial also may materially and adversely affect our business, financial condition, results of operations or cash flows.

The current pandemic of COVID-19 and the future outbreak of other highly infectious or contagious diseases, could seriously harm our research, development and commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.

Broad-based business or economic disruptions could adversely affect our ongoing or planned research, development and commercialization activities. For example, in December 2019, an outbreak of a novel strain of coronavirus originated in Wuhan, China, and has since spread globally. To date, the COVID-19 pandemic has caused significant disruptions to the U.S. and global economy and has contributed to significant volatility in financial markets. The global impact of the outbreak is continually evolving and, as the virus spreads and additional cases are identified, many countries, including the U.S., have reacted by instituting quarantines, restrictions on travel and mandatory closures of businesses. Since March 2020, certain states and cities, including where we or the third parties with whom we engage operate, have reacted by instituting quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of business that may continue to operate, and/or restrictions on the types of construction projects that may continue. For example, on March 23, 2020, the Governor of Massachusetts ordered all individuals living in the Commonwealth of Massachusetts to stay at their place of residence for an indefinite period of time (subject to certain exceptions to facilitate authorized necessary activities) to mitigate the impact of the COVID-19 pandemic. The Governor of Michigan issued a substantially similar executive order applicable to Michigan residents on March 23, 2020. In both instances, the executive orders exempted certain individuals needed to maintain continuity of operations of critical infrastructure sectors as determined by the federal government, and the governors of both Massachusetts and Michigan have clarified that biopharmaceutical research and development is essential and exempt. Since March, the steps taken by many state and local officials have helped to slow the spread of the virus in certain regions of the United States. As a result, some states – including Massachusetts and Michigan – have instituted plans to ease the restrictions on workplaces and individuals in an effort to reopen the economies of those regions. On May 18, 2020, the governor of Massachusetts issued an order and report outlining the phased reopening of physical workplaces. Similarly, on May 18, 2020, the State of Michigan issued Executive Orders 2020-91 and 2020-92 allowing the re-opening of some businesses that had been formerly ordered to be closed. Both state orders require businesses to implement mandatory training and protection measures for their employees who continue to work in the office setting.

In March 2020, we put in place a comprehensive workplace protection plan, which institutes protective measures in response to the COVID-19 pandemic. These measures include mandatory employee training on social distancing and hygiene protocols, conducting daily health screenings of all employees, vendors and visitors entering our facilities, canceling of all commercial international travel, requesting that employees limit non-essential personal travel, enhancing our facilities’ janitorial and sanitary procedures, making certain physical modifications and enhancements to our facilities to enable effective social distancing among employees, providing certain personal protective equipment to employees working in our offices, encouraging employees to work from home to the extent their job function enables them to do so, limiting third-party access to our facilities, encouraging the use of virtual employee meetings, modifying the manner and schedule of on-site production activities, and providing guidance to our field-based commercial teams concerning their communications and contact with customers and healthcare professionals. We are reviewing these measures regularly as the situation evolves, and we are likely to take additional actions as we learn more and as instruction is provided by national, state and local governmental agencies. Both these existing measures and any future actions we take may result in continued disruption to our business.



The extent to which the COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious disease, impacts our preclinical studies, clinical trial operations and current or future commercialization efforts will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of such pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. The rapid development and fluidity of this situation precludes any prediction as to the full adverse impact of the COVID-19 pandemic. Nevertheless, the COVID-19 pandemic may adversely affect our business, financial condition and results of operations, and it may have the effect of heightening many of the risks described herein, including the below.

•The implantation of MACI is an elective surgical procedure. On March 13, 2020 and March 14, 2020, the American College of Surgeons and United States Surgeon General, respectively, recommended that each hospital, health system, and surgeon minimize, postpone, or cancel electively scheduled surgeries, which resulted in a reduction in MACI sales. The stated purpose for these recommendations was that every elective surgery could spread COVID-19 within a facility, use up personal protective equipment (PPE) which may be needed by healthcare workers treating COVID-19 patients, and burden hospital workforce who may be needed to respond to COVID-19. These recommendations were followed by numerous state-level executive orders either banning or partially banning elective surgeries. By April 3, 2020, 31 U.S. states had issued executive mandates calling for the suspension of elective or non-essential surgeries.

•As a result of these restrictions, beginning in mid-March 2020, the Company started to experience a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders. Those cancellations negatively impacted the Company’s results of operations for the first and second quarters of 2020. Continued and prolonged material disruption of the Company’s employees, distributors, suppliers or customers will impact its sales and operating results that could lead to potential impairments to inventory and accounts receivable. As the number of COVID-19 cases began to decrease in certain parts of the United States, many states began easing their respective moratoriums on elective surgeries, however, the recent resurgence of the virus in certain parts of the country have led to the re-imposition of elective surgical procedure restrictions including Florida, California, Mississippi, Tennessee, Arizona and Texas. The Company’s MACI business will continue to be negatively impacted as long as multiple state orders remain in effect restricting elective surgical procedures. We believe Epicel may be less directly impacted by the pandemic given the critical nature of severe burn injuries, however trauma injury admissions have been reported to be reduced due to the various COVID-19 related restrictions. Given the rare nature of the severe burns Epicel treats, it is difficult to ascertain whether a similar decline is occurring with severe burns.

•We are currently conducting the PEAK (A Study of MACI in Patients Aged 10 to 17 Years with Symptomatic Chondral or Osteochondral Defects of the Knee) Study at ten (10) sites throughout the United States. Although it is premature to draw any conclusions at this time, given the reduction of elective surgical procedures as a result of COVID-19, the Company anticipates a decreased rate of patient enrollment to the PEAK Study. Additionally, the PEAK Study or another of our clinical trials may experience difficulties associated with patient visits and study monitoring, which may be paused or delayed due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including closure of site access to outside medical monitors, quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trials, interruption or delays in the operations of the FDA, heightened exposure of patients, principal investigators and site staff to COVID-19 if an outbreak occurs in their geography, or other reasons related to the COVID-19 pandemic. Further, patients who are already recruited into our clinical trials may be unable or unwilling to attend follow-up visits within the timelines specified in our trial protocols, potentially impacting our ability to meet our clinical trial endpoints. An outbreak may also affect employees of third-party contract research organizations located in affected geographies that we rely upon to carry out our clinical trials.

•We continue to manufacture MACI and Epicel and we maintain a significant safety back-up of all key raw materials. We do not expect current supply chain interruptions will impact the Company’s ongoing manufacturing operations. However, we currently rely on third parties to, among other things, manufacture and supply raw materials, which are used to produce our products, and supply other goods and services to run our business. If any such third parties in our supply chain are adversely impacted by current or future restrictions resulting from the COVID-19 pandemic for an extended period of time, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture our products and product candidates and conduct our research and development operations, or for potential commercial launch of any of our product candidates, if approved. With respect to customer delivery, MACI final product has an established shelf life of 6 days and established shipping shelf life of 3 days. Currently, MACI is picked-up by courier and shipped by commercial air or


ground transportation to our customers’ locations. Epicel final product has an established shelf life of 24 hours and is hand carried to customer hospital sites by courier. Transportation is primarily commercial or charter airline. Although we have not experienced material shipping delays or increased costs to date, significant disruption of air travel could result in the inability to deliver MACI or Epicel final products to customer sites within appropriate timeframes, which would have a material adverse effect on our business and results of operations.

•We have closed much of our office space and requested that most of our personnel, including the majority of our administrative employees, work remotely. Our continued reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. We continue to manufacture MACI and Epicel but have largely restricted on-site staff to only those personnel and contractors who must perform essential activities related to the manufacture, production and delivery of our products. However, the continued spread or resurgence of COVID-19 or similar infectious diseases in the U.S. may lead to further government-imposed quarantines and restrictions, which may result in the closure of our administrative offices, with our employees working outside of our offices for an extended period of time. These actions may also result in the disruption of our manufacturing operations, which are currently accomplished within our administrative offices. Additionally, such quarantines and restrictions may adversely affect our ability to conduct certain product enhancement and business development activities.

•Our continued reliance on personnel working from home may also increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, institutional review boards and ethics committees, third party contractors and suppliers, clinical trial sites and other important agencies and contractors. Our business operations may be further disrupted if any of our employees, officers or board of directors contract an illness related to COVID-19 and are unable to perform their duties. For example, COVID-19 illness could impact members of management or our board of directors resulting in absenteeism from management meetings or meetings of the directors or committees of directors, and making it more difficult for management to effectively oversee our daily operations, or to convene the quorums of the full board of directors or its committees needed to conduct meetings for the management of our affairs.

•A spread or resurgence of the COVID-19 virus, may cause our employees, and employees of third-party contractors and licensees, including MediWound, responsible for conducting research and development activities to be unable to access laboratories and places of business for an extended period of time as a result of the temporary closure of such workspaces and the possibility that governmental authorities further modify current restrictions. As a result, this could delay timely completion of ongoing clinical trials or preclinical activities, and our ability to select future development candidates.

•NexoBrid is currently a pre-commercial product in North America. On June 30, 2020, the Company announced that it submitted a BLA to the FDA seeking marketing approval for Nexobrid in the United States. However, health regulatory agencies globally, including the FDA, may experience disruptions in their operations as a result of the continued spread of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials or consider our regulatory submissions and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development, study and ultimate commercialization of our product candidates.

•The trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the continued spread or resurgence of the COVID-19 pandemic could materially and adversely affect our business and the value of our common stock.

•Given the economic downturn and increased unemployment in the U.S. related to COVID-19, millions of individuals have lost and may lose their employer-based insurance coverage, which may adversely affect our ability to commercialize our products. In addition, market disruption and rising unemployment caused by the COVID-19 pandemic may lead to delays in obtaining insurance coverage and reimbursement of newly approved products as well as an increase in the numbers of uninsured patients and patients who may no longer be able to afford their co-insurance or co-pay obligations. These factors may lead to decreased utilization of our products, which could reduce revenue. The outbreak of COVID-19 may also negatively impact our commercialization strategy for our products and product


candidates, if approved. Hospitals and other medical institutions have reduced and diverted staffing, diverted resources to patients suffering COVID-19 and limited hospital access for non-patients, which may include our sales personnel. Hospitals may continue and increase these and similar measures in the future should the COVID-19 virus continue to spread or surge in certain areas. In addition, continued travel restrictions due to COVID-19 could impact the ability of our sales personnel to travel to customers. We have encouraged our sales personnel to conduct many of their interactions with physicians and patients through the use of webinars, telemedicine, direct-to-consumer advertising and social media. These circumstances may adversely affect the ability of our sales professionals to effectively market our products to physicians in the future, which may have a negative impact on our potential sales and our market penetration.

If any of these risks related to the impact of the COVID-19 pandemic were to occur, our preclinical activities, clinical development progress, data and timelines, commercialization efforts including any potential revenue from sales, supply chain continuity, and general business operations, could be delayed and/or materially harmed and our business, prospects, financial condition, and results of operations would suffer as a result. The extent to which the current pandemic, or a future pandemic, impacts our business and operations will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and governmental actions to contain the outbreak or treat its impact, which are highly uncertain and cannot be predicted with confidence.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
 
Not applicable.

Item 3.  Defaults Upon Senior Securities
 
Not applicable.

Item 4. Mine Safety Disclosures
 
Not applicable.
 
Item 5. Other Information
 
Not applicable.
 


Item 6.  Exhibits
 
The Exhibits listed in the Exhibit Index are filed as a part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX
 
Exhibit No. Description
   
31.1**
31.2**
32.1**
32.2**
101.INS**Inline XBRL Instance Document
101.SCH**Inline XBRL Taxonomy Extension Schema Document
101.CAL**Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB**Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE**Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF**Inline XBRL Taxonomy Extension Definition Linkbase Document
104
 
** Filed herewith.



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: August 5, 2020
 
 VERICEL CORPORATION
  
  
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
  
  
 /s/ GERARD MICHEL
 Gerard Michel
 Chief Financial Officer and Vice President, Corporate Development
 (Principal Financial Officer)



 EX-31.1 2 ex311ceocertificationq.htm EX-31.1 CEO CERTIFICATION Document

EXHIBIT 31.1
 
CERTIFICATION
 
I, Dominick C. Colangelo, certify that:
 
1.                        I have reviewed this Quarterly Report on Form 10-Q of Vericel Corporation;
 
2.                        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.                        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.                        The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.                        The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2020
 
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
 


 EX-31.2 3 ex312cfocertificationq.htm EX-31.2 CFO CERTIFICATION Document

EXHIBIT 31.2
 
CERTIFICATION
 
I, Gerard J. Michel, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Vericel Corporation;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2020
 
 /s/ GERARD J. MICHEL
 Gerard J. Michel
 Chief Financial Officer and Vice President
 of Corporate Development
 (Principal Financial and Accounting Officer)
 


 EX-32.1 4 ex321ceosoxcertificati.htm EX-32.1 CEO SOX CERTIFICATION Document

EXHIBIT 32.1
 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Vericel Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), the following:
 
(1)         The Report fully complies with the requirements of section 13(a) and 15(d) of the Securities Exchange Act of 1934; and
 
(2)         The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:  August 5, 2020
 
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
 
A signed original of this written statement required by Section 906 has been provided to Vericel Corporation and will be retained by Vericel Corporation and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-32.2 5 ex322cfosoxcertificati.htm EX-32.2 CFO SOX CERTIFICATION Document

EXHIBIT 32.2
 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Vericel Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), the following:
 
(1)         The Report fully complies with the requirements of section 13(a) and 15(d) of the Securities Exchange Act of 1934; and
 
(2)         The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:  August 5, 2020
 
 /s/ GERARD MICHEL
 Gerard Michel
 Chief Financial Officer and Vice President, Corporate Development
 (Principal Financial Officer)
 
A signed original of this written statement required by Section 906 has been provided to Vericel Corporation and will be retained by Vericel Corporation and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.SCH 6 vcel-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Basis of Presentation - (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Basis of Presentation - Supplementary cash flows information (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Basis of Presentation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2109104 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Revenue - (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Revenue - Schedules of concentration of risk (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - Selected Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Selected Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Selected Balance Sheet Components - Schedule of inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2119106 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Leases - Assets And Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Stock-Based Compensation - Schedule of non-cash stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2130109 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2133110 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 2334308 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2435416 - Disclosure - Net Loss Per Common Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2136111 - Disclosure - Nexobrid License and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 2437417 - Disclosure - Nexobrid License and Supply Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2138112 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vcel-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vcel-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vcel-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Restricted stock units granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Leases Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Other Nonoperating Income (Expense) Short term investments Investments Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments City Area Code City Area Code Prepaid and other current assets Increase (Decrease) in Other Current Assets Product Information [Line Items] Product Information [Line Items] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of product sales Cost of Goods and Services Sold Estimated Fair Value Debt securities, fair value Debt Securities, Available-for-sale Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Cash Equivalents and Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Sales Initial milestone License Agreement, Initial Milestone, Sales License Agreement, Initial Milestone, Sales Equity Components [Axis] Equity Components [Axis] Title of 12(b) Security Title of 12(b) Security Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Current portion of operating lease liabilities Operating Operating Lease, Liability, Current Supplementary cash flows information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Right-of-use asset and lease liability recognized Right-of-Use Asset Obtained in Exchange for Finance Lease Liability LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] Stock-Based Compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Summary of valuation of the Company's investments and financial instruments that are measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] U.S. asset-backed securities Asset-backed Securities Asset-backed Securities [Member] Prior Plans Prior Plans [Member] Represents the information pertaining to the Prior Plans consisting of 1992 Stock Option Plan, the 2001 Stock Option Plan and the Amended and Restated 2004 Equity Incentive Plan. Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Measurements Fair Value Disclosures [Text Block] Accounts Receivable Concentration Accounts Receivable [Member] Financing right-of-use lease Finance Lease, Right-of-Use Asset, before Accumulated Amortization Loss from operations Operating Income (Loss) Customer [Domain] Customer [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Number of specialty pharmacies Number of Contracted Specialty Pharmacies Number of Contracted Specialty Pharmacies Subsequent Event Type [Domain] Subsequent Event Type [Domain] Lease liability current Lease Liability Current Lease Liability Current Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] CONCENTRATION Concentration Risk [Line Items] Other non-current assets and liabilities, net Increase (Decrease) in Other Operating Liabilities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Restricted stock withheld for employee tax remittance Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Issuance of stock upon restricted stock unit vesting Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Long term investments Debt Securities, Available-for-sale, Noncurrent ASSETS Assets Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Furniture, fixtures and office equipment Furniture and Fixtures [Member] Number of reportable segments Number of Reportable Segments Other income (expense): Other Nonoperating Income (Expense) [Abstract] Entity Shell Company Entity Shell Company Shares vested in period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cover [Abstract] Cover [Abstract] Omnibus Incentive Plan 2019 Omnibus Incentive Plan 2019 [Member] Omnibus Incentive Plan 2019 [Member] Accounts payable Accounts Payable, Current Document Type Document Type Research and development Research and Development Expense [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Right-of-use leased assets Operating Operating Lease, Right-of-Use Asset Accounts receivable (net of allowance for doubtful accounts of $207 and $306, respectively) Accounts Receivable, after Allowance for Credit Loss, Current Finished goods Inventory, Finished Goods, Gross Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Increase in number of shares available for issuance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Increase (Decrease) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Increase (Decrease) Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Restricted cash Restricted Cash, Noncurrent Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Weighted average number of common shares outstanding (Basic and Diluted) (in shares) Basic and diluted EPS: weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Customer [Axis] Customer [Axis] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Maturities of short term investments Proceeds from Maturities, Prepayments and Calls of Short-term Investments Total operating expenses Operating Expenses Allowance for doubtful accounts Allowance for Doubtful Other Receivables, Current Document Quarterly Report Document Quarterly Report Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other long-term liabilities Other Liabilities, Noncurrent Payable Payment for License Agreement Payment for License Agreement Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Warrants Warrant [Member] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Compensation expense related to stock options and restricted stock units granted, net of forfeitures APIC, Share-based Payment Arrangement, Increase for Cost Recognition Level 2 Fair Value, Inputs, Level 2 [Member] Through Intermediary Sales Channel, Through Intermediary [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Other current assets Other Assets, Current Assets And Liabilities Assets And Liabilities, Leases [Table Text Block] Assets And Liabilities, Leases [Table Text Block] Inventory Inventory Inventory, Net Product sales, net Increase (decrease) to revenues Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Unusual Risk or Uncertainty, Nature [Axis] Unusual Risk or Uncertainty, Nature [Axis] Assets, fair value Assets, Fair Value Disclosure Epicel Epicel [Member] Epicel [Member] Basis of Presentation Basis of Accounting [Text Block] Accounts receivable Increase (Decrease) in Receivables Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Concentration risk (as a percent) Concentration Risk, Percentage Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Ratio of full value awards against share reserve Share-based Compensation Arrangement by Share-based Payment Award, Ratio of Full Value Awards Against Share Reserve Share-based Compensation Arrangement by Share-based Payment Award, Ratio of Full Value Awards Against Share Reserve Entity Emerging Growth Company Entity Emerging Growth Company Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Foreign currency translation loss Foreign Currency Transaction Gain (Loss), Realized Grant-date fair value of restricted stock units granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Intrinsic Value, Nonvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Intrinsic Value, Nonvested Customer concentration Customer Concentration Risk [Member] Statement Statement [Line Items] Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Schedule of accrued expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible List] Statement [Table] Statement [Table] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities U.S. government securities US Government Agencies Debt Securities [Member] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Total non-cash stock-based compensation expense Share-based Payment Arrangement, Expense Products and Services [Table] Products and Services [Table] Classified as: Balance Sheet Location [Axis] Shares issued under the Employee Stock Purchase Plan Shares issued under the Employee Stock Purchase Plan (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Counterparty Name [Axis] Counterparty Name [Axis] Common stock, no par value; shares authorized — 75,000; shares issued and outstanding — 45,194 and 44,864, respectively Common Stock, Value, Issued Net loss per share attributable to common shareholders (Basic and Diluted) (in dollars per share) Earnings Per Share, Basic and Diluted Commercial paper Commercial Paper [Member] Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Right-of-use assets Right Of Use Asset Right Of Use Asset Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Selling, general and administrative Selling, General and Administrative Expenses [Member] Change in revenue recognized due to 0.5% change in uncollectible percentage Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] COVID-19 potential impacts Corona Virus Pandemic [Member] Corona Virus Pandemic Denominator for basic and diluted EPS: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventory: Inventory, Net [Abstract] Time-and-materials contract Time-and-materials Contract [Member] Weighted-average grant date fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Common stock available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Leases Lessee, Finance Leases [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Nonemployee directors Share-based Payment Arrangement, Nonemployee [Member] Computer equipment and software Computer Equipment And Computer Software Intangible Asset [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks. Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Amendment Flag Amendment Flag Awards available for future grant under the Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Selected Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Net cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Accrued expenses Accrued Liabilities, Current [Abstract] Financial Instruments [Domain] Financial Instruments [Domain] Lease liability noncurrent Lease Liability Noncurrent Lease Liability Noncurrent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Organization Nature of Operations [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and shareholders’ equity Liabilities and Equity Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Other comprehensive gain Accumulated Other Comprehensive Income (Loss), Net of Tax Raw materials Inventory, Raw Materials, Gross Additions to property, plant and equipment included in accounts payable Capital Expenditures Incurred but Not yet Paid Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Schedules of concentration of risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Employee related accruals Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Local Phone Number Local Phone Number Contract rate Fixed-price Contract [Member] Financial Instrument [Axis] Financial Instrument [Axis] Type of Adoption [Domain] Accounting Standards Update [Domain] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from computations of diluted net loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Marketable Securities [Line Items] Marketable Securities [Line Items] Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Change in estimate of uncollectible (percent) Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage Short-term lease costs (less than) Short-term Lease, Cost Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Employee stock Employee Stock [Member] Equity Component [Domain] Equity Component [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Grantee Status [Domain] Grantee Status [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Liabilities Liabilities [Abstract] Entity Address, Address Line One Entity Address, Address Line One Gross profit Gross Profit Construction in process Construction in Progress [Member] Selling, general and administrative Selling, General and Administrative Expense Bonus related compensation Accrued Bonuses, Current Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Finance Finance Lease, Liability, Noncurrent Unusual Risk or Uncertainty, Nature [Domain] Unusual Risk or Uncertainty, Nature [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other liabilities Other Liabilities, Current Entity Current Reporting Status Entity Current Reporting Status Plan Name [Axis] Plan Name [Axis] Work-in-process Inventory, Work in Process, Gross Money market funds Cash and Cash Equivalents, Fair Value Disclosure Leases [Abstract] Leases [Abstract] Issuance of stock upon restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Concentration Risk [Table] Concentration Risk [Table] Total assets Assets Total current assets Assets, Current Earnings Per Share [Abstract] Earnings Per Share [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Total property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Weighted average grant-date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Entity Small Business Entity Small Business Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Cost of goods sold Cost of Sales [Member] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Entity Interactive Data Current Entity Interactive Data Current Other income (expense) Interest Expense Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Operating lease liabilities Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities Depreciation and amortization expense Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Short term investments Short-term Investments [Member] Less accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Revenue, Product and Service [Extensible List] Revenue, Product and Service [Extensible List] Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Finance Lease, Liability, Statement of Financial Position [Extensible List] Finance Lease, Liability, Statement of Financial Position [Extensible List] Shares issued under the Employee Stock Purchase Plan (in shares) Shares purchased during period (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of non-cash stock-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Property and equipment, net: Property, Plant and Equipment [Line Items] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Operating lease expense Operating Lease, Expense Amortization and interest accretion related to operating leases Operating Lease, Right Of Use Asset, Amortization Operating Lease, Right Of Use Asset, Amortization Inventory Increase (Decrease) in Inventories Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Biopsy kits Biopsy Kits [Member] Biopsy Kits [Member] Document Fiscal Year Focus Document Fiscal Year Focus Accounts payable Increase (Decrease) in Accounts Payable Leasehold improvements Leasehold Improvements [Member] Directly to consumer Sales Channel, Directly to Consumer [Member] Revenue Concentration Revenue Benchmark [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Accrued expenses Increase (Decrease) in Accrued Liabilities Non-cash information: Noncash Investing and Financing Items [Abstract] Max contingent consideration License Agreement, Contingent Consideration, Maximum License Agreement, Contingent Consideration, Maximum Adjustments to reconcile net loss to net cash provided by (used for) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common stock granted since inception (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Stock option exercises (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Finance lease expense Finance Lease, Interest Expense Related Party Transactions [Abstract] Related Party Transactions [Abstract] Corporate Note Securities Corporate Note Securities [Member] Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other income (expense) Nonoperating Income (Expense) Unrealized gain on investments Unrealized gain on investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Finance Finance Lease, Right-of-Use Asset, after Accumulated Amortization Machinery and equipment Machinery and Equipment [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Implants Implants [Member] Implants [Member] Service-based stock options Share-based Payment Arrangement, Option [Member] MediWound Ltd MediWound Ltd [Member] MediWound Ltd [Member] Research and development Research and Development Expense Cash equivalents Cash Equivalents [Member] Grantee Status [Axis] Grantee Status [Axis] Subsequent event Subsequent Event [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Plan Name [Domain] Plan Name [Domain] Total property and equipment, gross Property, Plant and Equipment, Gross Net proceeds from common stock issuance due to stock option exercises Proceeds from Stock Options Exercised Interest paid (net of interest capitalized) Interest Paid, Excluding Capitalized Interest, Operating Activities Employee stock purchase plan and service-based stock options Employee Stock And Employee Stock Option [Member] Employee Stock And Employee Stock Option [Member] US Government Debt Securities US Government Debt Securities [Member] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Long term investments Long-term Investments [Member] Long-term Investments [Member] Revenues Revenues Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Income Statement [Abstract] Income Statement [Abstract] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Loss on sale of fixed assets Gain (Loss) on Disposition of Assets Operating lease liabilities Operating Operating Lease, Liability, Noncurrent Accrued expenses Accrued expenses Accrued Liabilities, Current Finance Finance Lease, Liability, Current Number of therapy products Number of Products Number of Products Current assets: Assets, Current [Abstract] Interest income Investment Income, Interest Contingent consideration License Agreement, Contingent Consideration License Agreement, Contingent Consideration Depreciation expense Depreciation Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Award Type [Axis] Award Type [Axis] Consideration payment for license License Agreement, Consideration License Agreement, Consideration Counterparty Name [Domain] Counterparty Name [Domain] Expenditures for property, plant and equipment Payments to Acquire Property, Plant, and Equipment Security Exchange Name Security Exchange Name Provider or Facility Provider or Facility [Member] Provider or Facility [Member] Entity Tax Identification Number Entity Tax Identification Number Restricted cash Restricted Cash Purchases of short term investments Payments to Acquire Short-term Investments Accumulated Deficit Retained Earnings [Member] Credit Losses Debt Securities, Available-for-sale, Allowance for Credit Loss Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Liabilities that are measured at fair value on a recurring basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Revenue Concentration Risk Disclosure [Text Block] Award Type [Domain] Award Type [Domain] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Trading Symbol Trading Symbol Non-current Liabilities, Noncurrent [Abstract] Document Transition Report Document Transition Report Corporate notes Corporate Debt Securities [Member] Nexobrid License and Supply Agreements License Agreement [Text Block] License Agreement [Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Schedule of inventory Schedule of Inventory, Current [Table Text Block] Stock compensation expense Share-based Payment Arrangement, Noncash Expense Other Proceeds from (Payments for) Other Financing Activities Payments on employee's behalf for taxes related to vesting of restricted stock unit awards Payment, Tax Withholding, Share-based Payment Arrangement Net Loss Per Common Share Earnings Per Share [Text Block] Marketable Securities [Table] Marketable Securities [Table] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of fair value of securities, not including cash Debt Securities, Available-for-sale [Table Text Block] Current liabilities: Current Liabilities, Current [Abstract] Other accrued expenses Accrued Expenses, Other, Current Represents other accrued expenses, current. Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Recurring Fair Value, Recurring [Member] Restricted stock withheld for employee tax remittance (in shares) Restricted stock withheld for employee tax remittance (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Short term investments Short-term Investments EX-101.PRE 10 vcel-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 vcel-20200630_htm.xml IDEA: XBRL DOCUMENT 0000887359 2020-01-01 2020-06-30 0000887359 2020-07-31 0000887359 2020-06-30 0000887359 2019-12-31 0000887359 2020-04-01 2020-06-30 0000887359 2019-04-01 2019-06-30 0000887359 2019-01-01 2019-06-30 0000887359 us-gaap:CommonStockMember 2019-12-31 0000887359 us-gaap:WarrantMember 2019-12-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000887359 us-gaap:RetainedEarningsMember 2019-12-31 0000887359 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000887359 2020-01-01 2020-03-31 0000887359 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000887359 us-gaap:CommonStockMember 2020-03-31 0000887359 us-gaap:WarrantMember 2020-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000887359 us-gaap:RetainedEarningsMember 2020-03-31 0000887359 2020-03-31 0000887359 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000887359 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000887359 us-gaap:CommonStockMember 2020-06-30 0000887359 us-gaap:WarrantMember 2020-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000887359 us-gaap:RetainedEarningsMember 2020-06-30 0000887359 us-gaap:CommonStockMember 2018-12-31 0000887359 us-gaap:WarrantMember 2018-12-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000887359 us-gaap:RetainedEarningsMember 2018-12-31 0000887359 2018-12-31 0000887359 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000887359 2019-01-01 2019-03-31 0000887359 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000887359 us-gaap:CommonStockMember 2019-03-31 0000887359 us-gaap:WarrantMember 2019-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000887359 us-gaap:RetainedEarningsMember 2019-03-31 0000887359 2019-03-31 0000887359 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000887359 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000887359 us-gaap:CommonStockMember 2019-06-30 0000887359 us-gaap:WarrantMember 2019-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000887359 us-gaap:RetainedEarningsMember 2019-06-30 0000887359 2019-06-30 0000887359 vcel:CoronaVirusPandemicMember 2020-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2020-04-01 2020-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2020-01-01 2020-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-04-01 2019-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2020-04-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2019-04-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2020-01-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2020-04-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2019-04-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2020-01-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2020-04-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2019-04-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2020-01-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2019-01-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2020-04-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2019-04-01 2019-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2020-01-01 2020-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2019-01-01 2019-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-04-01 2020-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-04-01 2019-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-04-01 2020-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-04-01 2019-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2020-01-01 2020-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-06-30 0000887359 vcel:EpicelMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0000887359 vcel:EpicelMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-04-01 2019-06-30 0000887359 vcel:EpicelMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0000887359 vcel:EpicelMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-06-30 0000887359 vcel:EpicelMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0000887359 vcel:EpicelMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000887359 us-gaap:MachineryAndEquipmentMember 2020-06-30 0000887359 us-gaap:MachineryAndEquipmentMember 2019-12-31 0000887359 us-gaap:FurnitureAndFixturesMember 2020-06-30 0000887359 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000887359 vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember 2020-06-30 0000887359 vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember 2019-12-31 0000887359 us-gaap:LeaseholdImprovementsMember 2020-06-30 0000887359 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000887359 us-gaap:ConstructionInProgressMember 2020-06-30 0000887359 us-gaap:ConstructionInProgressMember 2019-12-31 0000887359 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000887359 vcel:PriorPlansMember 2020-06-30 0000887359 vcel:OmnibusIncentivePlan2019Member us-gaap:CommonStockMember 2020-04-29 0000887359 vcel:OmnibusIncentivePlan2019Member 2020-04-28 0000887359 vcel:OmnibusIncentivePlan2019Member 2020-04-29 0000887359 vcel:OmnibusIncentivePlan2019Member 2020-06-30 0000887359 us-gaap:EmployeeStockMember 2020-06-30 0000887359 us-gaap:EmployeeStockMember 2015-01-01 2020-06-30 0000887359 us-gaap:EmployeeStockMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-31 0000887359 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000887359 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-01-01 2020-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-01-01 2020-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2020-04-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2019-04-01 2019-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2020-01-01 2020-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2019-01-01 2019-06-30 0000887359 us-gaap:MoneyMarketFundsMember 2020-06-30 0000887359 us-gaap:CommercialPaperMember 2020-06-30 0000887359 us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0000887359 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0000887359 us-gaap:AssetBackedSecuritiesMember 2020-06-30 0000887359 us-gaap:CashEquivalentsMember 2020-06-30 0000887359 us-gaap:ShortTermInvestmentsMember 2020-06-30 0000887359 us-gaap:MoneyMarketFundsMember 2019-12-31 0000887359 us-gaap:CommercialPaperMember 2019-12-31 0000887359 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000887359 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000887359 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000887359 us-gaap:CashEquivalentsMember 2019-12-31 0000887359 us-gaap:ShortTermInvestmentsMember 2019-12-31 0000887359 vcel:LongtermInvestmentsMember 2019-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000887359 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000887359 us-gaap:WarrantMember 2020-04-01 2020-06-30 0000887359 us-gaap:WarrantMember 2019-04-01 2019-06-30 0000887359 us-gaap:WarrantMember 2020-01-01 2020-06-30 0000887359 us-gaap:WarrantMember 2019-01-01 2019-06-30 0000887359 vcel:MediWoundLtdMember 2019-05-31 0000887359 vcel:MediWoundLtdMember 2019-05-01 2019-05-31 shares iso4217:USD iso4217:USD shares vcel:product vcel:segment vcel:pharmacy pure 0000887359 --12-31 2020 Q2 false 207000 306000 75000000 75000000 45194000 44864000 45194000 44864000 us-gaap:ProductMember us-gaap:ProductMember us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization us-gaap:OtherLiabilities us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent P4Y 10-Q true 2020-06-30 false 001-35280 VERICEL CORPORATION MI 94-3096597 64 Sidney Street Cambridge MA 02139 617 588-5555 Common Stock (No par value) VCEL NASDAQ Yes Yes Large Accelerated Filer false false false 45250402 55704000 26889000 25086000 42829000 23655000 32168000 8417000 6816000 2900000 2953000 115762000 111655000 7040000 7144000 89000 89000 23800000 25103000 0 9247000 146691000 153238000 4535000 6345000 7975000 7948000 5570000 5461000 41000 41000 18121000 19795000 20881000 22242000 93000 110000 39095000 42147000 499103000 489749000 146000 21000 -391653000 -378679000 107596000 111091000 146691000 153238000 20014000 26151000 46692000 47961000 8660000 9022000 18582000 17662000 11354000 17129000 28110000 30299000 3226000 21070000 6989000 24078000 16486000 16259000 34555000 29779000 19712000 37329000 41544000 53857000 -8358000 -20200000 -13434000 -23558000 147000 428000 453000 908000 1000 2000 3000 4000 -57000 -18000 10000 18000 89000 408000 460000 922000 -8269000 -19792000 -12974000 -22636000 -0.18 -0.45 -0.29 -0.52 45137000 43956000 45031000 43841000 -8269000 -19792000 -12974000 -22636000 84000 35000 125000 38000 -8185000 -19757000 -12849000 -22598000 44864000 489749000 0 21000 -378679000 111091000 -4705000 -4705000 3768000 3768000 57000 196000 196000 20000 224000 224000 36000 0 14000 163000 163000 41000 41000 44963000 493774000 0 62000 -383384000 110452000 -8269000 -8269000 4376000 4376000 188000 696000 696000 32000 257000 257000 11000 0 84000 84000 45194000 499103000 0 146000 -391653000 107596000 43578000 471180000 104000 -39000 -369014000 102231000 -2844000 -2844000 2628000 2628000 228000 780000 780000 19000 218000 218000 42000 42000 43825000 474806000 104000 3000 -371858000 103055000 -19792000 -19792000 4183000 4183000 227000 850000 850000 14000 211000 211000 35000 35000 44066000 480050000 104000 38000 -391650000 88542000 -12974000 -22636000 1079000 698000 8144000 6810000 -45000 -13000 -30000 0 25000 408000 1603000 1139000 1601000 1230000 -8513000 -2370000 -53000 -680000 -1692000 -2238000 27000 -2229000 -1537000 -1007000 0 -187000 1665000 -18225000 5657000 32402000 32797000 45477000 1186000 1224000 25954000 11851000 1373000 2059000 163000 0 -14000 -9000 1196000 2050000 28815000 -4324000 26978000 18286000 55793000 13962000 Organization<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced cell therapies for the sports medicine and severe burn care markets. Vericel currently markets two cell therapy products, MACI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and Epicel</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, in the United States. Vericel obtained both products in May 2014, as part of the acquisition of certain assets and the assumption of certain liabilities from Sanofi, a French </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">société anonyme</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (Sanofi). </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MACI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Company also markets Epicel</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA). The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of biopharmaceuticals for use in the treatment of specific diseases. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;padding-right:72pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">COVID-19</span></div><div style="text-indent:13.5pt;padding-right:72pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The novel coronavirus (COVID-19) outbreak was first reported by China in late December 2019 and rapidly spread globally. The World Health Organization (WHO) declared the outbreak a pandemic on March 11, 2020 and the President of the United States declared a national health emergency two days later. Subsequently most states' governments, including those in Massachusetts and Michigan where the Company's operations are located, issued orders requiring businesses that do not conduct essential services to temporarily close their physical workplaces to employees and customers. The status of such orders varies on a state-by-state basis and is likely to continue to vary. Because Vericel is deemed an essential business, the Company is exempt from these state orders in their current form.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding being an essential business, the Company’s business and operations have been, and are expected to continue to be, adversely impacted by the effects of COVID-19 as a result of various factors including, without limitation, patients’ potential reluctance to undergo elective surgical procedures, healthcare facility restrictions regarding elective surgical procedures, the recent economic downturn due to the pandemic, the imposition of related public health measures and travel and business restrictions and disruptions to the ability of the Company’s employees to perform their jobs.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The implantation of MACI is an elective surgical procedure. On March 13, 2020 and March 14, 2020, the American College of Surgeons and United States Surgeon General, respectively, recommended that each hospital, health system, and surgeon minimize, postpone, or cancel electively scheduled surgeries, which has resulted in a reduction in MACI sales. The stated purpose for these recommendations was that every elective surgery could spread COVID-19 within a facility, use up personal protective equipment (PPE) which may be needed by healthcare workers treating COVID-19 patients, and burden hospital workforce who may be needed to respond to COVID-19. These recommendations were followed by numerous state level executive orders either banning or partially banning elective surgeries. As a result of these restrictions, beginning in mid-March 2020, the Company started to experience a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders. By early April 2020, 45 states, representing over 95% of total U.S. surgical capacity had issued either mandates or recommendations and guidelines suspending elective surgical procedures. These restrictions began to ease in May and, by the end of June 2020, states representing an estimated 90% total U.S. surgical capacity had lifted restrictions suspending elective procedures. It is likely that restrictions will continue to be both lifted and re-imposed as regional COVID 19 cases rates fall and rise. The Company’s MACI business will continue to be negatively impacted so long as multiple state orders and/or facilities restrict elective surgical procedures.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;">Going Concern</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.  As of June 30, 2020, the Company had an accumulated deficit of $391.7 million and incurred a net loss of $8.3 million and $13.0 million for the three and six months ended June 30, 2020, respectively.  The Company had cash and cash equivalents of $55.8 million and investments of $25.1 million as of June 30, 2020. The Company expects that existing cash, cash equivalents and investments will be sufficient to support the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company’s</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">current operations through at least 12 months from the issuance of these financial statements.</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, the continuing effects of the COVID-19 pandemic may require the Company to engage in layoffs, furloughs and/or reductions in salary, all of which may result in irrecoverable losses of customers and significantly impact long-term liquidity.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#263238;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If</span><span style="background-color:rgb(255,255,255, 0.0);color:#263238;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> elective surgery restrictions are reinstated on a widespread basis, significantly impacting </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the Company's business, the Company may need to a</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ccess additional capital; however, the Company may not be able to obtain financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any financing may adversely affect the holdings or the rights of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company’s</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> shareholders.</span></div> 2 1 -391700000 -8300000 -13000000.0 55800000 25100000 Basis of Presentation<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements as of June 30, 2020 and for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six months ended</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> June 30, 2020 are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in U.S. GAAP requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to continue to contain it or treat COVID-19, as well as the economic impact on our customers. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. As of June 30, 2020, the Company has not recorded impairments to investments, inventory, other current assets or long-lived assets as a result of the COVID-19 pandemic and does not expect material impairments in the future. The Company has assessed the impact of COVID-19 on accounts receivables (see note 4).</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on February 25, 2020 (Annual Report).</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Consolidated Statement of Cash Flows</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents certain supplementary cash flows information for the six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.415%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.429%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplementary Cash Flows information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash information:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset and lease liability recognized</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">429 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property, plant and equipment included in accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">365 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest paid (net of interest capitalized)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:13.5pt;"><span><br/></span></div><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total cash, cash equivalents, and restricted cash of $55.8 million as of June 30, 2020, shown in the statement of cash flows is comprised of cash and cash equivalents of $55.7 million and restricted cash of $0.1 million which is included in other long term assets on the consolidated balance sheet. As of June 30, 2019, cash and cash equivalents were $14.0 million and the Company did not have any restricted cash.</span></div> <div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents certain supplementary cash flows information for the six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.415%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.429%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplementary Cash Flows information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash information:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset and lease liability recognized</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">429 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">560 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property, plant and equipment included in accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">365 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest paid (net of interest capitalized)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 429000 560000 55000 365000 3000 4000 55800000 55700000 100000 14000000.0 0 Recent Accounting Pronouncements <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Measuring Credit Losses on Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FASB issued updated guidance on measuring credit losses on financial instruments. The guidance removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Prior to the updated guidance, credit losses are recognized when it is probable that the loss has been incurred. The revised guidance removes all recognition thresholds and requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that a company expected to collect over the instrument’s contractual life. The Accounting Standard Update (ASU) 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses (Topic 326), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">became effective for the Company January 1, 2020. See note 4 and note 8 for further discussion.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value Measurement Disclosure</span></div><div style="text-indent:9pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FASB issued updated guidance through ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The revised guidance is intended to develop a more consistent disclosure framework that will increase clarity, remove, modify and add certain fair value disclosures to improve the effectiveness of the Company’s disclosures in the notes of the financial statements. This guidance became effective for the Company January 1, 2020 and had no impact to its condensed consolidated financial statements.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Simplifying the Accounting for Income Taxes</span></div><div><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Simplifying the Accounting for Income Taxes (ASC 740).</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company is currently in the process of evaluating the impact to its condensed consolidated financial statements.</span></div> Recent Accounting Pronouncements <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Measuring Credit Losses on Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FASB issued updated guidance on measuring credit losses on financial instruments. The guidance removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Prior to the updated guidance, credit losses are recognized when it is probable that the loss has been incurred. The revised guidance removes all recognition thresholds and requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that a company expected to collect over the instrument’s contractual life. The Accounting Standard Update (ASU) 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses (Topic 326), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">became effective for the Company January 1, 2020. See note 4 and note 8 for further discussion.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value Measurement Disclosure</span></div><div style="text-indent:9pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FASB issued updated guidance through ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The revised guidance is intended to develop a more consistent disclosure framework that will increase clarity, remove, modify and add certain fair value disclosures to improve the effectiveness of the Company’s disclosures in the notes of the financial statements. This guidance became effective for the Company January 1, 2020 and had no impact to its condensed consolidated financial statements.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Simplifying the Accounting for Income Taxes</span></div><div><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Simplifying the Accounting for Income Taxes (ASC 740).</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company is currently in the process of evaluating the impact to its condensed consolidated financial statements.</span></div> Revenue<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition and Net Product Sales</span></div><div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes product revenue from sales of MACI kits, MACI implants and Epicel grafts following the five-step model in Accounting Standards Codification 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ASC 606).</span></div><div style="text-indent:9pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MACI Kits </span></div><div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">MACI kits are sold directly to hospitals based on contracted rates in the approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit at which time the customer (the facility) is in control of the kit. The kit provides the doctor the ability to biopsy a sampling of cells to provide to the Company that can be used later to manufacture the implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cell tissue. The customer’s order of an implant is separate from the process of ordering the kit. Therefore, the sale of the kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">MACI Implants</span></div><div style="text-indent:11.25pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (Orsini) and AllCare Plus Pharmacy, Inc. (AllCare) to distribute its MACI product in arrangements whereby the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to receive payment from customers. The Company has engaged a third-party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical (DMS) for military implants. The sales directly to DMS are sold at a contracted rate. </span></div><div style="text-indent:11.25pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenues from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration which the Company expects to collect in exchange for MACI implants (the transaction price) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and other than customary prompt pay discounts, there are typically no forms of variable consideration. </span></div><div style="text-indent:11.25pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When the Company sells MACI the patient is responsible for payment, however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates or a fee schedule. Net product revenue is recognized net of contractual allowances, which considers historical collection experience from both the payer and patient and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. These estimates include the impact of contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company's accounts receivable in accordance with </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ASC 326, Financial Instruments - Credit Losses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assesses risk and determines a loss percentage by pooling account receivables based on similar risk characteristics. The loss percentage is based on current and historical information as well as reasonable and supportable forecasts. This loss percentage was applied to the accounts receivables as of June 30, 2020. The total allowance for uncollectible consideration was $4.4 million as of June 30, 2020 and $3.9 million at December 31, 2019. The allowance includes less than $0.1 million of which is related to COVID-19 potential impacts on accounts receivable from third-party insurers, government payers, hospitals and patients. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes to the estimate of the amount of consideration that will not be collected could have a material impact to the revenue recognized. A 0.5% change to the estimated uncollectible percentage could result in approximately a $0.1 million decrease in the revenue recognized for the six months ended June 30, 2020.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in estimates of the transaction price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior period sales for the three and six months ended June 30, 2020 resulted in a decrease to revenue of $0.2 million and increase to revenue of $1.1 million, respectively, and an increase to revenue of $0.09 million and $0.05 million, respectively for the same period in 2019. The changes in estimates recorded during the three and six months ended June 30, 2020, were primarily due to completion of the billing claims process for implants that occurred in late 2019. Upon completion of the billing claims process, the Company concluded that it was probable that a significant reversal in the amount of revenue recognized would not occur.</span></div><div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Epicel</span></div><div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company sells Epicel directly to hospitals based on contracted rates stated in the approved contract or purchase order. Similar to MACI, there is no obligation to manufacture skin grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenues from sales of Epicel upon delivery to the hospital at which time the customer is in control of the skin grafts and the claim is billable to the hospital. </span></div><div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue by Product and Customer </span></div><div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table and description below shows the products from which the Company generated its revenue:</span></div><div style="text-align:justify;margin-top:14pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:46.736%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:10.332%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.332%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.332%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.338%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue by product (in thousands) </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MACI implants and kits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants based on contracted rate sold through a specialty pharmacy (a)</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,790 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,989 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,218 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,776 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants subject to third party reimbursement sold through a specialty pharmacy (b)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,819 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,459 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,335 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,202 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants sold direct based on contracted rates (c)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,806 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,450 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,916 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,676 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants sold direct subject to third party reimbursement (d)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,016 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biopsy kits - direct bill</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">811 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,099 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in estimates related to prior periods (e)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(248)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,095 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Epicel</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">     Direct bill (hospital)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,910 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,328 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,301 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,555 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,014 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,151 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,692 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,961 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below. </span></div><div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:18.760%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.554%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.873%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue Concentration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable Concentration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Epicel</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 2 4400000 3900000 100000 0.005 -100000 -200000 1100000 90000.00 50000.00 <div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table and description below shows the products from which the Company generated its revenue:</span></div><div style="text-align:justify;margin-top:14pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:46.736%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:10.332%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.542%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.332%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.332%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.338%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue by product (in thousands) </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MACI implants and kits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants based on contracted rate sold through a specialty pharmacy (a)</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,790 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,989 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,218 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,776 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants subject to third party reimbursement sold through a specialty pharmacy (b)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,819 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,459 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,335 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,202 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants sold direct based on contracted rates (c)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,806 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,450 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,916 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,676 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Implants sold direct subject to third party reimbursement (d)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">589 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,016 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biopsy kits - direct bill</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">348 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">557 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">811 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,099 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in estimates related to prior periods (e)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(248)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,095 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Epicel</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">     Direct bill (hospital)</span></td><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,910 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,328 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,301 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,555 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,014 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,151 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,692 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,961 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period. </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 9790000 12989000 21218000 22776000 2819000 3459000 6335000 6202000 1806000 3450000 4916000 6676000 589000 281000 1016000 603000 348000 557000 811000 1099000 -248000 87000 1095000 50000 4910000 5328000 11301000 10555000 20014000 26151000 46692000 47961000 <div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below. </span></div><div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:18.760%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.280%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.554%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.873%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue Concentration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable Concentration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Epicel</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 0.06 0.06 0.10 0.08 0.03 0.02 Selected Balance Sheet Components<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory as of June 30, 2020 and December 31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:67.546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.496%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,853 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,085 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">513 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">541 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,417 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,816 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Property and Equipment</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and Equipment, net as of June 30, 2020 and December 31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:67.546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.496%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,152 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture, fixtures and office equipment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">810 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">775 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,393 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,174 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,256 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,256 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,311 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">859 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing right-of-use lease</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,178 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,138)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,040 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,144 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense for the three and six months ended June 30, 2020 was $0.5 million and $1.1 million, respectively, and $0.4 million and $0.7 million for the same periods in 2019.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accrued Expenses</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued Expenses as of June 30, 2020 and December 31, 2019 are as follows:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.970%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.528%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.139%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.528%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.435%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bonus related compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,872 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,116 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee related accruals</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,578 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,785 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,525 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,047 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,975 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,948 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory as of June 30, 2020 and December 31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:67.546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.496%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,853 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,085 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">513 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">541 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,417 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,816 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 7853000 6085000 513000 541000 51000 190000 8417000 6816000 <div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and Equipment, net as of June 30, 2020 and December 31, 2019:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:67.546%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.496%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,152 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture, fixtures and office equipment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">810 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">775 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,393 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,174 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,256 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,256 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,311 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">859 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing right-of-use lease</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,178 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,364 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,138)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,040 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,144 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 3279000 3152000 810000 775000 6393000 6174000 5256000 5256000 1311000 859000 129000 148000 17178000 16364000 10138000 9220000 7040000 7144000 500000 1100000 400000 700000 <div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued Expenses as of June 30, 2020 and December 31, 2019 are as follows:</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.970%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.528%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.139%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.528%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.435%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bonus related compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,872 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,116 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee related accruals</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,578 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,785 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,525 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,047 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,975 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,948 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2872000 5116000 2578000 1785000 2525000 1047000 7975000 7948000 Leases<div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases offsite warehouse space, vehicles and computer equipment. Certain of the Company’s lease agreements include lease payments that are adjusted periodically for an index or rate. The leases are initially measured using the projected payments adjusted for the index or rate in effect at the commencement date. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. All operating lease commitments with a lease term greater than 12 months are recognized as right to use assets and liabilities, on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the balance sheet and for both the three and six months ended June 30, 2020 and 2019, lease expense of less than </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$0.1 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was recorded related to short-term leases.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> contribution toward the cost of tenant improvements is recorded as a reduction of the operating lease assets. For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six months ended</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June 30, 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company recognized $1.4 million and $2.9 million of operating lease expense and $1.3 million and $2.6 million for the same periods in 2019. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For both the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six months ended June 30, 2020 and 2019, the Company recognized </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">less than $0.1 million of financing lease expense. The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company’s leases contain non-lease components and activities that do not transfer a good or service to the Company. The Company elected not to combine lease and non-lease components and therefore non-lease costs were not included in the net lease assets or lease liabilities.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:11.489%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:53.278%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.516%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.518%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,800 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,103 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,570 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,461 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,611 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,502 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,881 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,242 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,974 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,352 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> Leases<div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases offsite warehouse space, vehicles and computer equipment. Certain of the Company’s lease agreements include lease payments that are adjusted periodically for an index or rate. The leases are initially measured using the projected payments adjusted for the index or rate in effect at the commencement date. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. All operating lease commitments with a lease term greater than 12 months are recognized as right to use assets and liabilities, on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the balance sheet and for both the three and six months ended June 30, 2020 and 2019, lease expense of less than </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$0.1 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was recorded related to short-term leases.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> contribution toward the cost of tenant improvements is recorded as a reduction of the operating lease assets. For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six months ended</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June 30, 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company recognized $1.4 million and $2.9 million of operating lease expense and $1.3 million and $2.6 million for the same periods in 2019. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For both the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six months ended June 30, 2020 and 2019, the Company recognized </span><span style="background-color:rgb(255,255,255, 0.0);color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">less than $0.1 million of financing lease expense. The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company’s leases contain non-lease components and activities that do not transfer a good or service to the Company. The Company elected not to combine lease and non-lease components and therefore non-lease costs were not included in the net lease assets or lease liabilities.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:11.489%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:53.278%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.516%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.518%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,800 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,103 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,570 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,461 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,611 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,502 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,881 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,242 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,974 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,352 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 100000 100000 100000 100000 1400000 2900000 1300000 2600000 100000 100000 100000 100000 <div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:11.489%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:53.278%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.516%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.518%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,800 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,103 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,251 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,570 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,461 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,611 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,502 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,881 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,242 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">110 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,974 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,352 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 23800000 25103000 129000 148000 23929000 25251000 5570000 5461000 41000 41000 5611000 5502000 20881000 22242000 93000 110000 20974000 22352000 Stock-Based Compensation<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option, Restricted Stock Units and Equity Incentive Plans</span></div><div style="text-indent:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has historically had various stock incentive plans and agreements that provide for the issuance of nonqualified and incentive stock options and restricted stock units as well as other equity awards.  Such awards may be granted by the Company’s Board of Directors to certain of the Company’s employees, directors and consultants.  </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options and restricted stock units granted to employees and non-employees under these plans expire no later than ten years from the date of grant and generally become exercisable over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMzRmOWFjYzgyMjRlOGRhZTBhNjcyNDExNTBhOWMwL3NlYzplMzM0ZjlhY2M4MjI0ZThkYWUwYTY3MjQxMTUwYTljMF82MS9mcmFnOjNjNWU1NGU3YWVmZjRjZTM5OTk0NGNkZTk2MTFkZTgzL3RleHRyZWdpb246M2M1ZTU0ZTdhZWZmNGNlMzk5OTQ0Y2RlOTYxMWRlODNfNjI4_d60a7dd2-4de7-4c4a-9382-6e2e5cba913d">four</span> year period, under a graded-vesting methodology for stock options and annually on the anniversary grant date for restricted stock units, following the date of grant.  The Company generally issues new shares upon the exercise of stock options or vesting of restricted stock units. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2019 Omnibus Incentive Plan (2019 Plan) was approved on May 1, 2019 and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units.  The exercise price of stock options granted under the 2019 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant.  The 2019 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan and the 2017 Omnibus Incentive Plan (Prior Plans), and no new grants have been granted under the Prior Plans after approval.  However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2019 Plan.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Amended and Restated 2019 Omnibus Incentive Plan (Amended and Restated 2019 Plan) was approved on April 29, 2020. Amendments to the Amended and Restated 2019 Omnibus Plan included increasing the total number of shares of the Company's common stock reserved for issuance under the 2019 Plan by 2,400,000 shares, a revised ratio at which "full- value" awards are counted against the share reserve from 1.25 to 1.4, and extending the term of the plan to April 29, 2030. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, there were 4,267,255 shares available for future grant under the Amended and Restated 2019 Plan.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:4.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:6.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employees are able to purchase stock under the Vericel Corporation Employee Stock Purchase Plan (ESPP). The ESPP allows for the issuance of an aggregate of 1,000,000 shares of common stock of which 672,907 have been issued since the inception of the benefit in 2015. Participation in this plan is available to substantially all employees. The ESPP is a compensatory plan accounted for under the expense recognition provisions of the share-based payment accounting standards. Compensation expense is recorded based on the fair market value of the purchase options at the grant date, which corresponds to the first day of each purchase period and is amortized over the purchase period. In July 2020, employees purchased 44,137 shares resulting in proceeds from the sale of common stock of $0.3 million under the ESPP for the second quarter of 2020. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:6.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Service-Based Stock Options</span></div><div style="text-indent:6.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June 30, 2020, the Company granted service-based options to purchase common stock of 110,750 and 1,296,890, respectively, and 152,500 and 1,638,510, respectively, for the same periods in 2019.  The exercise price of the options is the fair market value per share of common stock on the grant date, generally vest over four years (other than non-employee director options which vest over one year) and have a term of ten years. The Company issues new shares upon the exercise of stock options.  The weighted average grant-date fair value of service-based options granted during the three and six months ended June 30, 2020 was $8.82 and $8.66, respectively and $11.94 and $12.74, respectively, for the same periods in 2019.</span></div><div style="text-indent:4.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June 30, 2020 and 2019, the Company granted 10,700 and 196,836, service-based restricted stock units, respectively and 10,500 and 186,922, respectively, for the same periods in 2019. The restricted stock units vest annually over four years in equal installments commencing on the first anniversary of the grant date (other than non-employee director options which vest over one year from the grant date). The Company issues new shares upon the vesting of restricted stock units. Restricted stock awards are recorded at fair value at the date of grant, which is based on the closing share price on the grant date. Compensation expense is recorded for restricted stock units that are expected to vest based on their fair value at grant date and is amortized over the expected vesting period. The weighted average grant-date fair value of restricted stock units granted during the three and six months ended June 30, 2020 was $14.49 and $11.41, respectively and $16.62 and $17.71, respectively, for the same periods in 2019. The aggregate fair value of restricted stock units granted in the three and six months ended June 30, 2020 was $0.2 million and $2.2 million, respectively and $0.2 million and $3.3 million, respectively, for the same periods in 2019.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of 36,212 units vesting during the three months ended March 31, 2020, 13,872 shares were withheld for payment of taxes on the employee's behalf and retired from the 2019 Plan. During the three months ended June 30, 2020, 10,500 units vested and no shares were withheld for payment of taxes, as no shares are withheld at vesting for shares awarded to the Company's Board of Directors.</span></div><div><span><br/></span></div><div style="text-indent:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Compensation Expense</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-cash stock-based compensation expense (employee stock purchase plan, service-based stock options and restricted stock units) included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table: </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.656%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.645%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.645%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.645%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.650%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">568 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">716 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">997 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">976 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">484 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">886 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,060 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,410 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,325 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,581 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,087 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,424 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,377 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,183 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,144 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,810 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> P10Y 0 2400000 1.25 1.4 4267255 1000000 672907 44137 300000 110750 1296890 152500 1638510 P4Y P1Y P10Y 8.82 8.66 11.94 12.74 10700 196836 10500 186922 P4Y P1Y 14.49 11.41 16.62 17.71 200000 2200000 200000 3300000 36212 13872 10500 0 <div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-cash stock-based compensation expense (employee stock purchase plan, service-based stock options and restricted stock units) included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table: </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.656%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.645%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.645%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.645%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.650%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">568 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">716 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">997 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">976 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">484 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">886 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,060 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,410 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,325 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,581 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,087 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,424 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,377 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,183 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,144 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,810 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 568000 716000 997000 976000 484000 886000 1060000 1410000 3325000 2581000 6087000 4424000 4377000 4183000 8144000 6810000 Cash Equivalents and Investments<div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Marketable debt securities held by the Company are classified as available-for-sale </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">pursuant to ASC 320, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Investments – Debt and Equity Securities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> and carried at fair value in the accompanying consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities as of June 30, 2020 and December 31, 2019:</span></div><div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.309%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.935%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.143%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,840 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,776 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. asset-backed securities</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,640 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,926 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,071 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short term investments</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,086 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="9" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,071 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:right;margin-top:8pt;margin-bottom:8pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.935%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.350%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.603%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,369 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,291 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. asset-backed securities</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,503 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,436 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,457 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,829 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,247 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="9" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,457 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:13.5pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">December 31, 2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, we held both short-term and long-term investments. Investments classified as short-term have maturities of less than one year. Investments classified as long-term are those that: (i) have a maturity of greater than one year, and (ii) we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Company's investment strategy is to buy short-duration marketable securities with a high credit rating. As of June 30, 2020, all marketable securities held by the Company had remaining contractual maturities of three years or less.</span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">U</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">nrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders’ equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Financial Instruments - Credit Losses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">, to determine if the impairment is credit-related or non credit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and non credit-related impairment is recognized in other comprehensive income, net of taxes. There were no material realized losses on marketable securities for the three and six months ended June 30, 2020 and 2019. </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The Company evaluated its investments for impairment under ASC 326. Any allowance for credit losses are recorded at the lower of either the fair market value less book value or the difference between the present value of future cash flows and the book value. As of June 30, 2020, the analysis under ASU 2016-13 and the current macroeconomic impact of the COVID-19 pandemic did not result in material allowances for credit losses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;"> </span>There have been no impairments of the Company’s assets measured and carried at fair value as of June 30, 2020. he following tables summarize the gross unrealized gains and losses of the Company’s marketable securities as of June 30, 2020 and December 31, 2019:<div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.309%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.935%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.695%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.143%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credit Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,840 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,776 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. asset-backed securities</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,640 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,926 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,071 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short term investments</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,086 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="9" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,071 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:right;margin-top:8pt;margin-bottom:8pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.935%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.350%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.603%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,369 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,291 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. asset-backed securities</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,503 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,436 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,457 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,829 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,247 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="9" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,457 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 44985000 0 0 0 44985000 3685000 0 0 0 3685000 8840000 55000 0 0 8895000 7776000 67000 0 0 7843000 4640000 23000 0 0 4663000 69926000 145000 0 0 70071000 44985000 25086000 70071000 5381000 0 0 5381000 11892000 0 0 11892000 18369000 11000 0 18380000 11291000 4000 0 11295000 10503000 6000 0 10509000 57436000 21000 0 57457000 5381000 42829000 9247000 57457000 Fair Value Measurements<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s fair value measurements are classified and disclosed in one of the following three categories:</span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> There was no movement between Level 1 and Level 2 or between Level 2 and Level 3 from December 31, 2019 to June 30, 2020. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities and asset-backed securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%;"><tr><td style="width:1.0%;"/><td style="width:22.885%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.709%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurement category</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurement category</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,071 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,086 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,457 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,076 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of the cash equivalents and marketable securities are based on observable market prices. See note 8 for impact of ASU 2016-13 on the investment valuation.</span></div> The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%;"><tr><td style="width:1.0%;"/><td style="width:22.885%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.563%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.709%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurement category</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value measurement category</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,685 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,892 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,895 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,843 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,295 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,071 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,985 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,086 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57,457 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52,076 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table> 44985000 44985000 0 0 5381000 5381000 0 0 3685000 0 3685000 0 11892000 0 11892000 0 8895000 0 8895000 0 18380000 0 18380000 0 7843000 0 7843000 0 11295000 0 11295000 0 4663000 0 4663000 0 10509000 0 10509000 0 70071000 44985000 25086000 0 57457000 5381000 52076000 0 Net Loss Per Common Share<div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.777%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.116%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Amounts in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,269)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,974)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,636)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted EPS: weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,137 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,956 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,031 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,841 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share attributable to common shareholders (basic and diluted)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.45)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.52)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Anti-dilutive shares excluded from the calculation of diluted earnings per share</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(amounts in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock unit awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a) Common equivalent shares are not included in the diluted per share calculation where the effect of their inclusion would be anti-dilutive.  </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> <div style="text-indent:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.777%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.116%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Amounts in thousands, except per share amounts)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,269)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,792)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,974)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,636)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted EPS: weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,137 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,956 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,031 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,841 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share attributable to common shareholders (basic and diluted)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.45)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.52)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Anti-dilutive shares excluded from the calculation of diluted earnings per share</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(amounts in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock unit awards</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:justify;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a) Common equivalent shares are not included in the diluted per share calculation where the effect of their inclusion would be anti-dilutive.  </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> -8269000 -19792000 -12974000 -22636000 45137000 43956000 45031000 43841000 -0.18 -0.45 -0.29 -0.52 6000000.0 5600000 6000000.0 5600000 300000 200000 300000 200000 0 100000 0 100000 NexoBrid License and Supply Agreements<div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound Ltd. (MediWound) to commercialize NexoBrid</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and any improvements to NexoBrid in all countries of North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NexoBrid is currently in clinical development in North America, and pursuant to the terms of the license agreement, MediWound will continue to conduct all clinical activities described in the development plan to support the BLA filing with the United States Food and Drug Administration (FDA) under the supervision of a Central Steering Committee comprised of members of each party. On June 30, 2020, the Company announced the submission of the BLA to the FDA seeking the approval of NexoBrid. NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic in the United States, European Union and other international markets. </span></div><div style="text-indent:13.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company paid MediWound $17.5 million in consideration of the license. The $17.5 million upfront payment was recorded to research and development expense during 2019, as the license was considered in process research and development.  The Company is also obligated to pay MediWound $7.5 million upon U.S. regulatory approval of the BLA for NexoBrid and up to $125 million contingent upon meeting certain sales milestones.  The first sales milestone of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75 million.  The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. The U.S. Biomedical Advanced Research and Development Authority (BARDA) has committed to procure NexoBrid, and the Company will pay a percentage of gross profits to MediWound on initial committed amounts and a royalty on any additional BARDA purchases of NexoBrid beyond the initial committed amount.  The Company also entered into a supply agreement with MediWound under which MediWound will manufacture NexoBrid for the Company on a unit price basis which may be increased based on a published index. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply. As of June 30, 2020, the milestone payments are not yet probable and therefore, not considered a liability.</span></div> 17500000 17500000 7500000 125000000 7500000 75000000 Commitments and Contingencies <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:13.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's purchase commitments consist of minimum purchase amounts of materials used in the Company's cell manufacturing process to manufacture its marketed cell therapy products.</span></div> XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 6 Months Ended
Jun. 30, 2020
Jul. 31, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2020  
Document Transition Report false  
Entity File Number 001-35280  
Entity Registrant Name VERICEL CORPORATION  
Entity Incorporation, State or Country Code MI  
Entity Tax Identification Number 94-3096597  
Entity Address, Address Line One 64 Sidney Street  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02139  
City Area Code 617  
Local Phone Number 588-5555  
Title of 12(b) Security Common Stock (No par value)  
Trading Symbol VCEL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   45,250,402
Entity Central Index Key 0000887359  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 55,704 $ 26,889
Short term investments 25,086 42,829
Accounts receivable (net of allowance for doubtful accounts of $207 and $306, respectively) 23,655 32,168
Inventory 8,417 6,816
Other current assets 2,900 2,953
Total current assets 115,762 111,655
Property and equipment, net 7,040 7,144
Restricted cash 89 89
Right-of-use leased assets 23,800 25,103
Long term investments 0 9,247
Total assets 146,691 153,238
Current liabilities:    
Accounts payable 4,535 6,345
Accrued expenses 7,975 7,948
Current portion of operating lease liabilities 5,570 5,461
Other liabilities 41 41
Total current liabilities 18,121 19,795
Operating lease liabilities 20,881 22,242
Other long-term liabilities 93 110
Total liabilities 39,095 42,147
COMMITMENTS AND CONTINGENCIES
Shareholders’ equity:    
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding — 45,194 and 44,864, respectively 499,103 489,749
Other comprehensive gain 146 21
Accumulated deficit (391,653) (378,679)
Total shareholders’ equity 107,596 111,091
Total liabilities and shareholders’ equity $ 146,691 $ 153,238
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 207 $ 306
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 45,194,000 44,864,000
Common stock, shares outstanding (in shares) 45,194,000 44,864,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
Product sales, net $ 20,014 $ 26,151 $ 46,692 $ 47,961
Revenue, Product and Service [Extensible List]     us-gaap:ProductMember  
Cost of product sales 8,660 9,022 $ 18,582 17,662
Cost, Product and Service [Extensible List]     us-gaap:ProductMember  
Gross profit 11,354 17,129 $ 28,110 30,299
Research and development 3,226 21,070 6,989 24,078
Selling, general and administrative 16,486 16,259 34,555 29,779
Total operating expenses 19,712 37,329 41,544 53,857
Loss from operations (8,358) (20,200) (13,434) (23,558)
Other income (expense):        
Interest income 147 428 453 908
Other income (expense) (1) (2) (3) (4)
Interest expense (57) (18) 10 18
Total other income (expense) 89 408 460 922
Net loss $ (8,269) $ (19,792) $ (12,974) $ (22,636)
Net loss per share attributable to common shareholders (Basic and Diluted) (in dollars per share) $ (0.18) $ (0.45) $ (0.29) $ (0.52)
Weighted average number of common shares outstanding (Basic and Diluted) (in shares) 45,137 43,956 45,031 43,841
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net loss $ (8,269) $ (19,792) $ (12,974) $ (22,636)
Other comprehensive loss:        
Unrealized gain on investments 84 35 125 38
Comprehensive loss $ (8,185) $ (19,757) $ (12,849) $ (22,598)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Warrants
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2018   43,578      
Beginning balance at Dec. 31, 2018 $ 102,231 $ 471,180 $ 104 $ (39) $ (369,014)
Increase (Decrease) in Shareholders' Equity          
Net loss (2,844)       (2,844)
Compensation expense related to stock options and restricted stock units granted, net of forfeitures 2,628 $ 2,628      
Stock option exercises (in shares)   228      
Stock option exercises 780 $ 780      
Shares issued under the Employee Stock Purchase Plan (in shares)   19      
Shares issued under the Employee Stock Purchase Plan 218 $ 218      
Unrealized gain on investments 42     42  
Ending balance (in shares) at Mar. 31, 2019   43,825      
Ending balance at Mar. 31, 2019 103,055 $ 474,806 104 3 (371,858)
Beginning balance (in shares) at Dec. 31, 2018   43,578      
Beginning balance at Dec. 31, 2018 102,231 $ 471,180 104 (39) (369,014)
Increase (Decrease) in Shareholders' Equity          
Net loss (22,636)        
Unrealized gain on investments 38        
Ending balance (in shares) at Jun. 30, 2019   44,066      
Ending balance at Jun. 30, 2019 88,542 $ 480,050 104 38 (391,650)
Beginning balance (in shares) at Mar. 31, 2019   43,825      
Beginning balance at Mar. 31, 2019 103,055 $ 474,806 104 3 (371,858)
Increase (Decrease) in Shareholders' Equity          
Net loss (19,792)       (19,792)
Compensation expense related to stock options and restricted stock units granted, net of forfeitures 4,183 $ 4,183      
Stock option exercises (in shares)   227      
Stock option exercises 850 $ 850      
Shares issued under the Employee Stock Purchase Plan (in shares)   14      
Shares issued under the Employee Stock Purchase Plan 211 $ 211      
Unrealized gain on investments 35     35  
Ending balance (in shares) at Jun. 30, 2019   44,066      
Ending balance at Jun. 30, 2019 88,542 $ 480,050 104 38 (391,650)
Beginning balance (in shares) at Dec. 31, 2019   44,864      
Beginning balance at Dec. 31, 2019 111,091 $ 489,749 0 21 (378,679)
Increase (Decrease) in Shareholders' Equity          
Net loss (4,705)       (4,705)
Compensation expense related to stock options and restricted stock units granted, net of forfeitures 3,768 $ 3,768      
Stock option exercises (in shares)   57      
Stock option exercises 196 $ 196      
Shares issued under the Employee Stock Purchase Plan (in shares)   20      
Shares issued under the Employee Stock Purchase Plan 224 $ 224      
Issuance of stock upon restricted stock unit vesting (in shares)   36      
Issuance of stock upon restricted stock unit vesting 0        
Restricted stock withheld for employee tax remittance (in shares)   (14)      
Restricted stock withheld for employee tax remittance (163) $ (163)      
Unrealized gain on investments 41     41  
Ending balance (in shares) at Mar. 31, 2020   44,963      
Ending balance at Mar. 31, 2020 110,452 $ 493,774 0 62 (383,384)
Beginning balance (in shares) at Dec. 31, 2019   44,864      
Beginning balance at Dec. 31, 2019 111,091 $ 489,749 0 21 (378,679)
Increase (Decrease) in Shareholders' Equity          
Net loss (12,974)        
Unrealized gain on investments 125        
Ending balance (in shares) at Jun. 30, 2020   45,194      
Ending balance at Jun. 30, 2020 107,596 $ 499,103 0 146 (391,653)
Beginning balance (in shares) at Mar. 31, 2020   44,963      
Beginning balance at Mar. 31, 2020 110,452 $ 493,774 0 62 (383,384)
Increase (Decrease) in Shareholders' Equity          
Net loss (8,269)       (8,269)
Compensation expense related to stock options and restricted stock units granted, net of forfeitures 4,376 $ 4,376      
Stock option exercises (in shares)   188      
Stock option exercises 696 $ 696      
Shares issued under the Employee Stock Purchase Plan (in shares)   32      
Shares issued under the Employee Stock Purchase Plan 257 $ 257      
Issuance of stock upon restricted stock unit vesting (in shares)   11      
Issuance of stock upon restricted stock unit vesting 0        
Unrealized gain on investments 84     84  
Ending balance (in shares) at Jun. 30, 2020   45,194      
Ending balance at Jun. 30, 2020 $ 107,596 $ 499,103 $ 0 $ 146 $ (391,653)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Operating activities:    
Net loss $ (12,974) $ (22,636)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:    
Depreciation and amortization expense 1,079 698
Stock compensation expense 8,144 6,810
Foreign currency translation loss 45 13
Loss on sale of fixed assets 30 0
Amortization of premiums and discounts on marketable securities (25) (408)
Amortization and interest accretion related to operating leases 1,603 1,139
Changes in operating assets and liabilities:    
Inventory (1,601) (1,230)
Accounts receivable 8,513 2,370
Prepaid and other current assets 53 680
Accounts payable (1,692) (2,238)
Accrued expenses 27 (2,229)
Operating lease liabilities (1,537) (1,007)
Other non-current assets and liabilities, net 0 (187)
Net cash provided by (used for) operating activities 1,665 (18,225)
Investing activities:    
Purchases of short term investments (5,657) (32,402)
Maturities of short term investments 32,797 45,477
Expenditures for property, plant and equipment (1,186) (1,224)
Net cash provided by investing activities 25,954 11,851
Financing activities:    
Net proceeds from common stock issuance due to stock option exercises 1,373 2,059
Payments on employee's behalf for taxes related to vesting of restricted stock unit awards (163) 0
Other (14) (9)
Net cash provided by financing activities 1,196 2,050
Net increase in cash, cash equivalents, and restricted cash 28,815 (4,324)
Cash, cash equivalents, and restricted cash at beginning of period 26,978 18,286
Cash, cash equivalents, and restricted cash at end of period $ 55,793 $ 13,962
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Organization
 6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
 
Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced cell therapies for the sports medicine and severe burn care markets. Vericel currently markets two cell therapy products, MACI® and Epicel®, in the United States. Vericel obtained both products in May 2014, as part of the acquisition of certain assets and the assumption of certain liabilities from Sanofi, a French société anonyme (Sanofi).

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Company also markets Epicel® (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA). The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of biopharmaceuticals for use in the treatment of specific diseases.

COVID-19

The novel coronavirus (COVID-19) outbreak was first reported by China in late December 2019 and rapidly spread globally. The World Health Organization (WHO) declared the outbreak a pandemic on March 11, 2020 and the President of the United States declared a national health emergency two days later. Subsequently most states' governments, including those in Massachusetts and Michigan where the Company's operations are located, issued orders requiring businesses that do not conduct essential services to temporarily close their physical workplaces to employees and customers. The status of such orders varies on a state-by-state basis and is likely to continue to vary. Because Vericel is deemed an essential business, the Company is exempt from these state orders in their current form.

Notwithstanding being an essential business, the Company’s business and operations have been, and are expected to continue to be, adversely impacted by the effects of COVID-19 as a result of various factors including, without limitation, patients’ potential reluctance to undergo elective surgical procedures, healthcare facility restrictions regarding elective surgical procedures, the recent economic downturn due to the pandemic, the imposition of related public health measures and travel and business restrictions and disruptions to the ability of the Company’s employees to perform their jobs.

The implantation of MACI is an elective surgical procedure. On March 13, 2020 and March 14, 2020, the American College of Surgeons and United States Surgeon General, respectively, recommended that each hospital, health system, and surgeon minimize, postpone, or cancel electively scheduled surgeries, which has resulted in a reduction in MACI sales. The stated purpose for these recommendations was that every elective surgery could spread COVID-19 within a facility, use up personal protective equipment (PPE) which may be needed by healthcare workers treating COVID-19 patients, and burden hospital workforce who may be needed to respond to COVID-19. These recommendations were followed by numerous state level executive orders either banning or partially banning elective surgeries. As a result of these restrictions, beginning in mid-March 2020, the Company started to experience a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders. By early April 2020, 45 states, representing over 95% of total U.S. surgical capacity had issued either mandates or recommendations and guidelines suspending elective surgical procedures. These restrictions began to ease in May and, by the end of June 2020, states representing an estimated 90% total U.S. surgical capacity had lifted restrictions suspending elective procedures. It is likely that restrictions will continue to be both lifted and re-imposed as regional COVID 19 cases rates fall and rise. The Company’s MACI business will continue to be negatively impacted so long as multiple state orders and/or facilities restrict elective surgical procedures.
Going Concern

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.  As of June 30, 2020, the Company had an accumulated deficit of $391.7 million and incurred a net loss of $8.3 million and $13.0 million for the three and six months ended June 30, 2020, respectively.  The Company had cash and cash equivalents of $55.8 million and investments of $25.1 million as of June 30, 2020. The Company expects that existing cash, cash equivalents and investments will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these financial statements. However, the continuing effects of the COVID-19 pandemic may require the Company to engage in layoffs, furloughs and/or reductions in salary, all of which may result in irrecoverable losses of customers and significantly impact long-term liquidity. If elective surgery restrictions are reinstated on a widespread basis, significantly impacting the Company's business, the Company may need to access additional capital; however, the Company may not be able to obtain financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying condensed consolidated financial statements as of June 30, 2020 and for the three and six months ended June 30, 2020 are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in U.S. GAAP requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to continue to contain it or treat COVID-19, as well as the economic impact on our customers. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. As of June 30, 2020, the Company has not recorded impairments to investments, inventory, other current assets or long-lived assets as a result of the COVID-19 pandemic and does not expect material impairments in the future. The Company has assessed the impact of COVID-19 on accounts receivables (see note 4).
 
These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on February 25, 2020 (Annual Report).
Consolidated Statement of Cash Flows

The following table presents certain supplementary cash flows information for the six months ended June 30, 2020 and 2019:
Six Months Ended June 30,
(In thousands)20202019
Supplementary Cash Flows information:
Non-cash information:
Right-of-use asset and lease liability recognized$429  $560  
Additions to property, plant and equipment included in accounts payable55  365  
Cash information:
Interest paid (net of interest capitalized)$3  $4  

Total cash, cash equivalents, and restricted cash of $55.8 million as of June 30, 2020, shown in the statement of cash flows is comprised of cash and cash equivalents of $55.7 million and restricted cash of $0.1 million which is included in other long term assets on the consolidated balance sheet. As of June 30, 2019, cash and cash equivalents were $14.0 million and the Company did not have any restricted cash.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Recent Accounting Pronouncements
 6 Months Ended
Jun. 30, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]  
Recent Accounting Pronouncements Recent Accounting Pronouncements
Measuring Credit Losses on Financial Instruments

The FASB issued updated guidance on measuring credit losses on financial instruments. The guidance removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Prior to the updated guidance, credit losses are recognized when it is probable that the loss has been incurred. The revised guidance removes all recognition thresholds and requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that a company expected to collect over the instrument’s contractual life. The Accounting Standard Update (ASU) 2016-13, Financial Instruments-Credit Losses (Topic 326), became effective for the Company January 1, 2020. See note 4 and note 8 for further discussion.

Fair Value Measurement Disclosure

The FASB issued updated guidance through ASU 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The revised guidance is intended to develop a more consistent disclosure framework that will increase clarity, remove, modify and add certain fair value disclosures to improve the effectiveness of the Company’s disclosures in the notes of the financial statements. This guidance became effective for the Company January 1, 2020 and had no impact to its condensed consolidated financial statements.

Simplifying the Accounting for Income Taxes

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company is currently in the process of evaluating the impact to its condensed consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue
 6 Months Ended
Jun. 30, 2020
Risks and Uncertainties [Abstract]  
Revenue Revenue
Revenue Recognition and Net Product Sales
The Company recognizes product revenue from sales of MACI kits, MACI implants and Epicel grafts following the five-step model in Accounting Standards Codification 606, Revenue Recognition, (ASC 606).
MACI Kits
MACI kits are sold directly to hospitals based on contracted rates in the approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit at which time the customer (the facility) is in control of the kit. The kit provides the doctor the ability to biopsy a sampling of cells to provide to the Company that can be used later to manufacture the implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cell tissue. The customer’s order of an implant is separate from the process of ordering the kit. Therefore, the sale of the kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.
MACI Implants
The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (Orsini) and AllCare Plus Pharmacy, Inc. (AllCare) to distribute its MACI product in arrangements whereby the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to receive payment from customers. The Company has engaged a third-party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical (DMS) for military implants. The sales directly to DMS are sold at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenues from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration which the Company expects to collect in exchange for MACI implants (the transaction price) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and other than customary prompt pay discounts, there are typically no forms of variable consideration.

When the Company sells MACI the patient is responsible for payment, however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates or a fee schedule. Net product revenue is recognized net of contractual allowances, which considers historical collection experience from both the payer and patient and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. These estimates include the impact of contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company's accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling account receivables based on similar risk characteristics. The loss percentage is based on current and historical information as well as reasonable and supportable forecasts. This loss percentage was applied to the accounts receivables as of June 30, 2020. The total allowance for uncollectible consideration was $4.4 million as of June 30, 2020 and $3.9 million at December 31, 2019. The allowance includes less than $0.1 million of which is related to COVID-19 potential impacts on accounts receivable from third-party insurers, government payers, hospitals and patients. Changes to the estimate of the amount of consideration that will not be collected could have a material impact to the revenue recognized. A 0.5% change to the estimated uncollectible percentage could result in approximately a $0.1 million decrease in the revenue recognized for the six months ended June 30, 2020.

Changes in estimates of the transaction price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior period sales for the three and six months ended June 30, 2020 resulted in a decrease to revenue of $0.2 million and increase to revenue of $1.1 million, respectively, and an increase to revenue of $0.09 million and $0.05 million, respectively for the same period in 2019. The changes in estimates recorded during the three and six months ended June 30, 2020, were primarily due to completion of the billing claims process for implants that occurred in late 2019. Upon completion of the billing claims process, the Company concluded that it was probable that a significant reversal in the amount of revenue recognized would not occur.
Epicel
The Company sells Epicel directly to hospitals based on contracted rates stated in the approved contract or purchase order. Similar to MACI, there is no obligation to manufacture skin grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenues from sales of Epicel upon delivery to the hospital at which time the customer is in control of the skin grafts and the claim is billable to the hospital.
Revenue by Product and Customer
The following table and description below shows the products from which the Company generated its revenue:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2020201920202019
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)$9,790  $12,989  $21,218  $22,776  
Implants subject to third party reimbursement sold through a specialty pharmacy (b)2,819  3,459  6,335  6,202  
Implants sold direct based on contracted rates (c)1,806  3,450  4,916  6,676  
Implants sold direct subject to third party reimbursement (d)589  281  1,016  603  
Biopsy kits - direct bill348  557  811  1,099  
Change in estimates related to prior periods (e)(248) 87  1,095  50  
Epicel
     Direct bill (hospital)4,910  5,328  11,301  10,555  
Total revenue$20,014  $26,151  $46,692  $47,961  
(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.
(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period.
Concentration of Credit Risk

The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below.
Revenue ConcentrationAccounts Receivable Concentration
Three Months Ended June 30,Six Months Ended June 30,June 30,December 31,
202020192020201920202019
Epicel6 %6 %10 %8 %3 %2 %
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Selected Balance Sheet Components
 6 Months Ended
Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]  
Selected Balance Sheet Components Selected Balance Sheet Components
 
Inventory

Inventory as of June 30, 2020 and December 31, 2019:
 
(In thousands)June 30, 2020December 31, 2019
Raw materials$7,853  $6,085  
Work-in-process513  541  
Finished goods51  190  
Inventory$8,417  $6,816  
 
Property and Equipment

Property and Equipment, net as of June 30, 2020 and December 31, 2019:
 
(In thousands)June 30, 2020December 31, 2019
Machinery and equipment$3,279  $3,152  
Furniture, fixtures and office equipment810  775  
Computer equipment and software6,393  6,174  
Leasehold improvements5,256  5,256  
Construction in process1,311  859  
Financing right-of-use lease129  148  
Total property and equipment, gross17,178  16,364  
Less accumulated depreciation(10,138) (9,220) 
$7,040  $7,144  
 
Depreciation expense for the three and six months ended June 30, 2020 was $0.5 million and $1.1 million, respectively, and $0.4 million and $0.7 million for the same periods in 2019.
 
Accrued Expenses

Accrued Expenses as of June 30, 2020 and December 31, 2019 are as follows:
 
(In thousands)June 30, 2020December 31, 2019
Bonus related compensation$2,872  $5,116  
Employee related accruals2,578  1,785  
Other accrued expenses2,525  1,047  
Accrued expenses$7,975  $7,948  
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
 6 Months Ended
Jun. 30, 2020
Leases [Abstract]  
Leases Leases
The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases offsite warehouse space, vehicles and computer equipment. Certain of the Company’s lease agreements include lease payments that are adjusted periodically for an index or rate. The leases are initially measured using the projected payments adjusted for the index or rate in effect at the commencement date. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. All operating lease commitments with a lease term greater than 12 months are recognized as right to use assets and liabilities, on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the balance sheet and for both the three and six months ended June 30, 2020 and 2019, lease expense of less than $0.1 million was recorded related to short-term leases.

The contribution toward the cost of tenant improvements is recorded as a reduction of the operating lease assets. For the three and six months ended June 30, 2020, the Company recognized $1.4 million and $2.9 million of operating lease expense and $1.3 million and $2.6 million for the same periods in 2019.

For both the three and six months ended June 30, 2020 and 2019, the Company recognized less than $0.1 million of financing lease expense. The Company’s leases contain non-lease components and activities that do not transfer a good or service to the Company. The Company elected not to combine lease and non-lease components and therefore non-lease costs were not included in the net lease assets or lease liabilities.

Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:

(In thousands)ClassificationJune 30, 2020December 31, 2019
Assets
OperatingRight-of-use assets$23,800  $25,103  
FinanceProperty and equipment, net129  148  
$23,929  $25,251  
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$5,570  $5,461  
FinanceOther liabilities41  41  
$5,611  $5,502  
Non-current
OperatingOperating lease liabilities$20,881  $22,242  
FinanceOther long-term liabilities93  110  
$20,974  $22,352  
Leases Leases
The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases offsite warehouse space, vehicles and computer equipment. Certain of the Company’s lease agreements include lease payments that are adjusted periodically for an index or rate. The leases are initially measured using the projected payments adjusted for the index or rate in effect at the commencement date. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. All operating lease commitments with a lease term greater than 12 months are recognized as right to use assets and liabilities, on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the balance sheet and for both the three and six months ended June 30, 2020 and 2019, lease expense of less than $0.1 million was recorded related to short-term leases.

The contribution toward the cost of tenant improvements is recorded as a reduction of the operating lease assets. For the three and six months ended June 30, 2020, the Company recognized $1.4 million and $2.9 million of operating lease expense and $1.3 million and $2.6 million for the same periods in 2019.

For both the three and six months ended June 30, 2020 and 2019, the Company recognized less than $0.1 million of financing lease expense. The Company’s leases contain non-lease components and activities that do not transfer a good or service to the Company. The Company elected not to combine lease and non-lease components and therefore non-lease costs were not included in the net lease assets or lease liabilities.

Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:

(In thousands)ClassificationJune 30, 2020December 31, 2019
Assets
OperatingRight-of-use assets$23,800  $25,103  
FinanceProperty and equipment, net129  148  
$23,929  $25,251  
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$5,570  $5,461  
FinanceOther liabilities41  41  
$5,611  $5,502  
Non-current
OperatingOperating lease liabilities$20,881  $22,242  
FinanceOther long-term liabilities93  110  
$20,974  $22,352  
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
 
Stock Option, Restricted Stock Units and Equity Incentive Plans
 
The Company has historically had various stock incentive plans and agreements that provide for the issuance of nonqualified and incentive stock options and restricted stock units as well as other equity awards.  Such awards may be granted by the Company’s Board of Directors to certain of the Company’s employees, directors and consultants. 

Options and restricted stock units granted to employees and non-employees under these plans expire no later than ten years from the date of grant and generally become exercisable over a four year period, under a graded-vesting methodology for stock options and annually on the anniversary grant date for restricted stock units, following the date of grant.  The Company generally issues new shares upon the exercise of stock options or vesting of restricted stock units.

The 2019 Omnibus Incentive Plan (2019 Plan) was approved on May 1, 2019 and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units.  The exercise price of stock options granted under the 2019 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant.  The 2019 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan and the 2017 Omnibus Incentive Plan (Prior Plans), and no new grants have been granted under the Prior Plans after approval.  However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2019 Plan.

The Amended and Restated 2019 Omnibus Incentive Plan (Amended and Restated 2019 Plan) was approved on April 29, 2020. Amendments to the Amended and Restated 2019 Omnibus Plan included increasing the total number of shares of the Company's common stock reserved for issuance under the 2019 Plan by 2,400,000 shares, a revised ratio at which "full- value" awards are counted against the share reserve from 1.25 to 1.4, and extending the term of the plan to April 29, 2030.
 
As of June 30, 2020, there were 4,267,255 shares available for future grant under the Amended and Restated 2019 Plan.

Employee Stock Purchase Plan

Employees are able to purchase stock under the Vericel Corporation Employee Stock Purchase Plan (ESPP). The ESPP allows for the issuance of an aggregate of 1,000,000 shares of common stock of which 672,907 have been issued since the inception of the benefit in 2015. Participation in this plan is available to substantially all employees. The ESPP is a compensatory plan accounted for under the expense recognition provisions of the share-based payment accounting standards. Compensation expense is recorded based on the fair market value of the purchase options at the grant date, which corresponds to the first day of each purchase period and is amortized over the purchase period. In July 2020, employees purchased 44,137 shares resulting in proceeds from the sale of common stock of $0.3 million under the ESPP for the second quarter of 2020.

Service-Based Stock Options
 
During the three and six months ended June 30, 2020, the Company granted service-based options to purchase common stock of 110,750 and 1,296,890, respectively, and 152,500 and 1,638,510, respectively, for the same periods in 2019.  The exercise price of the options is the fair market value per share of common stock on the grant date, generally vest over four years (other than non-employee director options which vest over one year) and have a term of ten years. The Company issues new shares upon the exercise of stock options.  The weighted average grant-date fair value of service-based options granted during the three and six months ended June 30, 2020 was $8.82 and $8.66, respectively and $11.94 and $12.74, respectively, for the same periods in 2019.
Restricted Stock Units

During the three and six months ended June 30, 2020 and 2019, the Company granted 10,700 and 196,836, service-based restricted stock units, respectively and 10,500 and 186,922, respectively, for the same periods in 2019. The restricted stock units vest annually over four years in equal installments commencing on the first anniversary of the grant date (other than non-employee director options which vest over one year from the grant date). The Company issues new shares upon the vesting of restricted stock units. Restricted stock awards are recorded at fair value at the date of grant, which is based on the closing share price on the grant date. Compensation expense is recorded for restricted stock units that are expected to vest based on their fair value at grant date and is amortized over the expected vesting period. The weighted average grant-date fair value of restricted stock units granted during the three and six months ended June 30, 2020 was $14.49 and $11.41, respectively and $16.62 and $17.71, respectively, for the same periods in 2019. The aggregate fair value of restricted stock units granted in the three and six months ended June 30, 2020 was $0.2 million and $2.2 million, respectively and $0.2 million and $3.3 million, respectively, for the same periods in 2019.

As a result of 36,212 units vesting during the three months ended March 31, 2020, 13,872 shares were withheld for payment of taxes on the employee's behalf and retired from the 2019 Plan. During the three months ended June 30, 2020, 10,500 units vested and no shares were withheld for payment of taxes, as no shares are withheld at vesting for shares awarded to the Company's Board of Directors.

Stock Compensation Expense
 
Non-cash stock-based compensation expense (employee stock purchase plan, service-based stock options and restricted stock units) included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table: 
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2020201920202019
Cost of goods sold$568  $716  $997  $976  
Research and development484  886  $1,060  1,410  
Selling, general and administrative3,325  2,581  $6,087  4,424  
Total non-cash stock-based compensation expense$4,377  $4,183  $8,144  $6,810  
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Cash Equivalents and Investments
 6 Months Ended
Jun. 30, 2020
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Investments Cash Equivalents and Investments
Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities as of June 30, 2020 and December 31, 2019:
June 30, 2020
Gross UnrealizedEstimated Fair Value
Amortized CostGainsLossesCredit Losses
Money market funds$44,985  $—  $—  —  $44,985  
Commercial paper3,685  —  —  —  3,685  
Corporate notes8,840  55  —  —  8,895  
U.S. government securities7,776  67  —  —  7,843  
U.S. asset-backed securities4,640  23  —  —  4,663  
$69,926  $145  $—  $—  $70,071  
Classified as:
Cash equivalents$44,985  
Short term investments25,086  
$70,071  
December 31, 2019
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLosses
Money market funds$5,381  $—  $—  $5,381  
Commercial paper11,892  —  —  11,892  
Corporate notes18,369  11  —  18,380  
U.S. government securities11,291  4  —  11,295  
U.S. asset-backed securities10,503  6  —  10,509  
$57,436  $21  $—  $57,457  
Classified as:
Cash equivalents$5,381  
Short-term investments42,829  
Long term investments9,247  
$57,457  

As of June 30, 2020 and December 31, 2019, we held both short-term and long-term investments. Investments classified as short-term have maturities of less than one year. Investments classified as long-term are those that: (i) have a maturity of greater than one year, and (ii) we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale. The Company's investment strategy is to buy short-duration marketable securities with a high credit rating. As of June 30, 2020, all marketable securities held by the Company had remaining contractual maturities of three years or less.

Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders’ equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, Financial Instruments - Credit Losses, to determine if the impairment is credit-related or non credit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and non credit-related impairment is recognized in other comprehensive income, net of taxes. There were no material realized losses on marketable securities for the three and six months ended June 30, 2020 and 2019.
The Company evaluated its investments for impairment under ASC 326. Any allowance for credit losses are recorded at the lower of either the fair market value less book value or the difference between the present value of future cash flows and the book value. As of June 30, 2020, the analysis under ASU 2016-13 and the current macroeconomic impact of the COVID-19 pandemic did not result in material allowances for credit losses. There have been no impairments of the Company’s assets measured and carried at fair value as of June 30, 2020.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
 
The Company’s fair value measurements are classified and disclosed in one of the following three categories:
 
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
 
There was no movement between Level 1 and Level 2 or between Level 2 and Level 3 from December 31, 2019 to June 30, 2020. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities and asset-backed securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:
 June 30, 2020December 31, 2019
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$44,985  $44,985  $—  $—  $5,381  $5,381  $—  $—  
Commercial paper3,685  —  3,685  —  11,892  —  11,892  —  
Corporate notes8,895  —  8,895  —  18,380  —  18,380  —  
U.S. government securities7,843  —  7,843  —  11,295  —  11,295  —  
U.S. asset-backed securities4,663  —  4,663  —  10,509  —  10,509  —  
$70,071  $44,985  $25,086  $—  $57,457  $5,381  $52,076  $—  

The fair values of the cash equivalents and marketable securities are based on observable market prices. See note 8 for impact of ASU 2016-13 on the investment valuation.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share
 6 Months Ended
Jun. 30, 2020
Earnings Per Share [Abstract]  
Net Loss Per Common Share Net Loss Per Common Share
The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method:
 Three Months Ended June 30,Six Months Ended June 30,
(Amounts in thousands, except per share amounts)2020201920202019
Numerator:  
Net loss$(8,269) $(19,792) $(12,974) $(22,636) 
Denominator:   
Basic and diluted EPS: weighted-average common shares outstanding45,137  43,956  45,031  43,841  
Net loss per share attributable to common shareholders (basic and diluted)$(0.18) $(0.45) $(0.29) $(0.52) 
Anti-dilutive shares excluded from the calculation of diluted earnings per share(a) (amounts in millions):
Stock options6.0  5.6  6.0  5.6  
Restricted stock unit awards0.3  0.2  0.3  0.2  
Warrants—  0.1  —  0.1  
(a) Common equivalent shares are not included in the diluted per share calculation where the effect of their inclusion would be anti-dilutive. 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Nexobrid License and Supply Agreements
 6 Months Ended
Jun. 30, 2020
Related Party Transactions [Abstract]  
Nexobrid License and Supply Agreements NexoBrid License and Supply Agreements
On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound Ltd. (MediWound) to commercialize NexoBrid® and any improvements to NexoBrid in all countries of North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

NexoBrid is currently in clinical development in North America, and pursuant to the terms of the license agreement, MediWound will continue to conduct all clinical activities described in the development plan to support the BLA filing with the United States Food and Drug Administration (FDA) under the supervision of a Central Steering Committee comprised of members of each party. On June 30, 2020, the Company announced the submission of the BLA to the FDA seeking the approval of NexoBrid. NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic in the United States, European Union and other international markets.

In May 2019, the Company paid MediWound $17.5 million in consideration of the license. The $17.5 million upfront payment was recorded to research and development expense during 2019, as the license was considered in process research and development.  The Company is also obligated to pay MediWound $7.5 million upon U.S. regulatory approval of the BLA for NexoBrid and up to $125 million contingent upon meeting certain sales milestones.  The first sales milestone of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75 million.  The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. The U.S. Biomedical Advanced Research and Development Authority (BARDA) has committed to procure NexoBrid, and the Company will pay a percentage of gross profits to MediWound on initial committed amounts and a royalty on any additional BARDA purchases of NexoBrid beyond the initial committed amount.  The Company also entered into a supply agreement with MediWound under which MediWound will manufacture NexoBrid for the Company on a unit price basis which may be increased based on a published index. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply. As of June 30, 2020, the milestone payments are not yet probable and therefore, not considered a liability.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
 
The Company's purchase commitments consist of minimum purchase amounts of materials used in the Company's cell manufacturing process to manufacture its marketed cell therapy products.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation - (Policies)
 6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Recent Accounting Pronouncements Recent Accounting Pronouncements
Measuring Credit Losses on Financial Instruments

The FASB issued updated guidance on measuring credit losses on financial instruments. The guidance removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Prior to the updated guidance, credit losses are recognized when it is probable that the loss has been incurred. The revised guidance removes all recognition thresholds and requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that a company expected to collect over the instrument’s contractual life. The Accounting Standard Update (ASU) 2016-13, Financial Instruments-Credit Losses (Topic 326), became effective for the Company January 1, 2020. See note 4 and note 8 for further discussion.

Fair Value Measurement Disclosure

The FASB issued updated guidance through ASU 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The revised guidance is intended to develop a more consistent disclosure framework that will increase clarity, remove, modify and add certain fair value disclosures to improve the effectiveness of the Company’s disclosures in the notes of the financial statements. This guidance became effective for the Company January 1, 2020 and had no impact to its condensed consolidated financial statements.

Simplifying the Accounting for Income Taxes

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company is currently in the process of evaluating the impact to its condensed consolidated financial statements.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation (Tables)
 6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Supplementary cash flows information
The following table presents certain supplementary cash flows information for the six months ended June 30, 2020 and 2019:
Six Months Ended June 30,
(In thousands)20202019
Supplementary Cash Flows information:
Non-cash information:
Right-of-use asset and lease liability recognized$429  $560  
Additions to property, plant and equipment included in accounts payable55  365  
Cash information:
Interest paid (net of interest capitalized)$3  $4  
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2020
Risks and Uncertainties [Abstract]  
Disaggregation of Revenue
The following table and description below shows the products from which the Company generated its revenue:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2020201920202019
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)$9,790  $12,989  $21,218  $22,776  
Implants subject to third party reimbursement sold through a specialty pharmacy (b)2,819  3,459  6,335  6,202  
Implants sold direct based on contracted rates (c)1,806  3,450  4,916  6,676  
Implants sold direct subject to third party reimbursement (d)589  281  1,016  603  
Biopsy kits - direct bill348  557  811  1,099  
Change in estimates related to prior periods (e)(248) 87  1,095  50  
Epicel
     Direct bill (hospital)4,910  5,328  11,301  10,555  
Total revenue$20,014  $26,151  $46,692  $47,961  
(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.
(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period.
Schedules of concentration of risk
The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below.
Revenue ConcentrationAccounts Receivable Concentration
Three Months Ended June 30,Six Months Ended June 30,June 30,December 31,
202020192020201920202019
Epicel6 %6 %10 %8 %3 %2 %
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Selected Balance Sheet Components (Tables)
 6 Months Ended
Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]  
Schedule of inventory
Inventory as of June 30, 2020 and December 31, 2019:
 
(In thousands)June 30, 2020December 31, 2019
Raw materials$7,853  $6,085  
Work-in-process513  541  
Finished goods51  190  
Inventory$8,417  $6,816  
Schedule of property and equipment, net
Property and Equipment, net as of June 30, 2020 and December 31, 2019:
 
(In thousands)June 30, 2020December 31, 2019
Machinery and equipment$3,279  $3,152  
Furniture, fixtures and office equipment810  775  
Computer equipment and software6,393  6,174  
Leasehold improvements5,256  5,256  
Construction in process1,311  859  
Financing right-of-use lease129  148  
Total property and equipment, gross17,178  16,364  
Less accumulated depreciation(10,138) (9,220) 
$7,040  $7,144  
Schedule of accrued expenses
Accrued Expenses as of June 30, 2020 and December 31, 2019 are as follows:
 
(In thousands)June 30, 2020December 31, 2019
Bonus related compensation$2,872  $5,116  
Employee related accruals2,578  1,785  
Other accrued expenses2,525  1,047  
Accrued expenses$7,975  $7,948  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2020
Leases [Abstract]  
Assets And Liabilities
Total leased assets and liabilities as reassessed under the updated guidance and classified on the balance sheet, as of June 30, 2020 and December 31, 2019 are as follows:

(In thousands)ClassificationJune 30, 2020December 31, 2019
Assets
OperatingRight-of-use assets$23,800  $25,103  
FinanceProperty and equipment, net129  148  
$23,929  $25,251  
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$5,570  $5,461  
FinanceOther liabilities41  41  
$5,611  $5,502  
Non-current
OperatingOperating lease liabilities$20,881  $22,242  
FinanceOther long-term liabilities93  110  
$20,974  $22,352  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of non-cash stock-based compensation expense
Non-cash stock-based compensation expense (employee stock purchase plan, service-based stock options and restricted stock units) included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table: 
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2020201920202019
Cost of goods sold$568  $716  $997  $976  
Research and development484  886  $1,060  1,410  
Selling, general and administrative3,325  2,581  $6,087  4,424  
Total non-cash stock-based compensation expense$4,377  $4,183  $8,144  $6,810  
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Cash Equivalents and Investments (Tables)
 6 Months Ended
Jun. 30, 2020
Cash and Cash Equivalents [Abstract]  
Schedule of fair value of securities, not including cash he following tables summarize the gross unrealized gains and losses of the Company’s marketable securities as of June 30, 2020 and December 31, 2019:
June 30, 2020
Gross UnrealizedEstimated Fair Value
Amortized CostGainsLossesCredit Losses
Money market funds$44,985  $—  $—  —  $44,985  
Commercial paper3,685  —  —  —  3,685  
Corporate notes8,840  55  —  —  8,895  
U.S. government securities7,776  67  —  —  7,843  
U.S. asset-backed securities4,640  23  —  —  4,663  
$69,926  $145  $—  $—  $70,071  
Classified as:
Cash equivalents$44,985  
Short term investments25,086  
$70,071  
December 31, 2019
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLosses
Money market funds$5,381  $—  $—  $5,381  
Commercial paper11,892  —  —  11,892  
Corporate notes18,369  11  —  18,380  
U.S. government securities11,291  4  —  11,295  
U.S. asset-backed securities10,503  6  —  10,509  
$57,436  $21  $—  $57,457  
Classified as:
Cash equivalents$5,381  
Short-term investments42,829  
Long term investments9,247  
$57,457  
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
Summary of valuation of the Company's investments and financial instruments that are measured at fair value on a recurring basis The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:
 June 30, 2020December 31, 2019
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$44,985  $44,985  $—  $—  $5,381  $5,381  $—  $—  
Commercial paper3,685  —  3,685  —  11,892  —  11,892  —  
Corporate notes8,895  —  8,895  —  18,380  —  18,380  —  
U.S. government securities7,843  —  7,843  —  11,295  —  11,295  —  
U.S. asset-backed securities4,663  —  4,663  —  10,509  —  10,509  —  
$70,071  $44,985  $25,086  $—  $57,457  $5,381  $52,076  $—  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share (Tables)
 6 Months Ended
Jun. 30, 2020
Earnings Per Share [Abstract]  
Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method
The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method:
 Three Months Ended June 30,Six Months Ended June 30,
(Amounts in thousands, except per share amounts)2020201920202019
Numerator:  
Net loss$(8,269) $(19,792) $(12,974) $(22,636) 
Denominator:   
Basic and diluted EPS: weighted-average common shares outstanding45,137  43,956  45,031  43,841  
Net loss per share attributable to common shareholders (basic and diluted)$(0.18) $(0.45) $(0.29) $(0.52) 
Anti-dilutive shares excluded from the calculation of diluted earnings per share(a) (amounts in millions):
Stock options6.0  5.6  6.0  5.6  
Restricted stock unit awards0.3  0.2  0.3  0.2  
Warrants—  0.1  —  0.1  
(a) Common equivalent shares are not included in the diluted per share calculation where the effect of their inclusion would be anti-dilutive. 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Organization - Narrative (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
product
Mar. 31, 2020
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
product
segment
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]                
Number of therapy products | product 2       2      
Number of reportable segments | segment         1      
Accumulated deficit $ 391,653       $ 391,653   $ 378,679  
Net loss 8,269 $ 4,705 $ 19,792 $ 2,844 12,974 $ 22,636    
Cash, cash equivalents, and restricted cash 55,793   $ 13,962   55,793 $ 13,962 $ 26,978 $ 18,286
Short term investments $ 25,100       $ 25,100      
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation - Supplementary cash flows information (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Non-cash information:    
Right-of-use asset and lease liability recognized $ 429 $ 560
Additions to property, plant and equipment included in accounts payable 55 365
Interest paid (net of interest capitalized) $ 3 $ 4
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation - Narrative (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2019
Dec. 31, 2018
Accounting Policies [Abstract]        
Cash, cash equivalents, and restricted cash $ 55,793,000 $ 26,978,000 $ 13,962,000 $ 18,286,000
Cash and cash equivalents 55,704,000 $ 26,889,000 14,000,000.0  
Restricted cash $ 100,000   $ 0  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
pharmacy
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
pharmacy
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
CONCENTRATION          
Number of specialty pharmacies | pharmacy 2   2    
Allowance for doubtful accounts $ 4,400   $ 4,400   $ 3,900
Change in estimate of uncollectible (percent)     0.50%    
Change in revenue recognized due to 0.5% change in uncollectible percentage     $ 100    
Increase (decrease) to revenues 20,014 $ 26,151 46,692 $ 47,961  
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606          
CONCENTRATION          
Increase (decrease) to revenues (248) $ 87 1,095 $ 50  
COVID-19 potential impacts          
CONCENTRATION          
Allowance for doubtful accounts $ 100   $ 100    
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Disaggregation of Revenue [Line Items]        
Product sales, net $ 20,014 $ 26,151 $ 46,692 $ 47,961
Revenues 20,014 26,151 46,692 47,961
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606        
Disaggregation of Revenue [Line Items]        
Product sales, net (248) 87 1,095 50
Through Intermediary | Implants | Contract rate        
Disaggregation of Revenue [Line Items]        
Product sales, net 9,790 12,989 21,218 22,776
Through Intermediary | Implants | Time-and-materials contract        
Disaggregation of Revenue [Line Items]        
Product sales, net 2,819 3,459 6,335 6,202
Time-and-materials contract | Implants | Time-and-materials contract        
Disaggregation of Revenue [Line Items]        
Product sales, net 589 281 1,016 603
Provider or Facility | Implants | Contract rate        
Disaggregation of Revenue [Line Items]        
Product sales, net 1,806 3,450 4,916 6,676
Directly to consumer | Biopsy kits        
Disaggregation of Revenue [Line Items]        
Product sales, net 348 557 811 1,099
Directly to consumer | Epicel        
Disaggregation of Revenue [Line Items]        
Product sales, net $ 4,910 $ 5,328 $ 11,301 $ 10,555
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Schedules of concentration of risk (Details) - Customer concentration - Epicel
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Revenue Concentration          
Product Information [Line Items]          
Concentration risk (as a percent) 6.00% 6.00% 10.00% 8.00%  
Accounts Receivable Concentration          
Product Information [Line Items]          
Concentration risk (as a percent)     3.00%   2.00%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Selected Balance Sheet Components - Schedule of inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Inventory:    
Raw materials $ 7,853 $ 6,085
Work-in-process 513 541
Finished goods 51 190
Inventory $ 8,417 $ 6,816
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Selected Balance Sheet Components - Schedule of property and equipment, net (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Property and equipment, net:          
Financing right-of-use lease $ 129   $ 129   $ 148
Total property and equipment, gross 17,178   17,178   16,364
Less accumulated depreciation (10,138)   (10,138)   (9,220)
Property and equipment, net 7,040   7,040   7,144
Depreciation expense 500 $ 400 1,100 $ 700  
Machinery and equipment          
Property and equipment, net:          
Total property and equipment, gross 3,279   3,279   3,152
Furniture, fixtures and office equipment          
Property and equipment, net:          
Total property and equipment, gross 810   810   775
Computer equipment and software          
Property and equipment, net:          
Total property and equipment, gross 6,393   6,393   6,174
Leasehold improvements          
Property and equipment, net:          
Total property and equipment, gross 5,256   5,256   5,256
Construction in process          
Property and equipment, net:          
Total property and equipment, gross $ 1,311   $ 1,311   $ 859
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Selected Balance Sheet Components - Schedule of accrued expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Accrued expenses    
Bonus related compensation $ 2,872 $ 5,116
Employee related accruals 2,578 1,785
Other accrued expenses 2,525 1,047
Accrued expenses $ 7,975 $ 7,948
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Leases [Abstract]        
Short-term lease costs (less than) $ 0.1 $ 0.1 $ 0.1 $ 0.1
Operating lease expense 1.4 1.3 2.9 2.6
Finance lease expense $ 0.1 $ 0.1 $ 0.1 $ 0.1
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Assets And Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Assets    
Operating $ 23,800 $ 25,103
Finance 129 148
Right-of-use assets 23,929 25,251
Current    
Operating 5,570 5,461
Finance 41 41
Lease liability current 5,611 5,502
Non-current    
Operating 20,881 22,242
Finance 93 110
Lease liability noncurrent $ 20,974 $ 22,352
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization  
Finance Lease, Liability, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilities  
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesCurrent  
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesNoncurrent  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 66 Months Ended
Jul. 31, 2020
USD ($)
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
shares
Jun. 30, 2019
USD ($)
$ / shares
shares
Mar. 31, 2019
USD ($)
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2020
shares
Apr. 29, 2020
shares
Apr. 28, 2020
Stock-Based Compensation                    
Shares issued under the Employee Stock Purchase Plan (in shares) | $   $ 257 $ 224 $ 211 $ 218          
Employee stock                    
Stock-Based Compensation                    
Common stock available for issuance (in shares)   1,000,000       1,000,000   1,000,000    
Common stock granted since inception (in shares)               672,907    
Employee stock | Subsequent event                    
Stock-Based Compensation                    
Shares purchased during period (in shares) 44,137                  
Shares issued under the Employee Stock Purchase Plan (in shares) | $ $ 300                  
Service-based stock options                    
Stock-Based Compensation                    
Expiration period           10 years        
Vesting period           4 years        
Granted (in shares)   110,750   152,500   1,296,890 1,638,510      
Weighted average grant-date fair value (in dollars per share) | $ / shares   $ 8.82   $ 11.94   $ 8.66 $ 12.74      
Service-based stock options | Nonemployee directors                    
Stock-Based Compensation                    
Expiration period           10 years        
Vesting period           1 year        
Restricted Stock Units (RSUs)                    
Stock-Based Compensation                    
Vesting period           4 years        
Restricted stock units granted (shares)   10,700   10,500   196,836 186,922      
Weighted-average grant date fair value (in usd per share) | $ / shares   $ 14.49   $ 16.62   $ 11.41 $ 17.71      
Grant-date fair value of restricted stock units granted | $   $ 200   $ 200   $ 2,200 $ 3,300      
Shares vested in period (shares)   10,500 36,212              
Restricted stock withheld for employee tax remittance (in shares)   0 13,872              
Restricted Stock Units (RSUs) | Nonemployee directors                    
Stock-Based Compensation                    
Vesting period           1 year        
Common Stock                    
Stock-Based Compensation                    
Shares purchased during period (in shares)   32,000 20,000 14,000 19,000          
Shares issued under the Employee Stock Purchase Plan (in shares) | $   $ 257 $ 224 $ 211 $ 218          
Restricted stock withheld for employee tax remittance (in shares)     14,000              
Prior Plans                    
Stock-Based Compensation                    
Awards available for future grant under the Plan (in shares)   0       0   0    
Omnibus Incentive Plan 2019                    
Stock-Based Compensation                    
Awards available for future grant under the Plan (in shares)   4,267,255       4,267,255   4,267,255    
Ratio of full value awards against share reserve                 1.4 1.25
Omnibus Incentive Plan 2019 | Common Stock                    
Stock-Based Compensation                    
Increase in number of shares available for issuance (shares)                 2,400,000  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation - Schedule of non-cash stock-based compensation expense (Details) - Employee stock purchase plan and service-based stock options - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense $ 4,377 $ 4,183 $ 8,144 $ 6,810
Cost of goods sold        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense 568 716 997 976
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense 484 886 1,060 1,410
Selling, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense $ 3,325 $ 2,581 $ 6,087 $ 4,424
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Cash Equivalents and Investments (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Marketable Securities [Line Items]    
Amortized Cost $ 69,926 $ 57,436
Gains 145 21
Losses 0 0
Credit Losses 0  
Estimated Fair Value 70,071 57,457
Cash equivalents    
Marketable Securities [Line Items]    
Estimated Fair Value 44,985 5,381
Short term investments    
Marketable Securities [Line Items]    
Estimated Fair Value 25,086 42,829
Long term investments    
Marketable Securities [Line Items]    
Estimated Fair Value   9,247
Money market funds    
Marketable Securities [Line Items]    
Amortized Cost 44,985 5,381
Gains 0 0
Losses 0 0
Credit Losses 0  
Estimated Fair Value 44,985 5,381
Commercial paper    
Marketable Securities [Line Items]    
Amortized Cost 3,685 11,892
Gains 0 0
Losses 0 0
Credit Losses 0  
Estimated Fair Value 3,685 11,892
Corporate notes    
Marketable Securities [Line Items]    
Amortized Cost 8,840 18,369
Gains 55 11
Losses 0 0
Credit Losses 0  
Estimated Fair Value 8,895 18,380
U.S. government securities    
Marketable Securities [Line Items]    
Amortized Cost 7,776 11,291
Gains 67 4
Losses 0 0
Credit Losses 0  
Estimated Fair Value 7,843 11,295
U.S. asset-backed securities    
Marketable Securities [Line Items]    
Amortized Cost 4,640 10,503
Gains 23 6
Losses 0 0
Credit Losses 0  
Estimated Fair Value $ 4,663 $ 10,509
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value $ 70,071 $ 57,457
Recurring    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 70,071 57,457
Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 44,985 5,381
Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 25,086 52,076
Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 0 0
Commercial paper | Recurring    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 3,685 11,892
Commercial paper | Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Commercial paper | Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 3,685 11,892
Commercial paper | Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Corporate Note Securities | Recurring    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 8,895 18,380
Corporate Note Securities | Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Corporate Note Securities | Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 8,895 18,380
Corporate Note Securities | Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
US Government Debt Securities | Recurring    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 7,843 11,295
US Government Debt Securities | Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
US Government Debt Securities | Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 7,843 11,295
US Government Debt Securities | Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Asset-backed Securities    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 4,663 10,509
Asset-backed Securities | Recurring    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 4,663 10,509
Asset-backed Securities | Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Asset-backed Securities | Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 4,663 10,509
Asset-backed Securities | Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Money market funds | Recurring    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 44,985 5,381
Money market funds | Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 44,985 5,381
Money market funds | Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 0 0
Money market funds | Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Money market funds $ 0 $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Numerator:            
Net loss $ (8,269) $ (4,705) $ (19,792) $ (2,844) $ (12,974) $ (22,636)
Denominator for basic and diluted EPS:            
Basic and diluted EPS: weighted-average common shares outstanding (in shares) 45,137   43,956   45,031 43,841
Net loss per share attributable to common shareholders (Basic and Diluted) (in dollars per share) $ (0.18)   $ (0.45)   $ (0.29) $ (0.52)
Service-based stock options            
Denominator for basic and diluted EPS:            
Aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from computations of diluted net loss per common share (in shares) 6,000   5,600   6,000 5,600
Restricted Stock Units (RSUs)            
Denominator for basic and diluted EPS:            
Aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from computations of diluted net loss per common share (in shares) 300   200   300 200
Warrants            
Denominator for basic and diluted EPS:            
Aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from computations of diluted net loss per common share (in shares) 0   100   0 100
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Nexobrid License and Supply Agreements (Details) - MediWound Ltd
$ in Millions
 1 Months Ended
May 31, 2019
USD ($)
Related Party Transaction [Line Items]  
Consideration payment for license $ 17.5
Payable 17.5
Contingent consideration 7.5
Max contingent consideration 125.0
Sales Initial milestone $ 75.0
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 206 265 1 false 56 0 false 7 false false R1.htm 0001001 - Document - Cover Page Sheet http://vcel.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY Sheet http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Organization Sheet http://vcel.com/role/Organization Organization Notes 8 false false R9.htm 2103102 - Disclosure - Basis of Presentation Sheet http://vcel.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 2108103 - Disclosure - Recent Accounting Pronouncements Sheet http://vcel.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 2109104 - Disclosure - Revenue Sheet http://vcel.com/role/Revenue Revenue Notes 11 false false R12.htm 2114105 - Disclosure - Selected Balance Sheet Components Sheet http://vcel.com/role/SelectedBalanceSheetComponents Selected Balance Sheet Components Notes 12 false false R13.htm 2119106 - Disclosure - Leases Sheet http://vcel.com/role/Leases Leases Notes 13 false false R14.htm 2123107 - Disclosure - Stock-Based Compensation Sheet http://vcel.com/role/StockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 2127108 - Disclosure - Cash Equivalents and Investments Sheet http://vcel.com/role/CashEquivalentsandInvestments Cash Equivalents and Investments Notes 15 false false R16.htm 2130109 - Disclosure - Fair Value Measurements Sheet http://vcel.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 2133110 - Disclosure - Net Loss Per Common Share Sheet http://vcel.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 17 false false R18.htm 2136111 - Disclosure - Nexobrid License and Supply Agreements Sheet http://vcel.com/role/NexobridLicenseandSupplyAgreements Nexobrid License and Supply Agreements Notes 18 false false R19.htm 2138112 - Disclosure - Commitments and Contingencies Sheet http://vcel.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 2204201 - Disclosure - Basis of Presentation - (Policies) Sheet http://vcel.com/role/BasisofPresentationPolicies Basis of Presentation - (Policies) Policies http://vcel.com/role/RecentAccountingPronouncements 20 false false R21.htm 2305301 - Disclosure - Basis of Presentation (Tables) Sheet http://vcel.com/role/BasisofPresentationTables Basis of Presentation (Tables) Tables http://vcel.com/role/BasisofPresentation 21 false false R22.htm 2310302 - Disclosure - Revenue (Tables) Sheet http://vcel.com/role/RevenueTables Revenue (Tables) Tables http://vcel.com/role/Revenue 22 false false R23.htm 2315303 - Disclosure - Selected Balance Sheet Components (Tables) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsTables Selected Balance Sheet Components (Tables) Tables http://vcel.com/role/SelectedBalanceSheetComponents 23 false false R24.htm 2320304 - Disclosure - Leases (Tables) Sheet http://vcel.com/role/LeasesTables Leases (Tables) Tables http://vcel.com/role/Leases 24 false false R25.htm 2324305 - Disclosure - Stock-Based Compensation (Tables) Sheet http://vcel.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://vcel.com/role/StockBasedCompensation 25 false false R26.htm 2328306 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://vcel.com/role/CashEquivalentsandInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://vcel.com/role/CashEquivalentsandInvestments 26 false false R27.htm 2331307 - Disclosure - Fair Value Measurements (Tables) Sheet http://vcel.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://vcel.com/role/FairValueMeasurements 27 false false R28.htm 2334308 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://vcel.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://vcel.com/role/NetLossPerCommonShare 28 false false R29.htm 2402401 - Disclosure - Organization - Narrative (Details) Sheet http://vcel.com/role/OrganizationNarrativeDetails Organization - Narrative (Details) Details 29 false false R30.htm 2406402 - Disclosure - Basis of Presentation - Supplementary cash flows information (Details) Sheet http://vcel.com/role/BasisofPresentationSupplementarycashflowsinformationDetails Basis of Presentation - Supplementary cash flows information (Details) Details 30 false false R31.htm 2407403 - Disclosure - Basis of Presentation - Narrative (Details) Sheet http://vcel.com/role/BasisofPresentationNarrativeDetails Basis of Presentation - Narrative (Details) Details 31 false false R32.htm 2411404 - Disclosure - Revenue - (Details) Sheet http://vcel.com/role/RevenueDetails Revenue - (Details) Details 32 false false R33.htm 2412405 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://vcel.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 33 false false R34.htm 2413406 - Disclosure - Revenue - Schedules of concentration of risk (Details) Sheet http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails Revenue - Schedules of concentration of risk (Details) Details 34 false false R35.htm 2416407 - Disclosure - Selected Balance Sheet Components - Schedule of inventory (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails Selected Balance Sheet Components - Schedule of inventory (Details) Details 35 false false R36.htm 2417408 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails Selected Balance Sheet Components - Schedule of property and equipment, net (Details) Details 36 false false R37.htm 2418409 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails Selected Balance Sheet Components - Schedule of accrued expenses (Details) Details 37 false false R38.htm 2421410 - Disclosure - Leases - Narrative (Details) Sheet http://vcel.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 38 false false R39.htm 2422411 - Disclosure - Leases - Assets And Liabilities (Details) Sheet http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails Leases - Assets And Liabilities (Details) Details 39 false false R40.htm 2425412 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://vcel.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 40 false false R41.htm 2426413 - Disclosure - Stock-Based Compensation - Schedule of non-cash stock-based compensation expense (Details) Sheet http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails Stock-Based Compensation - Schedule of non-cash stock-based compensation expense (Details) Details 41 false false R42.htm 2429414 - Disclosure - Cash Equivalents and Investments (Details) Sheet http://vcel.com/role/CashEquivalentsandInvestmentsDetails Cash Equivalents and Investments (Details) Details http://vcel.com/role/CashEquivalentsandInvestmentsTables 42 false false R43.htm 2432415 - Disclosure - Fair Value Measurements (Details) Sheet http://vcel.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://vcel.com/role/FairValueMeasurementsTables 43 false false R44.htm 2435416 - Disclosure - Net Loss Per Common Share - Narrative (Details) Sheet http://vcel.com/role/NetLossPerCommonShareNarrativeDetails Net Loss Per Common Share - Narrative (Details) Details 44 false false R45.htm 2437417 - Disclosure - Nexobrid License and Supply Agreements (Details) Sheet http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails Nexobrid License and Supply Agreements (Details) Details http://vcel.com/role/NexobridLicenseandSupplyAgreements 45 false false All Reports Book All Reports vcel-20200630.htm ex311ceocertificationq.htm ex312cfocertificationq.htm ex321ceosoxcertificati.htm ex322cfosoxcertificati.htm vcel-20200630.xsd vcel-20200630_cal.xml vcel-20200630_def.xml vcel-20200630_lab.xml vcel-20200630_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vcel-20200630.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 206, "dts": { "calculationLink": { "local": [ "vcel-20200630_cal.xml" ] }, "definitionLink": { "local": [ "vcel-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "vcel-20200630.htm" ] }, "labelLink": { "local": [ "vcel-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "vcel-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "vcel-20200630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 355, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 15, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 20 }, "keyCustom": 20, "keyStandard": 245, "memberCustom": 11, "memberStandard": 39, "nsprefix": "vcel", "nsuri": "http://vcel.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://vcel.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Recent Accounting Pronouncements", "role": "http://vcel.com/role/RecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109104 - Disclosure - Revenue", "role": "http://vcel.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Selected Balance Sheet Components", "role": "http://vcel.com/role/SelectedBalanceSheetComponents", "shortName": "Selected Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - Leases", "role": "http://vcel.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - Stock-Based Compensation", "role": "http://vcel.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Cash Equivalents and Investments", "role": "http://vcel.com/role/CashEquivalentsandInvestments", "shortName": "Cash Equivalents and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130109 - Disclosure - Fair Value Measurements", "role": "http://vcel.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133110 - Disclosure - Net Loss Per Common Share", "role": "http://vcel.com/role/NetLossPerCommonShare", "shortName": "Net Loss Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136111 - Disclosure - Nexobrid License and Supply Agreements", "role": "http://vcel.com/role/NexobridLicenseandSupplyAgreements", "shortName": "Nexobrid License and Supply Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138112 - Disclosure - Commitments and Contingencies", "role": "http://vcel.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Basis of Presentation - (Policies)", "role": "http://vcel.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation - (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Basis of Presentation (Tables)", "role": "http://vcel.com/role/BasisofPresentationTables", "shortName": "Basis of Presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Revenue (Tables)", "role": "http://vcel.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Selected Balance Sheet Components (Tables)", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsTables", "shortName": "Selected Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Leases (Tables)", "role": "http://vcel.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://vcel.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Cash Equivalents and Investments (Tables)", "role": "http://vcel.com/role/CashEquivalentsandInvestmentsTables", "shortName": "Cash Equivalents and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Fair Value Measurements (Tables)", "role": "http://vcel.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334308 - Disclosure - Net Loss Per Common Share (Tables)", "role": "http://vcel.com/role/NetLossPerCommonShareTables", "shortName": "Net Loss Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberofProducts", "reportCount": 1, "unitRef": "product", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization - Narrative (Details)", "role": "http://vcel.com/role/OrganizationNarrativeDetails", "shortName": "Organization - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Basis of Presentation - Supplementary cash flows information (Details)", "role": "http://vcel.com/role/BasisofPresentationSupplementarycashflowsinformationDetails", "shortName": "Basis of Presentation - Supplementary cash flows information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Basis of Presentation - Narrative (Details)", "role": "http://vcel.com/role/BasisofPresentationNarrativeDetails", "shortName": "Basis of Presentation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i9d667ed6594f4ae7b6d7ff8bb9192c4e_I20190630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfContractedSpecialtyPharmacies", "reportCount": 1, "unitRef": "pharmacy", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Revenue - (Details)", "role": "http://vcel.com/role/RevenueDetails", "shortName": "Revenue - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i76688cda97c74797a06eeedde2b8f012_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://vcel.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ic71ccfdc90c34893a7870b266b256aee_D20200401-20200630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Revenue - Schedules of concentration of risk (Details)", "role": "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails", "shortName": "Revenue - Schedules of concentration of risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ic71ccfdc90c34893a7870b266b256aee_D20200401-20200630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Selected Balance Sheet Components - Schedule of inventory (Details)", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails", "shortName": "Selected Balance Sheet Components - Schedule of inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details)", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails", "shortName": "Selected Balance Sheet Components - Schedule of property and equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i76688cda97c74797a06eeedde2b8f012_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details)", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails", "shortName": "Selected Balance Sheet Components - Schedule of accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:ShortTermLeaseCost", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Leases - Narrative (Details)", "role": "http://vcel.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermLeaseCost", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Leases - Assets And Liabilities (Details)", "role": "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails", "shortName": "Leases - Assets And Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i5c44b26b6b4c4c649ada4a1f62194487_D20150101-20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "iebac3fa4af6c43ec87eda5fc8e707c7a_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Stock-Based Compensation - Schedule of non-cash stock-based compensation expense (Details)", "role": "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails", "shortName": "Stock-Based Compensation - Schedule of non-cash stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "iebac3fa4af6c43ec87eda5fc8e707c7a_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Cash Equivalents and Investments (Details)", "role": "http://vcel.com/role/CashEquivalentsandInvestmentsDetails", "shortName": "Cash Equivalents and Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i6380b317f6be45bf85cc6af6f58be851_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Fair Value Measurements (Details)", "role": "http://vcel.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ia4d232892f444a779a7d6ffa9a6ddfaa_I20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - Net Loss Per Common Share - Narrative (Details)", "role": "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails", "shortName": "Net Loss Per Common Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ia943eaf9227e449fa2972a5a3b19a021_D20200401-20200630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i25024f2382014fd188363b1c7cb1b26a_I20190531", "decimals": "-5", "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437417 - Disclosure - Nexobrid License and Supply Agreements (Details)", "role": "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails", "shortName": "Nexobrid License and Supply Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i25024f2382014fd188363b1c7cb1b26a_I20190531", "decimals": "-5", "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ib3e0b1a713a342f8a3be397b51c4b807_D20200401-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i7bb2c2ad302f4396abf430bef6e9f0a0_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY", "role": "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "i228822290b734caaa60e3c4ba8ec490a_D20190101-20190331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://vcel.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Basis of Presentation", "role": "http://vcel.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20200630.htm", "contextRef": "ifbdf69e8bc8442a6b0502be8bcd4ca90_D20200101-20200630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 56, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://vcel.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r44", "r88" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r145", "r196", "r199", "r369" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r145", "r196", "r199", "r369" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r143", "r196", "r197", "r336", "r367", "r368" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r143", "r196", "r197", "r336", "r367", "r368" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable Concentration" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r17", "r146", "r147" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $207 and $306, respectively)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r79" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r8", "r9", "r32" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Bonus related compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r47", "r48", "r49", "r360", "r377", "r381" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Other comprehensive gain" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r46", "r49", "r50", "r91", "r92", "r93", "r264", "r372", "r373" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r96", "r97", "r98", "r100", "r161", "r162", "r163", "r164", "r167", "r168", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r252", "r253", "r254", "r255", "r337", "r338", "r339", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ], "lang": { "en-US": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Restricted stock withheld for employee tax remittance" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r219", "r222", "r248", "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Compensation expense related to stock options and restricted stock units granted, net of forfeitures" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used for) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AirlineProductsAndServicesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.", "label": "Products and Services [Table]", "terseLabel": "Products and Services [Table]" } } }, "localname": "AirlineProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r222", "r235", "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total non-cash stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r23", "r148", "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation allowance for receivables classified as other, due within one year or the normal operating cycle, if longer.", "label": "Allowance for Doubtful Other Receivables, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from computations of diluted net loss per common share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r157", "r210" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "U.S. asset-backed securities", "verboseLabel": "Asset-backed Securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails", "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r132", "r135", "r141", "r160", "r261", "r265", "r280", "r345", "r358" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r42", "r86", "r160", "r261", "r265", "r280" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r269" ], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r152", "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r150", "r153", "r175", "r349" ], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value", "verboseLabel": "Debt securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails", "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r151", "r175" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r223", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Classified as:" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r267", "r268" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r82", "r83", "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Additions to property, plant and equipment included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationSupplementarycashflowsinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r27", "r80" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationNarrativeDetails", "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r80", "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "terseLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationNarrativeDetails", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://vcel.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r283" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r210", "r274" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r35", "r190", "r350", "r363" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r187", "r188", "r189", "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r91", "r92" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r193" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, no par value; shares authorized \u2014 75,000; shares issued and\u00a0outstanding \u2014 45,194 and 44,864, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r52", "r54", "r55", "r59", "r352", "r366" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r122", "r123", "r145", "r277", "r278" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r122", "r123", "r145", "r277", "r278", "r383" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r122", "r123", "r145", "r277", "r278", "r383" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "verboseLabel": "Revenue" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "CONCENTRATION" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r122", "r123", "r145", "r277", "r278" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r120", "r122", "r123", "r124", "r277", "r279" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r122", "r123", "r145", "r277", "r278" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r196", "r200" ], "lang": { "en-US": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [ "r196", "r200" ], "lang": { "en-US": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r196", "r203" ], "lang": { "en-US": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r196", "r203" ], "lang": { "en-US": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r210", "r217", "r382" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNoteSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).", "label": "Corporate Note Securities [Member]", "terseLabel": "Corporate Note Securities" } } }, "localname": "CorporateNoteSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r61", "r336" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r121", "r145" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r154", "r175", "r178", "r179" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "terseLabel": "Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Schedule of fair value of securities, not including cash" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r78", "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r78", "r131" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common shareholders (Basic and Diluted) (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r114", "r115", "r116", "r117" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee related accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Service-based stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r91", "r92", "r93", "r97", "r105", "r107", "r118", "r164", "r193", "r194", "r242", "r243", "r244", "r254", "r255", "r284", "r285", "r286", "r287", "r288", "r289", "r372", "r373", "r374" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Liabilities that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r269", "r270", "r271", "r275" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r270", "r309", "r310", "r311" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r269", "r270", "r272", "r273", "r276" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r210", "r211", "r216", "r217", "r270", "r309" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r210", "r211", "r216", "r217", "r270", "r310" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r270", "r311" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r269", "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of valuation of the Company's investments and financial instruments that are measured at fair value on a recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r309", "r310", "r311" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r274", "r276" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r296", "r298", "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r294" ], "calculation": { "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r294" ], "calculation": { "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r293" ], "calculation": { "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "vcel_RightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r293" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Financing right-of-use lease" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r157", "r158", "r170", "r171", "r172", "r173", "r174", "r176", "r177", "r180", "r181", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails", "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FixedPriceContractMember": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which amount of consideration is fixed.", "label": "Fixed-price Contract [Member]", "terseLabel": "Contract rate" } } }, "localname": "FixedPriceContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r281", "r282" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "negatedLabel": "Foreign currency translation loss" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture, fixtures and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r78" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss on sale of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r218", "r220", "r233" ], "lang": { "en-US": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r60", "r86", "r132", "r134", "r137", "r140", "r142", "r160", "r280" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other non-current assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r56", "r130", "r291", "r292", "r353" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Other income (expense)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r73", "r75", "r81" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid (net of interest capitalized)" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationSupplementarycashflowsinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r37" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r40" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r39" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r38" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r63", "r129" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Short term investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r159", "r343", "r356", "r388" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Cash Equivalents and Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r86", "r136", "r160", "r262", "r265", "r266", "r280" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r86", "r160", "r280", "r346", "r362" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r86", "r160", "r262", "r265", "r266", "r280" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:", "verboseLabel": "Current" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails", "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r119", "r125" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r76", "r79" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r51", "r53", "r58", "r79", "r86", "r96", "r101", "r102", "r103", "r104", "r106", "r107", "r111", "r132", "r134", "r137", "r140", "r142", "r160", "r280", "r351", "r365" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails", "http://vcel.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r94", "r95", "r98", "r99", "r108", "r109", "r110", "r165", "r166", "r204", "r205", "r207", "r208", "r245", "r256", "r257", "r258", "r340", "r341", "r342", "r376", "r377", "r378", "r379", "r381" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash information:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationSupplementarycashflowsinformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/OrganizationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r132", "r134", "r137", "r140", "r142" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r294" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r294" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r293" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "vcel_RightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating", "verboseLabel": "Right-of-use leased assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r259", "r260", "r263" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain on investments", "verboseLabel": "Unrealized gain on investments" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r32" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payments on employee's behalf for taxes related to vesting of restricted stock unit awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r67" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Expenditures for property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r68" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedTerseLabel": "Purchases of short term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r223", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r66", "r68" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments", "terseLabel": "Maturities of short term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r70", "r72", "r89" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r69", "r237" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Net proceeds from common stock issuance due to stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r184", "r296", "r298" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r43", "r185", "r298" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r12", "r183", "r293" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r29", "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r28", "r183" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "verboseLabel": "Property and equipment, net:" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r183" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r251", "r390" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r85", "r344", "r359" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r13", "r85", "r389" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r194", "r246", "r361", "r376", "r381" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/OrganizationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r91", "r92", "r93", "r97", "r105", "r107", "r164", "r242", "r243", "r244", "r254", "r255", "r372", "r374" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r127", "r128", "r133", "r138", "r139", "r143", "r144", "r145", "r195", "r196", "r336" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product sales, net", "verboseLabel": "Increase (decrease) to revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r57", "r86", "r127", "r128", "r133", "r138", "r139", "r143", "r144", "r145", "r160", "r280", "r354" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r300", "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use asset and lease liability recognized" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationSupplementarycashflowsinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Directly to consumer" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Through Intermediary" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r122", "r145" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Concentration" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Supplementary cash flows information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/BasisofPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r222", "r234", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r222", "r234", "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of non-cash stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r24", "r25", "r26" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r29", "r185" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r87", "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r223", "r236" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r120", "r122", "r123", "r124", "r277", "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of concentration of risk" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Restricted stock units granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average grant date fair value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "verboseLabel": "Shares vested in period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Common stock granted since inception (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Awards available for future grant under the Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r221", "r227" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r218", "r233" ], "lang": { "en-US": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Nonemployee directors" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Restricted stock withheld for employee tax remittance (in shares)", "terseLabel": "Restricted stock withheld for employee tax remittance (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r14", "r347", "r348", "r357" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r384", "r385", "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short term investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r299", "r301" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs (less than)" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r91", "r92", "r93", "r97", "r105", "r107", "r118", "r164", "r193", "r194", "r242", "r243", "r244", "r254", "r255", "r284", "r285", "r286", "r287", "r288", "r289", "r372", "r373", "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r91", "r92", "r93", "r118", "r336" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r15", "r16", "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under the Employee Stock Purchase Plan (in shares)", "verboseLabel": "Shares purchased during period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r15", "r16", "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of stock upon restricted stock unit vesting (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r193", "r194", "r229" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r15", "r16", "r193", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Shares issued under the Employee Stock Purchase Plan", "verboseLabel": "Shares issued under the Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r193", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of stock upon restricted stock unit vesting" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r193", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r86", "r149", "r160", "r280" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r290", "r305" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r290", "r305" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r290", "r305" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Selected Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TimeAndMaterialsContractMember": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which amount of consideration is based on time and materials consumed.", "label": "Time-and-materials Contract [Member]", "terseLabel": "Time-and-materials contract" } } }, "localname": "TimeAndMaterialsContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r157", "r158", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails", "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r96", "r97", "r98", "r100", "r161", "r162", "r163", "r164", "r167", "r168", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r252", "r253", "r254", "r255", "r337", "r338", "r339", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ], "lang": { "en-US": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails", "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible List]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "extensibleListItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible List]", "terseLabel": "Revenue, Product and Service [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "extensibleListItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r210", "r355" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "US Government Debt Securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk or Uncertainty, Nature [Axis]", "terseLabel": "Unusual Risk or Uncertainty, Nature [Axis]" } } }, "localname": "UnusualRiskOrUncertaintyByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyNatureDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk or Uncertainty, Nature [Domain]", "terseLabel": "Unusual Risk or Uncertainty, Nature [Domain]" } } }, "localname": "UnusualRiskOrUncertaintyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average number of common shares outstanding (Basic and Diluted) (in shares)", "verboseLabel": "Basic and diluted EPS: weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Denominator for basic and diluted EPS:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "vcel_AccruedExpensesOtherCurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents other accrued expenses, current.", "label": "Accrued Expenses, Other, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "AccruedExpensesOtherCurrent", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_AssetsAndLiabilitiesLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Leases [Table Text Block]", "label": "Assets And Liabilities, Leases [Table Text Block]", "terseLabel": "Assets And Liabilities" } } }, "localname": "AssetsAndLiabilitiesLeasesTableTextBlock", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vcel_BiopsyKitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biopsy Kits [Member]", "label": "Biopsy Kits [Member]", "terseLabel": "Biopsy kits" } } }, "localname": "BiopsyKitsMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_ComputerEquipmentAndComputerSoftwareIntangibleAssetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Equipment And Computer Software Intangible Asset [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndComputerSoftwareIntangibleAssetMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "vcel_CoronaVirusPandemicMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corona Virus Pandemic", "label": "Corona Virus Pandemic [Member]", "terseLabel": "COVID-19 potential impacts" } } }, "localname": "CoronaVirusPandemicMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_EmployeeStockAndEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Stock And Employee Stock Option [Member]", "label": "Employee Stock And Employee Stock Option [Member]", "terseLabel": "Employee stock purchase plan and service-based stock options" } } }, "localname": "EmployeeStockAndEmployeeStockOptionMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/StockBasedCompensationScheduleofnoncashstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "vcel_EpicelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Epicel [Member]", "label": "Epicel [Member]", "terseLabel": "Epicel" } } }, "localname": "EpicelMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails", "http://vcel.com/role/RevenueSchedulesofconcentrationofriskDetails" ], "xbrltype": "domainItemType" }, "vcel_ImplantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Implants [Member]", "label": "Implants [Member]", "terseLabel": "Implants" } } }, "localname": "ImplantsMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease Liability Current", "label": "Lease Liability Current", "totalLabel": "Lease liability current" } } }, "localname": "LeaseLiabilityCurrent", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease Liability Noncurrent", "label": "Lease Liability Noncurrent", "totalLabel": "Lease liability noncurrent" } } }, "localname": "LeaseLiabilityNoncurrent", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "License Agreement, Consideration", "label": "License Agreement, Consideration", "terseLabel": "Consideration payment for license" } } }, "localname": "LicenseAgreementConsideration", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "License Agreement, Contingent Consideration", "label": "License Agreement, Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "LicenseAgreementContingentConsideration", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementContingentConsiderationMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "License Agreement, Contingent Consideration, Maximum", "label": "License Agreement, Contingent Consideration, Maximum", "terseLabel": "Max contingent consideration" } } }, "localname": "LicenseAgreementContingentConsiderationMaximum", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementInitialMilestoneSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "License Agreement, Initial Milestone, Sales", "label": "License Agreement, Initial Milestone, Sales", "terseLabel": "Sales Initial milestone" } } }, "localname": "LicenseAgreementInitialMilestoneSales", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License Agreement [Text Block]", "label": "License Agreement [Text Block]", "terseLabel": "Nexobrid License and Supply Agreements" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreements" ], "xbrltype": "textBlockItemType" }, "vcel_LongtermInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term Investments [Member]", "label": "Long-term Investments [Member]", "terseLabel": "Long term investments" } } }, "localname": "LongtermInvestmentsMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/CashEquivalentsandInvestmentsDetails" ], "xbrltype": "domainItemType" }, "vcel_MediWoundLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MediWound Ltd [Member]", "label": "MediWound Ltd [Member]", "terseLabel": "MediWound Ltd" } } }, "localname": "MediWoundLtdMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "domainItemType" }, "vcel_NumberOfContractedSpecialtyPharmacies": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Contracted Specialty Pharmacies", "label": "Number of Contracted Specialty Pharmacies", "terseLabel": "Number of specialty pharmacies" } } }, "localname": "NumberOfContractedSpecialtyPharmacies", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "integerItemType" }, "vcel_NumberofProducts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Products", "label": "Number of Products", "terseLabel": "Number of therapy products" } } }, "localname": "NumberofProducts", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/OrganizationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_OmnibusIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Omnibus Incentive Plan 2019 [Member]", "label": "Omnibus Incentive Plan 2019 [Member]", "terseLabel": "Omnibus Incentive Plan 2019" } } }, "localname": "OmnibusIncentivePlan2019Member", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease, Right Of Use Asset, Amortization", "label": "Operating Lease, Right Of Use Asset, Amortization", "terseLabel": "Amortization and interest accretion related to operating leases" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vcel_PaymentforLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment for License Agreement", "label": "Payment for License Agreement", "terseLabel": "Payable" } } }, "localname": "PaymentforLicenseAgreement", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/NexobridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_PriorPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to the Prior Plans consisting of 1992 Stock Option Plan, the 2001 Stock Option Plan and the Amended and Restated 2004 Equity Incentive Plan.", "label": "Prior Plans [Member]", "terseLabel": "Prior Plans" } } }, "localname": "PriorPlansMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_ProviderorFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Provider or Facility [Member]", "label": "Provider or Facility [Member]", "terseLabel": "Provider or Facility" } } }, "localname": "ProviderorFacilityMember", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage", "label": "Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage", "terseLabel": "Change in estimate of uncollectible (percent)" } } }, "localname": "RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "percentItemType" }, "vcel_RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount", "label": "Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount", "negatedTerseLabel": "Change in revenue recognized due to 0.5% change in uncollectible percentage" } } }, "localname": "RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "vcel_RightOfUseAsset": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Right Of Use Asset", "label": "Right Of Use Asset", "totalLabel": "Right-of-use assets" } } }, "localname": "RightOfUseAsset", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/LeasesAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Increase (Decrease)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Increase (Decrease)", "terseLabel": "Increase in number of shares available for issuance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "vcel_ShareBasedCompensationArrangementByShareBasedPaymentAwardRatioOfFullValueAwardsAgainstShareReserve": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Ratio of Full Value Awards Against Share Reserve", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Ratio of Full Value Awards Against Share Reserve", "terseLabel": "Ratio of full value awards against share reserve" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRatioOfFullValueAwardsAgainstShareReserve", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "pureItemType" }, "vcel_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Intrinsic Value, Nonvested", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Intrinsic Value, Nonvested", "verboseLabel": "Grant-date fair value of restricted stock units granted" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodAggregateIntrinsicValueNonvested", "nsuri": "http://vcel.com/20200630", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r391": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r392": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r393": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r394": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r395": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r396": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r45": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 64 0001628280-20-011753-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-20-011753-xbrl.zip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end